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ABSTRACT 
The aim of this dissertation was to develop an operational model to explain why the 
expected increase in the number of tuberculosis (TB) cases detected was not found in 
our empirical study, Policy Relevant Outcomes from Validating Evidence on ImpacT 
(PROVE IT), done in 142 health clinics in Cape Town after the roll-out of a new TB 
diagnostic test, Xpert MTB/RIF (Xpert). I then used the model to model the effect of 
interventions to improve the detection of TB and rifampicin resistant (RMP-R) TB. 
Strategies were modelled to reduce laboratory cost for detecting TB as well as the 
effect of introducing a more sensitive molecular diagnostic test, Xpert MTB/RIF Ultra 
(Ultra), as a replacement for Xpert on the number of TB and RMP-R TB cases 
detected. 
I developed and validated an operational model using a discrete event simulation 
approach for the detection of TB and RMP-R TB in a smear/culture-based algorithm 
and an Xpert-based algorithm using data from published articles as well as from the 
step-wedge analysis of the Xpert-based TB diagnostic algorithm in Cape Town 
(PROVE IT). The model was adapted to incorporate a more sensitive molecular 
diagnostic test as a replacement test for Xpert in the Xpert-based algorithm. All 
comparisons between algorithms were conducted with identical population 
characteristics and adherence to diagnostic algorithms. 
The empirical study found no increase in the number of TB cases detected (20.9% 
smear/culture-based and 17.7% with the Xpert-based algorithm) while the operational 
model, using identical population characteristics and adherence to diagnostic 
algorithms (adherence to algorithms as observed from the analysis of routine data in 
the empirical study), showed that there were more TB cases detected in the Xpert-
based algorithm than in the smear/culture-based algorithm (an increase of 13.3%) 
(Chapter 2). The model indicated that a decrease in background TB prevalence and 
the extensive use of culture testing for smear-negative HIV-positive TB cases during 
the smear/culture-based algorithm contributed to not finding an increase in the number 
of TB cases detected in the empirical study. 
When adherence to the diagnostic algorithms was modelled to be 100%, the model 
indicated a 95.4% increase in the number of RMP-R TB cases detected in the Xpert-
based algorithm compared to the smear/culture-based algorithm, while the empirical 
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study showed only a 54% increase (Chapter 3). This difference is attributable to the 
differences in drug susceptibility test (DST) screening strategy between algorithms as 
well as poor adherence to diagnostic algorithms. In the smear/culture-based algorithm, 
only high MDR-TB risk cases are screened for RMP-R pre-treatment compared to all 
presumptive TB cases screened for RMP-R with the Xpert-based algorithm. The 
empirical study found that the proportion of TB cases with DST undertaken pre-
treatment increased from 42.7% in the smear/culture-based algorithm to 78.9% in the 
Xpert-based algorithm. 
The model indicated that for the Xpert-based algorithm compared to the smear-
based algorithm (with 100% adherence to algorithms), the cost per TB case detected 
would increase by 114% with only a 5.5% increase in the number of TB cases 
detected (Chapter 3). Even though the model indicated a small increase in the 
number of TB cases detected, the real benefit of the Xpert-based algorithm is the 
95.4% increase in RMP-R TB cases detected with only a 15.8% increase in the cost 
per RMP-R TB case detected (Chapter 3). 
The model indicated that the best approach to improve the laboratory cost per TB case 
detected, would be a combined approach of increasing the TB prevalence among 
presumptive cases tested by using either a triage test or other pre-screening 
strategies, and a reduction in the price of Xpert cartridges (Chapter 4). With an increase 
in TB prevalence among presumptive cases tested to between 25.9% – 30.8% and the 
price of the Xpert cartridge reduced by 50%, the cost per TB case detected would 
range from US$50 to US$59, a level that is comparable with the cost per TB case 
detected in the smear/culture-based algorithm (US$48.77) found in the empirical 
laboratory costing study. 
Finally, when modelling the use of the not-yet released Xpert MTB/RIF Ultra as a 
replacement for Xpert MTB/RIF (Chapter 5), the number of TB cases detected would 
increase by 3.4% and RMP-R TB cases detected by 3.5%. The number of false-
positive TB cases detected with Ultra would however increase by 166.6%. We could 
not model the cost per TB case and cost per RMP-R TB case diagnosed with Ultra, as 
the price is not available yet. Ultra has small benefits over that of Xpert for both the 
number of TB and RMP-R TB cases detected and therefore the cost of introducing 
Ultra would be an important consideration in the decision to implement Ultra. The 
introduction of Ultra poses potential health system and patient related challenges due 
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to the high number of false-positive TB cases detected. Alternative strategies, such as 
alternative diagnostic algorithms, will have to be considered to find a balance between 
increased detection of TB cases and unnecessarily starting patients on TB treatment 
due to false positive results. 
The strengths of the model used in this dissertation are that the model was developed 
and validated using detailed routine data and information collected with the empirical 
study on health and laboratory processes in a large number of clinics. The model made 
a direct comparison between the algorithms taking into account differences in 
population characteristics and adherence to algorithms. Generalisability of findings 
from the model and the use of the model for other settings may be limited as the model 
was validated against data from a well-resourced, urban setting, with good health and 
laboratory infrastructure and therefore may not reflect reality in other settings, such as 
rural areas. 
The findings from the studies presented in this dissertation highlight the important role 
that an operation model can play in informing decision makers on the optimal use of a 
new diagnostic test in an operational setting, even after the rollout of the new test. 
Operational modelling can therefore be an effective tool to be used to assist the health 
department to optimise the way in which tests are currently used and could serve to 
inform decision makers about the implementation of new, more sensitive, diagnostic 
tests. 
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OPSOMMING 
Die doel van hierdie verhandeling was om ’n bedryfsmodel te ontwikkel wat verklaar 
waarom ons empiriese studie PROVE IT (“Policy Relevant Outcomes from Validating 
Evidence on ImpacT”), wat ná die bekendstelling van ’n nuwe TB-diagnostiese toets, 
Xpert MTB/RIF (Xpert), by 142 gesondheidsklinieke in Kaapstad gedoen is, nié die 
verwagte toename in opgespoorde tuberkulose- (TB-)gevalle weerspieël het nie. 
Daarna het ek die model gebruik om die uitwerking te modelleer van intervensies ter 
verbetering van die opsporing van TB en rifampisienweerstandige (“RMP-R”) TB. 
Strategieë is gemodelleer om laboratoriumkoste vir TB-opsporing te verlaag en om te 
bepaal watter uitwerking die bekendstelling van ’n meer sensitiewe molekulêre 
diagnostiese toets, Xpert MTB/RIF Ultra (Ultra), as plaasvervanger vir Xpert op die 
getal opgespoorde TB- en RMP-R TB-gevalle sal hê. 
Ek het ’n bedryfsmodel ontwikkel en valideer met behulp van ’n diskrete 
voorvalsimulasiebenadering vir die opsporing van TB en RMP-R TB in ’n smeer-/ 
kwekingsgebaseerde algoritme en ’n Xpert-gebaseerde algoritme. Hiervoor is data uit 
gepubliseerde artikels sowel as die stapsgewyse analise van die Xpert-gebaseerde 
TB-diagnostiese algoritme in Kaapstad (PROVE IT) gebruik. Die model is aangepas 
om ’n meer sensitiewe molekulêre diagnostiese toets as plaasvervanger vir Xpert by 
die Xpert-gebaseerde algoritme in te sluit. Alle vergelykings tussen algoritmes is met 
identiese populasiekenmerke en nakoming van diagnostiese algoritmes uitgevoer. 
Die empiriese studie het geen toename in die getal opgespoorde TB-gevalle gevind 
nie (20,9% smeer-/kwekingsgebaseerd en 17,7% met die Xpert-gebaseerde 
algoritme). Daarteenoor het die bedryfsmodel, wat gebruik gemaak het van identiese 
populasiekenmerke en nakoming van diagnostiese algoritmes (nakoming is 
waargeneem uit die ontleding van roetinedata in die empiriese studie), méér 
opgespoorde TB-gevalle in die Xpert-gebaseerde algoritme as in die smeer-/ 
kwekingsgebaseerde algoritme gevind (’n toename van 13,3%) (hoofstuk 2). Die 
model het getoon dat ’n afname in TB-agtergrondprevalensie en die omvattende 
gebruik van kwekingstoetse vir smeernegatiewe MIV-positiewe TB-gevalle in die 
smeer-/kwekingsgebaseerde algoritme daartoe bygedra het dat die empiriese studie 
nie ’n toename in opgespoorde TB-gevalle weerspieël het nie. 
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Toe nakoming van die diagnostiese algoritmes op 100% gemodelleer is, het die model 
op ’n toename van 95,4% in die getal opgespoorde RMP-R TB-gevalle in die Xpert-
gebaseerde algoritme vergeleke met die smeer-/kwekingsgebaseerde algoritme 
gedui, terwyl die empiriese studie ’n toename van slegs 54% getoon het (hoofstuk 3). 
Hierdie verskil kan toegeskryf word aan die verskillende middelvatbaarheidstoets- 
(“DST”-)siftingstrategieë vir die onderskeie algoritmes, sowel as swak nakoming van 
diagnostiese algoritmes. Met die smeer-/kwekingsgebaseerde algoritme word slegs 
gevalle met ’n hoë MDR-TB-risiko vir RMP-R-voorafbehandeling gesif; met die Xpert-
gebaseerde algoritme, daarteenoor, word alle vermoedelike TB-gevalle vir RMP-R 
gesif. Die empiriese studie het bevind dat die persentasie TB-gevalle wat na aanleiding 
van DST voorafbehandel is, toegeneem het van 42,7% in die smeer-/ 
kwekingsgebaseerde algoritme tot 78,9% in die Xpert-gebaseerde algoritme. 
Die model het aan die lig gebring dat die koste per opgespoorde TB-geval vir die Xpert-
gebaseerde algoritme vergeleke met die smeer-/kwekingsgebaseerde algoritme (met 
100% nakoming van algoritmes) met 114% sal styg, met ’n toename van slegs 5,5% 
in die getal opgespoorde TB-gevalle (hoofstuk 3). Hoewel die model op ’n klein 
toename in opgespoorde TB-gevalle gedui het, is die werklike voordeel van die Xpert-
gebaseerde algoritme die toename van 95,4% in opgespoorde RMP-R TB-gevalle, met 
’n styging van slegs 15,8% in die koste per opgespoorde geval (hoofstuk 3). 
Daarbenewens het die model getoon dat ’n gekombineerde benadering die beste sal 
wees om laboratoriumkoste per opgespoorde TB-geval te verbeter. So ’n 
gekombineerde benadering sal bestaan uit die verhoging van TB-prevalensie onder 
getoetste vermoedelike gevalle deur van hetsy ’n sorterings- (triage-)toets of ander 
voorafsiftingstrategieë gebruik te maak, sowel as ’n verlaging in die prys van Xpert-
toetshouers (“cartridges”) (hoofstuk 4). Met ’n styging in TB-prevalensie onder 
getoetste vermoedelike gevalle tot tussen 25,9% en 30,8%, en ’n verlaging van 50% 
in die prys van die Xpert-toetshouer, sal die koste per opgespoorde TB-geval tussen 
VS$50 en VS$59 wees – wat soortgelyk is aan die koste per opgespoorde TB-geval 
in die smeer-/kwekingsgebaseerde algoritme (VS$48,77) wat die empiriese 
laboratoriumkostestudie bepaal het. 
Laastens het die modellering van die gebruik van die tot nog toe nievrygestelde Xpert 
MTB/RIF Ultra as plaasvervanger vir Xpert MTB/RIF (hoofstuk 5) daarop gedui dat 
opgespoorde TB-gevalle met 3,4% en opgespoorde RMP-R TB-gevalle met 3,5% sal 
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toeneem. Die getal vals positiewe opgespoorde TB-gevalle met Ultra sal egter met 
166,6% styg. Aangesien die pryse nog nie bekend is nie, kon ons nie die koste 
modelleer per TB- en RMP-R TB-geval wat met Ultra gediagnoseer word nie. Ultra 
bied betreklik klein voordele bo Xpert wat die getal opgespoorde TB- en RMP-R TB-
gevalle betref, en daarom sal bekendstellingskoste ’n belangrike oorweging wees in 
die uiteindelike besluit om Ultra implementeer. Die bekendstelling van Ultra hou ook 
moontlike gesondheidsisteem- en pasiëntverwante uitdagings in weens die hoë getal 
vals positiewe opgespoorde TB-gevalle. Alternatiewe strategieë soos alternatiewe 
diagnostiese algoritmes sal oorweeg moet word om ’n balans te vind tussen beter 
opsporing van TB-gevalle en die onnodige aanvang van TB-behandeling vir pasiënte 
met vals positiewe resultate. 
Die sterkpunte van die model wat in hierdie verhandeling gebruik is, is dat dit ontwikkel 
en gestaaf is met behulp van gedetailleerde roetinedata en inligting wat met die 
empiriese studie oor gesondheids- en laboratoriumprosesse in ’n groot getal klinieke 
ingesamel is. Die model het die algoritmes direk vergelyk, met inagneming van 
verskille in populasiekenmerke en nakoming aan algoritmes. Die 
veralgemeenbaarheid van bevindinge en toepassing in ander omgewings kan egter 
beperk wees omdat die model gestaaf is met behulp van data uit ’n hulpbronryke, 
stedelike omgewing met goeie gesondheids- en laboratoriuminfrastruktuur, en dus nie 
noodwendig die realiteit in ander omgewings soos landelike gebiede weerspieël nie. 
Die bevindinge van die studies wat in hierdie verhandeling aangebied word, 
beklemtoon die belangrike rol wat ’n bedryfsmodel kan vervul om besluitnemers oor 
die optimale gebruik van ’n nuwe diagnostiese toets in ’n bedryfsomgewing in te lig, 
selfs ná die bekendstelling van die nuwe toets. Bedryfsmodellering kan dus ’n 
doeltreffende instrument wees vir die gesondheidsdepartement om die huidige gebruik 
van toetse te optimaliseer, en kan besluitnemers in die inwerkingstelling van nuwe, 
meer sensitiewe diagnostiese toetse bystaan.  
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ABBREVIATIONS  
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WHO  World Health Organisation 
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Chapter 1: Introduction 
1.1 Tuberculosis in a global context 
Tuberculosis (TB) remains a major cause of morbidity and mortality worldwide. Of the 
estimated 10.4 million incident TB cases (3.4 million bacteriologically confirmed) 
globally in 2015, 1.2 million were infected with the human immunodeficiency virus 
(HIV).1 The Africa region accounted for 26% of global TB cases, 31% of whom are 
estimated to be HIV co-infected.  The number of incident TB cases has been declining 
slowly with a 1.4% per year decline between 2000 to 2015.1 However, a decline in TB 
incidence of between 4% and 5% per year by 2020 is required in order to achieve the 
goals set by World Health Organisation (WHO) in the End TB strategy.1,2 In short, the 
End TB strategy set goals to achieve a 90% reduction in TB incidence rates by 2035 
compared to that in 2015. The short-term goal for 2020 is a 20% reduction in TB 
incidence compared to that in 2015.2,3 In 2015 there was a gap of 4.3 million between 
the estimated number of incident TB cases and the new TB cases notified to the 
WHO.1 
The multidrug-resistant tuberculosis (MDR-TB), defined as resistance to rifampicin 
and isoniazid, crisis persists with a slower decrease in incidence than with TB overall 
and even an increase in some areas.1 Of the 3.4 million bacteriologically confirmed 
TB cases notified globally in 2015, only 30% were reported to have had a drug 
susceptibility test (DST) for rifampicin and 132,120 rifampicin resistant (RMP-R) TB 
cases were detected. If all pulmonary TB (PTB) patients notified had a DST done, an 
estimated 340,000 RMP-R TB cases could have been detected. However, due to the 
lack of DST coverage only 40% of RMP-R TB cases (132,120) were detected and 
notified globally. In addition to the low DST coverage amongst cases already 
diagnosed with TB, there is a gap in diagnosing TB cases (see above)  Of the total 
estimated 580,000 incident RMP-R TB cases globally1, 240,000 were among 
undetected TB cases. 
The gaps between the estimated number of cases and the cases notified for TB and 
RMP-R TB, reflect a combination of under-diagnosis of cases and under-reporting of 
detected TB and RMP-R TB. Factors contributing to under-diagnosis of TB and RMP-
1
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R TB include amongst others poor access to health facilities, the failure to identify and 
test presumptive TB cases that do access health facilities and under-diagnosis due to 
the low sensitivity of the diagnostic test used. Sputum smear microscopy for acid-fast 
bacilli (smear microscopy) for instance is still widely used in many countries and due 
to its low sensitivity (particular in HIV-positive individuals) many TB case will remain 
undetected. The adherence to testing protocols, as stipulated in diagnostic algorithms, 
as well as the health characteristics (HIV-status, history of previous TB treatment) of 
an individual will affect the probability of successful TB detection. In addition, low 
availability of laboratory infrastructure for DST contributes to poor RMP-R TB case 
detection. 
1.2 TB in South Africa  
South Africa is one of the 22 high TB burden countries, with 454,000 (95% CI 294,000 
- 649,000) incident TB cases in 2015 and an estimated TB incidence rate of 834 cases 
per 100,000 population .1 The HIV epidemic is still a major driver of TB in South Africa. 
In 2015, 57% of TB cases were reported to be co-infected with HIV.1 The overall 
estimated HIV prevalence in South Africa is 12.7%, which amounts to approximately 
7,03 million people living with HIV in 2016.4 Individuals who are HIV-positive are at 
higher risk of TB than HIV-negative individuals.5 
TB incidence rates declined from a high of 977 per 100,000 in 2008 to 834 per 100,000 
in 2015.1 A study using a time series analysis of routine TB data found a similar decline 
in the incidence of microbiologically confirmed PTB cases from 848 per 100,000 in 
2008 to 774 per 100,000 in 2012.6 One of the reasons for the decline in TB incidence 
in South Africa could be attributed to the national increase in antiretroviral treatment 
(ART) uptake. The number of people on ART increased from 1.2 million in 2010 to 3.9 
million in 2016.7 A study conducted in one community in Cape Town reported a decline 
in TB prevalence amongst HIV-positive individuals from 9.2% in 2005 to 3.6% in 2008 
after the rollout of ART, contributing to the overall decline from 3.0% to 1.6% in HIV-
positive individuals while the TB prevalence in HIV-negative individuals was 
unchanged at 1.2% in 2005 and 1.0% in 2008.8 Even if HIV-positive individuals are on 
ART, they are still at an higher risk of developing TB disease than HIV-negative 
individuals.5  
2
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 1.3 Gaps in the number of estimated incident cases and the number notified to 
the WHO in South Africa 
1.3.1 TB cases 
In South Africa, the case detection gaps remain high with only 287,224 (63%) of the 
454,000 (95% CI 294,000 – 649,000) estimated incident TB cases detected and 
notified in 2015 (Figure 2).1  
 
Figure 1: Number of estimated incident TB and number of TB cases notified to the WHO.1 The graph 
shows WHO estimated number of incident TB cases and the number of TB cases notified to the WHO 
by the South African National TB Programme. 
The estimated number of incident TB cases (Figure 1) could be an underestimation, 
as South Africa has never had a national TB prevalence survey (a national TB 
prevalence survey is planned for 2017). The number of incident TB cases are 
estimated from the number of TB cases notified to the WHO. The TB cases notified to 
the WHO does not reflect all the TB cases in South Africa due to (1) TB cases not 
accessing health services or who access health services but are not tested for TB, (2) 
TB cases tested for TB but TB was not detected due to test sensitivity, (3) successfully 
detected cases that do not initiate TB treatment and (4) TB cases that initiate treatment 
but are not recorded in the routine TB surveillance system (ETR.net). 
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A number of studies conducted in South Africa indicated that between 17% and 33% 
of detected TB cases were not recorded and reported to WHO.9–11 In addition, other 
studies conducted in South Africa indicated that 15.5% to 34.7% of laboratory 
confirmed TB cases did not start TB treatment and were not recorded.12–16 
Individuals who are HIV-positive have a higher risk of developing TB and often TB is 
difficult to detect in HIV-positive individuals. Therefore the WHO policy on collaborative 
TB/HIV activities to reduce the burden of TB and HIV recommended that routine HIV 
testing and counselling should be offered to all presumptive TB cases and not only to 
patients diagnosed with TB – testing algorithms take this into account and additional 
tests are performed for HIV-positive individuals.17 In 2015, whilst 97% of TB cases on 
TB treatment in South Africa had a known HIV status, the proportion of presumptive 
TB cases that knew their HIV status during TB diagnostic screening was generally 
much lower and not well documented. A study conducted in India reported that only 
44.6% of presumptive TB cases knew their HIV status.18 Knowing the HIV status of a 
presumptive TB case influences the likelihood of successful TB detection. In South 
Africa, the TB diagnostic algorithm stipulates that all HIV-positive presumptive TB 
cases with a negative smear or Xpert result, receives a mycobacterial culture test 
(Figure 4 and 5).19  
1.3.2 RMP-R TB cases 
The WHO estimated that there were 20,000 (95% CI 13,000 – 27,000) RMP-R TB 
cases in South Africa in 2015.1 However, only 12,527 RMP-R TB cases were reported 
to WHO illustrating the significant gaps in the detection and initiation of treatment of 
RMP-R TB cases. These gaps included the 454,000 estimated incident TB cases, of 
whom only 63% were notified and only 68% of these notified TB cases were tested for 
RMP resistance. Of those who tested positive for RMP resistance, only 63% started 
MDR TB treatment and were thus recorded and reported.    
A drug resistance prevalence survey conducted in South Africa for the period 2012-
2014, reported that 4.6% (95% CI 3.5% - 5.7%) of TB cases were resistant to RMP.20 
A nationwide retrospective cohort study in South Africa assessing second-line 
treatment initiation reported that in 2013, after full national rollout of Xpert, only 59% 
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of RMP-R TB cases received an initial Xpert test and 63% of RMP-R TB cases 
detected started treatment.21 
Over the past decade, there has been an increase in the development of new TB 
diagnostic and drug susceptibility testing tools in an attempt to decrease the gaps in 
the overall number of estimated TB cases and RMP-R TB cases and those detected, 
recorded and ultimately notified to the WHO.22–24 
1.4 TB and RMP-R diagnostic tests 
1.4.1 Pre-molecular diagnostic tests 
1.4.1.1 TB diagnosis 
In most low and middle-income countries, the only TB diagnostic test available 
historically has been sputum smear microscopy with the availability of sputum culture 
in limited settings. The advantages of smear light microscopy are the simplicity in 
performing the test (no sophisticated technical expertise is required), low cost, high 
specificity in high TB endemic areas and ensuring that the most infectious TB cases 
can be identified. A major limitation of smear microscopy is low and variable sensitivity, 
particularly in HIV-positive individuals.22–24 The sensitivity of conventional light 
microscopy is 53.8% on a single smear and 11.1% higher if a second smear is done.25 
With fluorescence microscopy the sensitivity increases by 10% and with chemical 
treatment and centrifugation the overall increase is 18% compared to unprocessed 
direct smear.26,27 However, amongst HIV-positive cases the sensitivity of a single 
smear ranges from only 23% to 50%.28–30 
The gold standard of TB diagnosis is sputum culture for mycobacteria which has the 
disadvantage of being a slow and expensive test, requiring sophisticated laboratory 
infrastructure and technical expertise.31 A mycobacterial culture test on solid media 
takes up to 6 to 8 weeks, however, this delay has been reduced to between 8 and 16 
days with the introduction of new Mycobacterial Growth Inhibitor Tube (MGIT) liquid 
culture methods.32 
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Due to the low sensitivity of smear microscopy, especially in HIV-positive cases, and 
the limited availability of adequate laboratory infrastructure to perform mycobacterial 
culture testing many TB cases are missed or their diagnosis is delayed.33   
1.4.1.2 MDR-TB diagnosis 
Phenotypic (culture-based) DSTs that were used historically  can test for drug 
susceptibility for a wide spectrum of drugs: rifampicin, isoniazid, ethambutol, 
pyrazinamide, streptomycin, amikacin, kanamycin, capreomycin, ethionamide, 
ofloxacin, moxifloxacin.19,34 The limitation of phenotypic DSTs is that they require a 
positive culture result first before testing for susceptibility can start, which takes a 
further 2 to 3 weeks. 
1.4.2 Molecular (genotypic) diagnostic tests 
In order to address the limitations of smear microscopy and culture, a number of more 
sensitive and rapid molecular diagnostic tests have become available.22,23 The 
expectation was that these new molecular diagnostic tests would increase the number 
of cases detected and quicker diagnosis would facilitate early treatment initiation. Both 
of these factors could reduce the transmission of TB and ultimately the burden of TB. 
In addition, many of the new molecular diagnostic tests have the ability to test 
simultaneously for the presence of Mycobacterium tuberculosis complex (MTB) and 
drug resistance. Two of these new molecular tests have been implemented in South 
Africa: GenoType® MTBDRplus (Hain Lifescience, Nehren, Germany) Line Probe 
Assay (LPA)35, endorsed by the WHO in 2008, and Xpert® MTB/RIF (Cepheid, 
Sunnyvale, CA, USA)36, endorsed by the WHO in 2010. 
1.4.2.1 MTBDRplus Line Probe Assay  
A key benefit of LPA is the simultaneous diagnosis of MTB and drug susceptibility 
testing for both rifampicin and isoniazid resistance. A meta-analysis of ten LPA studies 
has reported high sensitivity for rifampicin resistance of 98.1% (95% CI 95.9 to 99.1) 
and specificity of 98.7% (95% CI 97.3 to 99.4) with sensitivity for isoniazid resistance 
of 84.3% (95% CI 76.6 to 89.8) and specificity of 99.5% (95% CI 97.5 to 99.9).37 A 
further benefit of LPA is the availability of a test result within 1 to 2 days with smear-
positive specimens; however, delays has been reported for smear-negative 
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specimens as the test is undertaken on culture isolates.37 A limitation of LPA is that it 
requires substantial technical skills and costly equipment, and is only suitable for use 
in large central laboratories.  
1.4.2.2 Xpert® MTB/RIF  
Xpert® MTB/RIF (Xpert) simultaneously detects MTB and RMP-R, however unlike 
LPA, Xpert does not detect isoniazid resistance. A Cochrane Review of fifteen studies 
with Xpert as the initial test replacing smear microscopy, reported a pooled sensitivity 
of 88% (95% CI 83 to 92) and specificity of 98% (95% CI 97 to 99) for detecting MTB, 
with a lower sensitivity for HIV-positive cases of 80% (95% CI 67 to 88).38 For 
rifampicin resistance the sensitivity was 94% (95% CI 87 to 97) and specificity was 
98% (95% CI 97 to 99). Key benefits of the Xpert test are that the equipment does not 
require a high level of technical skills and the equipment is suitable for placement in 
decentralised settings such as district and sub-district laboratories. The result from an 
Xpert test is available in less than 1 day (similar to smear microscopy and compared 
to 17 days for liquid culture and more than 30 days for solid culture).36 Compared to 
other phenotypic DST methods with an average of 75 days, Xpert detects rifampicin 
resistance in less than 1 day.36 
Xpert does come with some disadvantages such as; the shelf life of the cartridges is 
only 18 months, a very stable electricity supply is required for the Xpert instrument, 
the instrument needs to be recalibrated annually, adequate room temperature and 
very high cost of the cartridges. 
1.5 TB diagnostic algorithms in South Africa 
1.5.1 Smear/culture-based algorithm 
Shortly after the WHO policy statement release, South Africa implemented LPA in 
2008 as a replacement for conventional DST. From 2008 until 2011, South Africa used 
a smear/culture-based algorithm with LPA as one of the sequence of tests in the 
algorithm (Figure 2). The smear/culture-based algorithm had two distinctive arms that 
required different combinations of tests. The one arm addressed presumptive cases 
with no previous TB treatment or less than 4 weeks of TB treatment (low MDR-TB risk) 
and the second arm addressed presumptive TB cases with a history of previous TB 
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treatment, those from congregate settings or those in contact with an MDR-TB case 
(i.e. all those at high risk of MDR-TB). The smear/culture-based algorithm required 
that all presumptive TB cases submit two spot sputum specimens one hour apart and 
these were tested with fluorescence smear microscopy. In high MDR-TB risk 
presumptive cases, the second specimen underwent culture testing (BACTEC™ 
MGIT™ 960; BD, Spark, MD, USA). If the test was culture-positive, a LPA was 
undertaken. All new, smear-negative, HIV-positive individuals required a culture test. 
Presumptive TB Cases
2 sputum specimens submitted
Low MDR-TB risk
No previous TB or less 4 weeks 
of TB treatment
High MDR-TB risk
Previous TB or more than 4 
weeks of TB treatment, MDR-TB 
contact, health care worker, 
prisoner
Smear microscopy on both 
specimens
1st specimen smear microscopy 
2nd specimen smear, culture
Smear negative and HIV positive
3rd specimen smear,  culture
Culture positive
LPA for drug susceptibility 
testing
Smear/Culture-based 
Algorithm
 
Figure 2: Smear/culture-based algorithm as stipulated by the South African National TB Programme39 
With the smear/culture-based algorithm, all presumptive TB cases were required to submit two spot 
sputum specimens an hour apart to be tested with fluorescence smear microscopy. The second 
specimen underwent culture testing (BACTEC™ MGIT™ 960; BD, Spark, MD, USA) if the individual 
had a history of previous TB treatment, was from a congregate setting or had an MDR-TB contact. If 
culture-positive, a DST using GenoType® MTBDRplus LPA was undertaken. All new, smear-negative 
HIV-positive individuals required a culture test. 
Abbreviations: TB - tuberculosis; HIV – human immunodeficiency virus; LPA - line-probe assay. 
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1.5.2 Xpert-based algorithm 
As was the case with LPA, South Africa, was an early adopter of Xpert. After the WHO 
policy statement in 2010 recommending the use of Xpert as the initial test for all cases 
at high risk for MDR-TB or HIV-associated TB36, South Africa introduced Xpert in 2011 
as a replacement test for smear microscopy for all presumptive TB cases. The national 
scale-up was completed by 2013 in South Africa, with all facilities using the Xpert-
based algorithm. With the Xpert-based algorithm, one spot specimen was collected 
and tested with Xpert and if TB was detected a second specimen was required and 
underwent smear. If the Xpert test detected rifampicin resistance, a culture and LPA 
was undertaken. If the Xpert test was negative and the individual was HIV-positive, 
the second specimen underwent culture and LPA. In the Western Cape, South Africa, 
the algorithm was slightly different with two spot specimens taken (Figure 3).  
1.6 Challenges associated with implementing new diagnostic tests 
There has been an increase in the number of new TB and RMP-R TB diagnostic tests 
since 2007.23 Diagnostic tests, such as LPA and Xpert, were endorsed by the WHO 
based on limited data, largely based on the speed of diagnosing TB and RMP-R TB 
and improved test sensitivity.24,36 There are many other new diagnostic tests currently 
under development and testing, for example the Xpert Ultra (Cepheid, Sunnyvale, CA, 
USA) cartridge, Genedrive MTB/RIF (Epistem Ltd, Manchester, M13 9XX, UK), 
Signature Mapping™ for Tuberculosis Detection Diagnostic System (Applied Visual 
Sciences Inc., Virginia, US) and loop-mediated isothermal amplification (Eiken 
Chemical Company Ltd, Tokyo, Japan).40 
The endorsement by the WHO is an important step for the introduction of new 
diagnostic tests, however, numerous authors have suggested that the current process 
is not sufficient and that more evidence is needed to go beyond the accuracy 
(sensitivity and specificity) of a new proposed diagnostic test.22,41,42 Further evidence 
is required that a new diagnostic test would work effectively in a routine operational 
setting with limited resources and in specific epidemiological settings.43  The focus of 
policy recommendations issued by the WHO should be on the most cost-effective and 
efficient (more TB and RMP-TB cases detected with a shorter time to diagnosis) way 
of introducing and scaling up new diagnostic test within existing algorithms and varied 
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epidemiological settings. Policy recommendations are generally only based on 
demonstration studies, and recommendations with these specific focus areas 
mentioned above, are not possible at the time of endorsement due to the lack of data 
from implementation studies.   
Presumptive TB Cases
2 sputum specimens submitted
1st specimen Xpert ®MTB RIF
MTB positive 
rifampicin 
susceptible
MTB positive 
rifampicin 
resistant
MTB positive 
rifampicin 
inconclusive
MTB negative
2nd specimen
smear 
microscopy
2nd specimen
smear, culture
Culture positive
LPA for drug susceptibility 
testing
If HIV positive
2nd specimen
smear, culture 
Xpert-based 
Algorithm
 
Figure 3: Xpert-based algorithm as stipulated by the South African National TB Programme and as 
implemented in Cape Town.19 With the Xpert-based algorithm, two spot specimens were collected 
and the first was tested with Xpert. If TB was detected and RMP-susceptible, the second specimen 
underwent smear and if RMP-R or RMP-inconclusive was detected, a culture and LPA test was 
undertaken. The second specimen underwent culture and LPA if the Xpert test was negative and the 
individual was HIV-positive. 
Abbreviations: TB - tuberculosis; HIV – human immunodeficiency virus; MTB – mycobacterium 
tuberculosis; RIF – rifampicin; LPA - line-probe assay. 
These demonstration studies produce limited data with a focus on test accuracy under 
optimised programme conditions, operational aspects of the single test and some 
patient-related outcomes (for example diagnostic delay due to test turnaround 
times).44 A further limitation of demonstration studies is that they are usually performed 
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at sites selected for their capacity to perform the studies (generally at moderate scale), 
therefore, these studies over-estimate effectiveness due to greater resource 
availability than would be available in routine operational settings.22,45,46 
Due to the limitation of the WHO endorsement process for new diagnostic tests, it has 
been proposed that a three-stage process should be adopted in order to provide 
relevant evidence for the implementation of new TB diagnostic test.22,23  
The first stage would be before policy recommendations are released and should 
include technical details to inform the policy. The questions asked during this stage 
should include whether the new diagnostic test has the technical requirements 
(sensitivity and specificity) and would be operationally capable (test turnaround time, 
time to diagnosis and treatment, and improved case detection for TB and/or RMP-R 
TB) to improve TB diagnosis. Studies to provide data for this stage would include 
controlled validation and demonstration studies.        
The second stage would be before the new TB diagnostic test is scaled-up and should 
include evidence on the effectiveness of the test in terms of both cost and diagnosing 
more TB and RR-TB cases. During this stage it should be evaluated where best the 
new diagnostic test would fit taking existing diagnostic tests already used into 
consideration. It should be determined how and where the new test should be 
implemented in existing diagnostic algorithms and if specific populations (for example 
HIV-positive) would benefit based on the sensitivity and specificity of the new test as 
well as if drug resistance is tested for. Studies conducted to collect data during this 
stage should be done within routine programmatic conditions and at the level of the 
health system where the test would most likely be used (laboratory or point-of-care). 
These studies should be done in various countries representing various 
epidemiological populations (TB, RMP-R TB and HIV prevalence) and availability of 
health resources. Modelling during this stage could also be conducted to evaluate the 
effectiveness of the new test within various algorithms and populations with various 
epidemiological characteristics.  
The third and final stage would be during and after scale-up of the new diagnostic test. 
This stage should evaluate if the new diagnostic test has been implemented optimally 
and identify and test interventions to inform the optimum use of the new test within 
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routine operational settings, in respect of both cases detected and the cost per case 
detected. Questions such as the level of adherence to the newly introduced diagnostic 
algorithm, and if the appropriate epidemiological population (HIV-positive, TB cases 
with a previously history of TB treatment) benefits from the new test should be 
evaluated. The long-term sustainability of cost to the health system should also be 
determined. Data to evaluate this final stage could be collected from routine recording 
and reporting systems. During this stage previously developed models could be 
improved, or new models developed, through further knowledge and data collected 
during this final stage of evaluation.22,47  
1.7 Challenges in interpreting the implementation of new diagnostic tests 
The decision by policy makers about which new test to implement in a diagnostic 
algorithm can be complicated. Decision makers require much more information than 
what is usually available on performance of a test in ideal conditions. They need to 
understand the operational and pragmatic impact of the introduction of a new 
diagnostic test within an already existing diagnostic algorithm. Decision makers need 
to take many factors into consideration including the best combination of diagnostic 
tests, the resources required, who should be tested and the TB epidemiology in the 
setting (prevalence of TB, HIV coinfection and drug resistance). These factors are 
often not known by decision makers and therefore, expensive and time consuming 
clinical trials are required to make decisions,48 or decisions are made without all the 
necessary information. 
Decision makers require evidence on what the best combination of tests are for their 
context and which test should be used for which patients as well as whether the new 
diagnostic test would replace an existing test or used in combination with existing 
tools. A further factor that could also make a decision to implement a new test more 
complex is if the population characteristics changes over time, for instance, if the TB 
prevalence declines over time. These changes in population characteristics could 
influence the long-term sustainability of using the new diagnostic test considering that 
many of the new diagnostic tests are much more expensive compared to those already 
used in countries. Two studies conducted in South Africa for example, reported the 
cost per Xpert test performed at US$25.90 and US$14.93 compared to the cost for 
smear at US$1.58 and US$3.40.49,50 
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1.8 Modelling and the use of modelling in TB  
Models are simplified representations of complex real life scenarios, situations or 
processes. Modelling is useful in filling knowledge gaps when assessing the impact of 
interventions on a population-level or on a health system due to the lack of empirical 
evidence or in addition to empirical evidence. The information produced through 
modelling and the effects of potential interventions can also be used to plan future 
studies.47,51   
The advantage of modelling is that interventions that would take months or years to 
have an impact on the health system, in real life, can be modelled in a few minutes or 
hours. Sensitivity analysis can be used to investigate how certain variables affects a 
single, independent variable and how much changes in those variables will change 
the independent variable, for example, the impact of various levels of TB prevalence 
amongst presumptive cases on the number of TB cases detected. Models can be used 
to model situations as they occur in real life rather than the idealised situation, for 
example, the lack of adherence to policy. 
The data sources usually used to drive models are derived from published literature 
(i.e. meta-analysis, randomised control trials, cohort studies, global reports, 
unpublished literature, expert opinion, field data), and from assumptions. Therefore, 
models are only as good as the level of detail available to develop the logic of the 
model and the availability and accuracy of the data to drive the model.47,52  
Models and the assumptions they are based on will not always stay relevant as 
systems, procedures and settings change over time.47 Models should therefore be 
updated as more data becomes available or due to assumptions changing over time. 
The use of models by decision makers has been limited.47,53 The development and 
validation of models usually takes time and models may therefore not be ready in time 
for decision makers to be informed by model results.  Therefore, the balance between 
anticipating future policy questions and responding to current policy question is critical 
for models to be of any use in policy decisions.47  
Two modelling approaches previously used in TB control are transmission 
(epidemiological) modelling and operational modelling.  
13
Stellenbosch University  https://scholar.sun.ac.za
1.8.1 Transmission modelling 
Transmission modelling is a simplified means of describing the transmission of 
communicable disease, such as TB, through populations or individuals. These models 
are formulated through mathematical equations and generally divide the population 
under investigation within compartments based on disease status as represented in 
Figure 4. Transmission modelling can be used to predict the long-term impact of 
interventions on the community by projecting TB incidence, prevalence, and mortality.  
Risk factors Risk factors Risk factors Risk factors
Exposure TB Infection
Infectious 
TB
Non-
Infectious 
TB
Death
Susceptible (S) Infectious (I) Recovery (R)Births βI Ƴ 
µ µ µ 
A
B
 
Figure 4: (A) A schematic representation of different disease states in TB epidemiology. 
 
(B) Example of a simple transmission model representing different disease states. 
Differential equation involving variables S, I and R in respect of their rate of change in time t with an 
assumed death and birth rate µ using a fixed population N = S(t) + I(t) + R(t): 
 𝑆𝑆(𝑡𝑡)′ = 𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑
=  𝜇𝜇𝜇𝜇 − 𝑏𝑏𝑆𝑆𝑏𝑏 −  𝜇𝜇𝑆𝑆, 𝑏𝑏(𝑡𝑡)′ =  𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑
=  𝑏𝑏𝑆𝑆𝑏𝑏 − 𝑟𝑟𝑏𝑏 −  𝜇𝜇𝑏𝑏,R(t)’ =  𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑
=  𝑟𝑟𝑏𝑏 −  𝜇𝜇𝜇𝜇 
A TB transmission model was developed to evaluate the impact of different 
implementation strategies for scaling up the use of Xpert on TB incidence in India.54 
They developed a model of TB transmission, care-seeking behaviour, and 
diagnostic/treatment practices in India and explored the impact of six different Xpert 
rollout strategies. The model included the following six scenarios; (baseline scenario) 
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no improved diagnostic testing, (scenario 1) 40% of HIV-positive and high MDR-TB 
risk (had a history of previous TB treatment) presumptive TB cases presenting to the 
public sector had an Xpert, (scenario 2) the same as scenario 1 as well as an additional 
20% of other presumptive TB cases presenting to the public sector had an Xpert, 
(scenario 3) the same as scenario 1 as well as an additional 20% of other presumptive 
TB cases presenting to private practitioners had an Xpert, (scenario 4) a combination 
of scenarios 2 and 3, (scenario 5) 20% of all presumptive TB cases in public or private 
sector had an Xpert, (scenario 6) 20% of presumptive TB cases diagnosed with TB in 
the public sector were referred for further diagnosis to the private sector with no Xpert 
available in either sector.  
The model indicated that with the baseline scenario TB incidence would decrease 
annually by 2% over a 5 year period. The model indicated that the best strategy would 
be scenario 5 where 20% of all presumptive TB cases in public or private sector had 
an Xpert, with a 14.1% decrease in TB incidence. Results from the model suggest that 
the rollout of Xpert could substantially reduce the burden of tuberculosis due to current 
poor diagnosis of TB in India. The model also highlighted, that with the rollout of Xpert, 
the impact does not only rely on the sensitivity and specificity of the Xpert test but also 
on the behaviour of patients and providers, the level of access to new diagnostic tests 
and the availability of treatment following diagnosis. 
The impact of using a new TB diagnostic test in the United Republic of Tanzania was 
projected with the use of a TB transmission model.55 The model was calibrated using 
data from United Republic of Tanzania, including the epidemiology of tuberculosis and 
HIV infection. The influence of contextual factors and the impact of the introduction of 
a new more sensitive TB diagnostic on the projected TB epidemic was assessed. The 
model indicated that with the use of smear microscopy, the incidence of tuberculosis 
would decline by an average of 3.9% per year compared to a decline of 4.2% if a new 
more sensitive diagnostic test was added to the diagnostic algorithm. The decline in 
TB incidence however would be less if the algorithm with the new added diagnostic 
test is less sensitive than existing algorithm and if TB symptomatic individuals delayed 
accessing health services.  
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1.8.2 Operational modelling 
Many operational models use a discrete event simulation (DES) approach where the 
system is first defined in terms of its most important elements, including the items or 
people processed through the system, resources, activities, rules and the process 
flow. The required outputs of the model are defined (e.g. productivity, costs, 
identification of bottlenecks, capacity and sensitivity to changes), along with the key 
input parameters to be investigated. Once the system is defined and appropriate 
parameter inputs are assigned (e.g. the number of items entering the system, the 
quantity of resources and the time for completing particular activities), then simulations 
can be run to assess the relative effect of different input assumptions on the modelled 
outputs.56 
1.8.2.1 Operational models in commercial settings: 
Operational models in industrial and commercial settings are widely used to plan and 
assess the performance and efficiency of processes.57 A global company (Hayward 
Tyler) supplying mission-critical electric motors and pumps for the oils, gas, nuclear, 
industrial and chemical markets required a method of evaluating an ambitious plan to 
increase their business growth strategy and to visually communicate this strategy to 
employees, customers and investors.58 The company undertook a business 
transformation project to focus on maximising efficiency, align capacity to demand and 
boosting profitability. The company developed a predictive model representing a 
“virtual factory” of the manufacturing operations, as the operations would evolve over 
a 5 – 10 year period. The model incorporated the factory production plant capacity and 
performance, factory layout, equipment requirements, shift patterns, and production 
demands. The model identified the requirements that will need to be considered, in 
the business growth strategy, in order to meet production and client demands as well 
as to maximise profitability. 
1.8.2.2 Operational models in health settings: 
Operational models have also increasingly been used to improve performance of the 
health sector. The use of operational models in health systems is common in high-
income countries, but less so in middle- to low-income countries. A systematic review 
was done to evaluate the extent, quality and value of computer simulation modelling 
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in population health and health care delivery.59 The review found that simulation 
modelling was used in varied health care related areas, including hospital scheduling 
and organization, communicable disease screening, costs of illness and economic 
evaluation. The authors concluded that simulation modelling is a powerful method to 
inform policy makers in the provision of health care. 
A second review of the use of DES in modelling health-care systems found diverse 
objectives among these studies.60 The review concluded that most of the reviewed 
studies reported on unit specific issues to find solutions to specific problems in 
individual units of health-care systems, such as staff-demand mismatch in accident 
and emergency departments, reducing waiting times in outpatient clinics, and better-
utilising hospital beds. 
1.8.2.3 Operational models in TB: 
Operational modelling can be used to project the impact of interventions on health 
system costs and infrastructure, as well as patient access and outcomes. Operational 
modelling can therefore be used to evaluate how and where a new test should be 
implemented in existing diagnostic algorithms, as well as evaluate if specific 
populations (for example HIV-positive patients) benefit from the new test.  
A further benefit of an operational model is that the effect or lack of effect after the 
introduction of a new test can be evaluated in order to explain findings from routine 
data and empirical studies. Operational models can help understand the health system 
impact in relation to the number of TB and RMP-R TB cases detected and the cost per 
case detected.  
The key element that make up operational models are: entities - representing people 
or objects moving around a process (e.g. patients, specimens); attributes associated 
with entities (e.g. HIV status, previous history of TB treatment); queues representing 
waiting areas for entities (e.g. waiting rooms); activities where actions take place (e.g. 
sputum collection, return results); resources required to complete an activity (e.g. 
laboratory equipment and staff). Figure 5 is a simplified representation of such an 
operational model.  
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A study from United Republic of Tanzania used a discrete event simulation model with 
details on patient pathways to TB diagnosis integrated with a cost effectiveness 
analysis to enhance policy decisions on new diagnostics.56 The study used data from 
two TB diagnostic centres to map patient pathways for all presumptive TB cases and 
individuals treated for TB as well as to map sputum sample pathways through the 
laboratory. The model was used to determine the impacts and cost of three alternative 
TB diagnostic algorithms compared to Ziehl Neelsen microscopy (baseline scenario). 
The alternative TB diagnostic algorithms were light emitting diode (LED) fluorescence 
microscopy (scenario 1), and two alternative algorithms using the molecular diagnostic 
test such as Xpert MTB/RIF with full rollout (scenario 2) and partial rollout (scenario 3) 
only testing HIV-positive cases and individuals with a history of previous TB treatment 
with the new molecular test. All comparisons are relative to the baseline scenario.  
TB diagnostic and treatment centre
ReceptionWaiting area
Return resultSputum collection
Sputum transport
Sputum Result
Sputum reception 
and sorting
Smear microscopy
Culture and LPA
Xpert
Smear 
result
Culture 
result
Examine
Xpert result
Examination
slide
Prepare
slide
Prepare
cartridge
Load and
run machine
Sample
storage
Slide
storage
LPA
result
Sample
storage
Centralised diagnostic laboratory
Sample
storage
LPA
Prepare
culture
Sample
storage
Culture
Sample
storage
Prepare
LPA
 
 
Figure 5: A simplified representation of an operational model. The operational mode incorporated 
specimen flow from specimen collection, through laboratory test procedures, to a result being provided 
to the patient. 
The study found that operational modelling using DES could provide useful projections 
of the effects on the health system, running costs, and patient outcomes of alternative 
TB diagnostic strategies in the diagnostic centres of United Republic of Tanzania. The 
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model indicated that with the implementation of LED fluorescence microscopy the 
number of TB cases detected with a positive test result would increase per year from 
562 (95% CI 545 – 578) to 670 (95% CI 648 – 691) with scenario 1, 1060 (95% CI 
1041 – 1079) with scenario 2, and 898 (95% CI 882 – 915) with scenario 3. The 
number of false positive TB cases would decrease per year from 446 (95% CI 434 – 
458) to 355 (95% CI 343 – 367) with scenario 1, 53 (95% CI 48 – 57) with scenario 2, 
and 188 (95% CI 178 – 197) with scenario 3.  
1.9 Modelling and the impact of Xpert in South Africa  
An initial modelling study conducted using a transmission model, before the rollout of 
Xpert in South Africa, estimated the impact of rolling out Xpert on TB-associated 
morbidity and mortality, in five countries of southern Africa, including South Africa, 
over a 10 year period.61 This model, in the absence of pre-existing data, had to make 
use of assumptions including the prevalence of TB amongst presumptive cases and 
the time it would take for a diagnosis to be completed. The model compared two 
diagnostic algorithms, with the first algorithm (smear/culture-based) comprising of 
smear microscopy for all presumptive TB cases and culture testing for all smear-
negative presumptive TB cases with a history of previous TB and the second algorithm 
(Xpert-based) using Xpert on all presumptive TB cases who are HIV-positive or do not 
know their HIV status. 
The model indicated that over a 10 year period, the average number of TB cases 
correctly detected (true positive) with the smear/culture-based algorithm would be 
151,000 (95% CI 100,000 – 215,000) and 175,000 (95% CI 120,000 – 245,000) with 
the Xpert-based algorithm. The average diagnostic cost per presumptive TB case 
diagnosed would be US$31 (95% CI 25 – 38) with the smear/culture-based algorithm 
and US$45 (95% CI 40 – 50) with the Xpert-based algorithm. The average cost per 
true positive TB cases diagnosed would be US$181 (95% CI 117 – 287) with the 
smear/culture-based algorithm and US$211 (95% CI 136 – 334) with the Xpert-based 
algorithm.  
The model estimated a large population level impact over a 10 year period for all five 
countries with the rollout of Xpert as a result of more TB cases detected and a 
reduction in the time to initiating TB treatment. The model indicated a decline in TB 
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prevalence of 186 (95% CI 86 – 350) per 100,000 population, TB incidence by 35 
(95% CI 13 – 79) per 100,000 population and annual TB mortality by 50 (95% CI 23–
89) per 100,000 population.  
A population-level decision model estimated the impact and cost of scaling up Xpert 
in South Africa.62 The model indicated that with full scale up of Xpert the number of 
TB cases detected would increase by 30%-37% per year and the number of MDR-TB 
cases by 69%-71%. The cost per presumptive TB case tested would increase by 
between 53%-57% and the cost per TB case detected would increase 15%-17%.  
After the rollout of Xpert in South Africa, a number of studies were conducted to 
evaluate the implementation of Xpert in South Africa which. A prospective cluster-
randomised trial of Xpert compared to smear microscopy and culture conducted in a 
primary health care clinic in Cape Town, South Africa, showed an increase in the 
proportion of bacteriologically confirmed TB cases initiating TB treatment within 3 
months. The study reported that amongst presumptive TB cases, the yield of 
bacteriologically confirmed TB was 17% (167/1,003) with smear/culture and 26% 
(257/982) with Xpert (risk ratio 1.57, 95% CI 1.32–1.87, p = 0.001). Of these 
bacteriologically confirmed TB cases the proportion who initiated TB treatment within 
3 months was 23% (229/1,003) with smear/culture and 28% (277/982) with Xpert (risk 
ratio 1.24, 95% CI 1.06–1.44, p = 0.013).63 
The XTEND (Xpert for TB—Evaluating a New Diagnostic) trial was a pragmatic two 
arm cluster-randomised trial with the primary outcome to determine if mortality at 6 
months from enrolment differed between a smear/culture and an Xpert-based 
algorithm.64 The trial found no difference in 6-month mortality with Xpert (3.9% with 
Xpert compare to 5% with the smear/culture-based algorithm (adjusted risk ratio 1.10, 
95% CI 0.75 to 1.62).  
As part of the XTEND trial, a cross-sectional exit study was done to evaluate whether 
the likelihood of a health care worker requesting a sputum from individuals with TB 
symptoms who have already accessed a clinic, changed with the rollout of Xpert in 
South Africa.65 The study found that there was no significant difference between 
algorithms in the likelihood that a health care worker requesting a sputum for TB 
investigation, 26% in the Xpert and 19.8% in the smear/culture-based algorithm 
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(adjusted prevalence ratio 1.31, 95% CI 0.78 to 2.20). When restricted to all 
participants attending the clinic specifically due to TB symptoms the difference was 
49.1% with Xpert and 29.9% in the smear/culture-based algorithm adjusted 
prevalence ratio 1.38 (95% CI 0.88 to 2.16). As part of the same trial, an evaluation 
was done to determine the adherence to TB diagnostic algorithm after an initial sputum 
smear or Xpert-negative test for HIV-positive individuals.66 Adherence was higher in 
the smear/culture-based algorithm (32%) than in the Xpert-based algorithm (14%) 
(adjusted risk ratio 0.34, 95% CI 0.17 to 0.65).  
The PROVE IT (Policy Relevant Outcomes from Validating Evidence on ImpacT) 
study, done in Cape Town by the Desmond Tutu TB Centre, Stellenbosch University, 
evaluated the impact of the Xpert-based diagnostic algorithm within a routine 
operational setting in Cape Town.  
1.9.1 Three important findings from the Prove IT study are outlined below.  
1.9.1.1 TB yield  
A stepped-wedge analysis of TB yield (the proportion of presumptive cases diagnosed 
with TB) was undertaken in five sub-districts as facilities transitioned from using a 
smear/culture-based algorithm to an Xpert based algorithm over 7 time periods 
between 2010 and 2013.67 The study found a decline in TB yield over time from 23.6% 
(1911/8083) at T1 to 17.4% (1422/8126) at T7. This was possibly attributable to a 
declining TB prevalence. The decrease in yield was not attributable to an increase in 
case-finding as the proportion of the population tested did not increase over the seven 
time periods evaluated (the proportion of the population tested was 0.95%, 0.93%, 
0.85%, 0.84%. 0.80%, 0.84%, 0.89%). When the time-effect was taken into 
consideration, there was no difference in TB yield - TB yield was 19.3% in the Xpert-
based algorithm compared to 19.1% in the smear/culture-based algorithm with a risk 
difference of 0.3% (p=0.796). Factors that may well have contributed to the yield parity 
between algorithms included inconsistent implementation of the Xpert-based 
algorithm and the frequent use of culture tests in the smear/culture-based algorithm. 
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1.9.1.2 RMP-R TB yield  
TB cases included in the stepped-wedge study of TB yield in five sub-districts over 
seven one-month time periods, before, during and after the introduction of the Xpert-
based algorithm as described above, were analysed to assess the proportion of RMP-
R TB cases identified pre-treatment and during the course of 1st line TB treatment.68  
The study found that the Xpert-based algorithm was more effective in identifying RMP-
R TB cases than the smear/culture-based algorithm. Pre-treatment, there was a higher 
probability of having DST undertaken (RR=1.82, p<0.001) and of being diagnosed with 
RMP-R TB (RR=1.42, p<0.001) in the Xpert-based algorithm than in the 
smear/culture-based algorithm. During the course of 1st-line TB treatment, there was 
no significant differences between algorithms in either the proportion of TB cases with 
DST undertaken (RR=1.02, p=0.848) or with RMP-R TB diagnosed (RR=1.12, 
p=0.678). Overall 8.5% of TB cases were detected with RMP-R TB in the Xpert-based 
algorithm compared to 6% in the smear/culture-based algorithm.  
This difference was attributable to simultaneous screening for MTB and RMP-R in the 
Xpert-based algorithm. The study suggests that this is important and that the previous 
strategy of only screening those at high risk of RMP-R TB pre-treatment may have 
resulted in missed cases. The proportion screened and identified with RMP-R TB 
during the course of 1st line treatment was not higher in the smear/culture-based 
algorithm, suggesting that cases missed pre-treatment were not tested and diagnosed 
during the course of 1st line treatment.      
1.9.1.3 Laboratory costs  
Laboratory costs at the central National Health Laboratory were compared in the 
smear/culture-based algorithm (2011) and the Xpert-based algorithm (2013). The 
study used an ingredients-based costing approach based on the cost per unit and 
quantities utilised for buildings, equipment, consumables, staff and overheads.69 The 
allocation of costs was based on reviews of standard operating procedures and 
laboratory records as well as direct observation and timing of the test procedures. 
The study found a 43% increase in overall PTB laboratory costs from $440,967 in the 
smear/culture-based algorithm to $632,262 in the Xpert-based algorithm during 3-
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month periods in 2011 and 2013 (all costs were expressed in 2013 terms). The cost 
per TB case diagnosed increased by 157%, from $48.77 in the smear/culture-based 
algorithm to $125.32 in the Xpert-based algorithm. The mean total cost per RMP-R TB 
case diagnosed (cost for TB diagnosis plus marginal cost for RMP-R diagnosis) was 
similar at $190.14 in the smear/culture-based algorithm compared to $183.86 in the 
Xpert-based algorithm with 95 and 107 cases diagnosed in respective algorithms. The 
additional total diagnostic costs translated to a cost of $6,274 per additional RMP-TB 
case diagnosed in the Xpert-based algorithm compared to the smear/culture-based 
algorithm. The difference in TB prevalence between the two time periods and 
differences in adherence to the algorithms may have contributed to the increased cost 
per TB case diagnosed in the Xpert-based algorithm.  
All three of these observational studies had limitations. It was difficult to control for 
confounding due to for example the differences in background TB prevalence over 
time and differences in health system performance (e.g. clinicians adherence to TB 
diagnostic algorithms). Adherence to TB diagnostic algorithm is difficult to assess 
using routine laboratory data. Clinical staff requesting diagnostic tests may not always 
follow diagnostic algorithms as stipulated by policy, therefore, tests may sometimes 
be requested other than what is stipulated in the diagnostic algorithm (reflex testing) 
which may also include unnecessary repeat tests. These inconsistencies in adherence 
to diagnostic algorithm made it difficult to compare the performance of the 
smear/culture and Xpert-based algorithms. It was also difficult to address bias due to 
the non-random allocation of sites to different study arms.  
As part of the PROVE IT study of new TB diagnostics in South Africa, we developed 
an operational model using a discrete event simulation approach for the existing 
smear/culture-based algorithm and the newly introduced Xpert-based algorithm in 
Cape Town. The model was developed, validated and calibrated using data collected 
in PROVE IT, from the studies described above. 
1.10 Aim  
The overall aim of this dissertation was to develop and validate an operational model 
for the diagnosis of TB and RMP-R TB in Cape Town, that could be used to (1) explain 
why the expected increase in the number of TB cases detected (TB yield) was not 
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found, (2) model the effect of interventions to improve the detection of TB and RMP-
R TB in terms of the number of TB and RMP-TB cases detected, (3) model the impact 
of variable model inputs on laboratory cost for TB and RMP-TB detected, (4) model 
strategies to reduce laboratory cost for TB diagnosis and (5) model the effect of 
introducing a more sensitive molecular diagnostic test (for example Xpert Ultra) as a 
replacement for Xpert on the number of TB and RMP-R TB cases detected. 
1.11 Layout of this dissertation 
In chapter 2 (Operation modelling: The mechanisms influencing TB diagnostic 
yield in an Xpert based diagnostic algorithm), I address why the expected increase 
in the number of TB cases detected (TB yield) was not found in the PROVE IT 
empirical study. 
In this study, I used an operational model to compare the diagnostic yield in the 
smear/culture and Xpert-based algorithms and to investigate the mechanisms 
influencing TB yield in Cape Town. This allowed us to better understand why we did 
not find the expected increase in TB diagnostic yield in the PROVE IT empirical 
study.67 Detail regarding model development and validation as well as sensitivity 
analysis can be found in the supplement for chapter 2.  
In chapter 3 (Improving rifampicin resistant tuberculosis diagnosis with Xpert® 
MTB/RIF: modelling interventions and costs), I model interventions to improve the 
diagnosis of RMP-R TB in terms of the number of RMP-TB cases detected and cost. 
In this study, I used an operational model to compare the number and proportion of 
RMP-R TB cases identified, and the cost per RMP-R TB case identified between a 
smear/culture and an Xpert-based algorithm. Since adherence to the Xpert-based 
algorithm in South Africa has been sub-optimal, I also evaluated the effect of increased 
adherence to the algorithm and increased HIV testing amongst presumptive TB cases 
on the number and proportion of RMP-R TB cases identified. 
In chapter 4 (High laboratory cost predicted per tuberculosis case diagnosed 
with increased case finding without a triage strategy), I model strategies to reduce 
the cost per TB case detected.   
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In this study, I used the operational model to simulate the effect of increased case 
finding and triage strategies on laboratory costs per TB case detected and per 
additional TB case detected in the Xpert-based compared to the smear/culture-based 
algorithm. I also assessed the effect on laboratory costs if the Xpert cartridge price 
was reduced. 
In chapter 5 (Modelling the impact of Xpert® MTB/RIF Ultra as a replacement test 
for Xpert® MTB/RIF), I model the effect of introducing a more sensitive molecular 
diagnostic test (for example Xpert Ultra) on the number of TB and RMP-TB cases 
detected. 
In this study, I adapted the operational model to compare the detection of TB and 
RMP-TB cases between an Xpert-based algorithm, as currently implemented in Cape 
Town, South Africa, and the newly develop Xpert MTB/RIF Ultra (not yet 
implemented). 
1.12 Ethics approval and permissions 
Stellenbosch University’s Health Research Ethics Committee (IRB0005239) 
(N10/09/308) and The International Union Against Tuberculosis and Lung Disease’s 
(59/10) Ethics Advisory Group approved the study. The City Health Directorate, 
Western Cape Health Department and National Health Laboratory Service granted 
permission to use routine health data. 
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Chapter 2: Operation modelling: The mechanisms influencing 
TB diagnostic yield in an Xpert based diagnostic algorithm 
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Reprinted with permission of the International Union Against Tuberculosis and Lung 
Disease. Copyright © The Union. 
 
Summary: In this chapter, I address why the expected increase in the number of TB 
cases detected was not found in our empirical study (PROVE IT). I developed and 
validated an operational model using routine data from the empirical study 
representing TB diagnostic algorithms as implemented in Cape Town. I used the 
model to compare the number of TB cases detected in a smear/culture-based and an 
Xpert-based algorithm using identical input parameters (population characteristics and 
adherence to diagnostic algorithms) for both algorithms.  
The model indicated that, with identical population characteristics and adherence to 
diagnostic algorithms, there was an increase in the number of TB cases detected with 
the Xpert-based compared to the smear/culture-based algorithm. The model indicated 
that a decrease in TB prevalence during the rollout of Xpert as well as different levels 
in adherence to the diagnostic algorithms were some of the reasons that the empirical 
study did not find an increase in TB yield. Furthermore, in our setting, the high 
efficiency of the central laboratory as well as extensive use of culture testing for smear-
negative cases in the smear/culture-based algorithm limited the observed benefit of 
the rollout of the Xpert-based algorithm.  
 
 
 
 
My contributions: In this chapter, I did the development, validation and sensitivity 
analysis of the model. I conducted the overall data management and data analysis for 
this chapter as well as conceived, designed and performed the experiments of running 
the different scenarios in the model. I wrote the manuscript and submitted the final 
manuscript for publication to the peer-reviewed journal.  
Co-author contribution: Pren Naidoo, Ivor Langley and Nulda Beyers contributed 
with conceiving and designing experiments. The co-authors reviewed the draft 
manuscript and approved the final draft manuscript for submission.    
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Operational modelling: the mechanisms influencing TB
diagnostic yield in an XpertWMTB/RIF-based algorithm
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S UMMA R Y
S E T T I NG : Cape Town, South Africa.
OB J E C T I V E : To compare the diagnostic yield for smear/
culture and Xpertw MTB/RIF algorithms and to
investigate the mechanisms influencing tuberculosis
(TB) yield.
METHOD : We developed and validated an operational
model of the TB diagnostic process, first with the smear/
culture algorithm and then with the Xpert algorithm. We
modelled scenarios by varying TB prevalence, adherence
to diagnostic algorithms and human immunodeficiency
virus (HIV) status. This enabled direct comparisons of
diagnostic yield in the two algorithms to be made.
R E SU LT S : Routine data showed that diagnostic yield
had decreased over the period of the Xpert algorithm
roll-out compared to the yield when the smear/culture
algorithm was in place. However, modelling yield under
identical conditions indicated a 13.3% increase in
diagnostic yield from the Xpert algorithm compared to
smear/culture. The model demonstrated that the exten-
sive use of culture in the smear/culture algorithm and the
decline in TB prevalence are the main factors contrib-
uting to not finding an increase in diagnostic yield in the
routine data.
CON C L U S I O N : We demonstrate the benefits of an
operational model to determine the effect of scale-up
of a new diagnostic algorithm, and recommend that
policy makers use operational modelling to make
appropriate decisions before new diagnostic algorithms
are scaled up.
K E Y WORD S : TB diagnostic yield; modelling; simula-
tion; TB diagnosis
TUBERCULOSIS (TB) remains a major cause of
morbidity and mortality worldwide. Of the global
estimated 10.4 million incident TB cases in 2015, 1.2
million were infected with the human immunodefi-
ciency virus (HIV).1 The Africa region accounted for
26% of global TB cases, 31% of whom are estimated
to be HIV–co-infected. The main contributing factor
driving the TB epidemic is ongoing transmission due
to undiagnosed TB cases, diagnosed cases not
initiating treatment2–4 and diagnostic and treatment
initiation delays.5,6
Increased investment in recent years has resulted in a
number of new, more sensitive and rapid diagnostic
tests for TB, with the expectation that this would lead
to an increase in the number of cases diagnosed and
earlier diagnosis and initiation of treatment, thus
reducing transmission and, ultimately, the burden of
disease. One of these tests, the XpertwMTB/RIF assay
(Cepheid, Sunnyvale, CA, USA), was endorsed by the
World Health Organization (WHO) and recommend-
ed as the initial diagnostic test for those with suspected
multidrug-resistant TB (MDR-TB) or HIV-associated
pulmonary TB (PTB).7 South Africa replaced smear
microscopy with Xpert as the first test in the diagnostic
algorithm for all presumptive PTB cases in 2011.8
The decision by policy makers about which new
test to implement in a diagnostic algorithm can be
complicated, and factors to be considered include the
best combination of diagnostic tests, the resources
required, who should be tested and the TB epidemi-
ology in the setting (prevalence of TB, HIV co-
infection and drug resistance). Often many of these
factors are not known, and expensive and time-
consuming clinical trials are required to make
informed decisions,9 or decisions are made without
all the necessary information.
The variable results reported from studies evaluat-
ing the implementation of Xpert highlight the com-
plexity in deciding if and how a new diagnostic test
should be implemented within a diagnostic algorithm.
For example, a population-level decision model
estimated that full Xpert coverage would identify
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30% more TB cases (with yield increasing from 15%
to 19%) in South Africa in 2013 compared to smear
and culture.10 A prospective cluster-randomised trial
of Xpert compared to smear microscopy and culture
conducted in a primary care clinic in Cape Town,
South Africa, showed an increase in TB yield from
17% with smear and culture to 26% with Xpert.11 A
study conducted in North Ethiopia among household
contacts of TB index cases showed an increase of
64.3% in TB detection between smear microscopy
(12.8%) and Xpert (35.9%).12 However, other studies
in South Africa and Zimbabwe have not found
increases in TB yield.13,14 Xpert is expensive to
implement and use, and the health system and patient
impacts and benefits under routine operational condi-
tions are still uncertain.
Modelling as a framework to help with decision
making is an attractive and viable option to guide
policy makers in implementing new diagnostic tests
and algorithms. Operational modelling could identify
gaps within a health system and options for addressing
these.15 Projections of the impact of interventions on
patient access and outcomes and health system costs
and infrastructure could help guide policy makers on
which new diagnostic tests and algorithms should be
implemented.
As part of an evaluation of new TB diagnostics in
South Africa (Policy Relevant Outcomes from Vali-
dating Evidence on ImpacT, PROVE IT), we devel-
oped an operational model using a discrete event
simulation approach for the previous smear/culture-
based TB diagnostic algorithm and the newly
introduced Xpert-based algorithm in Cape Town
and validated the model outputs by comparing these
with routine TB programme data.16
We used the operational model to investigate the
mechanisms influencing TB yield in our setting and to
better understand why we did not find the expected
increase in TB diagnostic yield in our own empirical
study.16 We used simulated model scenarios, includ-
ing a decrease in TB prevalence, varying adherence to
protocol in diagnostic algorithms and knowledge of
HIV status to make direct comparisons of the
proportion of presumptive cases diagnosed as TB
(TB yield), missed cases (false-negatives) and unnec-
essarily treated cases (false-positives) in the smear/
culture and Xpert-based algorithms.
METHODS
Setting
The model was developed (Appendix Tables A.1 and
A.2* and Figures 1 and 2) and validated (Appendix
Table A.3) using routine National Health Laboratory
Service (NHLS) data collected for the period from 2010
to 2013 over seven time points (T1 to T7) in Cape
Town,16 one of the larger cities in South Africa, with a
population of 3.7 million in 2011 (national census
2011) and 28658 TB cases reported; 47% of TB cases
tested were co-infected with HIV (source: routine TB
programme data, Cape Town Health Directorate).
Municipal and provincial health authorities pro-
vided TB diagnostic services at 142 primary health
care (PHC) facilities. Sputum samples collected for
TB testing at PHC facilities were couriered to the
central NHLS on a daily basis for testing, and results
were returned via courier and fax.
Two diagnostic algorithms (Appendix Figure A.1)
were used in the study period. A smear/culture-based
TB algorithm was used before August 2011, with all
presumptive cases required to submit two spot
sputum samples taken at least 1 h apart. Both sputum
samples were examined using fluorescence microsco-
py after being chemically treated, centrifuged and
stained. Among previously treated presumptive cases,
the second sample was cultured using BACTECe
MGITe 960 (BD, Sparks, MD, USA) and tested for
drug suscept ibi l i ty us ing the GenoTypew
MTBDRplus (Hain LifeScience, Nehren, Germany)
line-probe assay (LPA). For new presumptive cases
who were smear-negative and HIV-infected, a third
sample was required for culture.
An Xpert-based algorithm was phased in from
August 2011 to February 2013, with Xpert replacing
smear microscopy for all presumptive cases. The first
of two sputum samples submitted was tested using
Xpert. If TB was detected, smear microscopy was
performed on the second sample. In HIV-infected
cases with negative Xpert results, the second sample
underwent culture and LPA. All definitions for terms
used throughout the article are given in Table 1.
Model development
TheWitness package, a discrete event and continuous
process simulator,17 was used to develop a compre-
hensive model to represent the diagnosis of PTB in
Cape Town. The model incorporated TB diagnostic
algorithms (Appendix Figure A.1) as well as patient
pathways and sample flow (Appendix Figure A.2)
from specimen collection through laboratory test
procedures to a result being provided to the patient
and treatment initiation.
Table 2 summarises the model validation, and a
detailed account of model development (Appendix
Tables A.1 and A.2), more details about validation
(Appendix Table A.3) as well as model sensitivity
analysis, are available in the online Appendix.
Simulated scenarios: comparing the smear/culture and
Xpert-based algorithms
To determine why the expected increase in TB yield
was not observed in our setting with the roll-out of the
* The appendix is available in the online version of this article, at
http://www.ingentaconnect.com/content/iuatld/ijtld/2017/
00000021/00000004/art00006
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Xpert-based algorithm, we modelled both algorithms
with identical input parameters to eliminate any
differences in population characteristics (TB preva-
lence, HIV status, history of previous anti-tuberculosis
treatment) during the time the smear/culture-based
algorithmwas in use and during the Xpert roll-out.We
used estimated prevalence data from the most recent
time point (T7) and an average of population
parameters (proportion of previously treated cases
and HIV status) over the seven time points. We ran the
model for a period of 3 years for each simulation.
In the base-case scenario (Scenario A), we set levels
of adherence to testing protocols in both algorithms
at 85%, and assumed that 50% of presumptive cases
knew their HIV status. Various other scenarios were
modelled (Table 3) and, unless otherwise specified,
the baseline parameters for Scenario A were main-
tained for all the following scenarios. In Scenario B,
the estimated TB prevalence among presumptive TB
cases was increased by 10%. In Scenario C, we
increased the number of cultures for smear-negative
and Xpert-negative presumptive TB cases to that
found in routine practice: smear/culture-based algo-
rithm: new HIV-negative 30% and HIV-positive
92%, previously treated HIV-negative 10% and
HIV-positive 95%; Xpert-based algorithm: new
HIV-negative 5% and HIV-positive 92%, previously
treated HIV-negative 10% and HIV-positive 95%.
In Scenario D, we assessed the effect of an increase
in known HIV status (from 50% to 85%) on outputs.
In Scenario E, we tested the effect of 100% adherence
to testing protocols in each algorithm, with 50% of
presumptive TB cases’ HIV status known. With
Scenario F, we increased both HIV status known
and adherence to testing protocols to 100%. With
Scenario G, the use of culture was removed from both
algorithms, as in most settings culture is not used as
extensively as in Cape Town or is not used at all as
part of the diagnostic algorithm. In Scenario H, we
lowered the test sensitivity of smear microscopy by
10%. Scenario input parameters are summarised in
Appendix Tables A.4 and A.5. For each scenario, we
compared TB yield between the algorithms for all TB
cases, and also assessed the proportion of missed
cases (false-negative or TB not detected but TB
present) and cases treated unnecessarily (false-posi-
tive or TB detected but no TB present). We undertook
Figure 1 Model output comparing observed yield and model
yield for all presumptive cases.
Figure 2 Model outputs from the scenarios comparing TB diagnostic yield (%) between
algorithms and sensitivity of input parameters. Diagnostic yield from routine data. Model with
routine data as input parameters. Scenario A: 85% adherence to algorithm and 50% of
presumptive cases know their HIV status; Scenario B: increase estimated TB prevalence among
presumptive cases by 10%; Scenario C: increase additional culture for smear or Xpert-negative
presumptive cases per routine practice; Scenario D: increased proportion (85%) of presumptive
cases know their HIV status; Scenario E: adherence (100%) to algorithms; Scenario F: increased
proportion (100%) of presumptive cases know their HIV status and adherence (100%) to
algorithms; Scenario G: remove culture as part of the sequence of tests required in each diagnostic
algorithm; Scenario H: lower the sensitivity of smear microscopy by 10%. TB¼ tuberculosis.
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the analysis for new and previously treated TB cases,
and for HIV-positive and HIV-negative TB cases
(Appendix Table A.6–A.13).
Analysis
All patient and laboratory test information was
written to a Microsoft SQL Server database (Micro-
Soft, Redmond, WA, USA). Model outputs were
aggregated by month over a 3-year period to produce
means and 95% confidence intervals (CIs) for
diagnostic yield and proportions that were false-
negative and false-positive. We used the t-test to
determine differences in means between observed and
modelled outputs for the model validation and
between algorithms for simulated scenarios. Differ-
ences are expressed as absolute values. All analyses
were undertaken using STATAversion 14 (StataCorp,
College Station, TX, USA).
Ethics statement
The study was approved by the Health Research
Ethics Committee at Stellenbosch University, Tyger-
berg, South Africa (IRB0005239) (N10/09/308) and
the Ethics Advisory Group at the International Union
Table 2 Model validation comparing TB yield from routine data and model outputs (%)
T1 T2 T3 T4 T5 T6 T7
Weighted
mean 6 SD
Mean difference
% (95%CI) P value
All presumptive cases
Smear/culture-based algorithm
Routine data 23.6 20.4 18.0 18.8 20.6 NA* NA* 20.9 6 2.1 0.1 (3.0 to 3.3)
Model outputs 23.4 20.8 18.7 17.3 17.4 NA* NA* 20.8 6 2.2 0.928
Xpert-based algorithm
Routine data NA* NA* 21.2 16.9 19.3 16.6 17.5 17.9 6 1.5 0.1 (1.8 to 1.6)
Model outputs NA* NA* 19.5 18.5 18.1 17.7 17.4 18.0 6 0.6 0.874
Overall
Routine data 23.6 20.4 19.4 17.4 19.5 16.6 17.5 19.2 6 2.2 0.0 (2.4 to 2.5)
Model outputs 23.4 20.8 19.1 18.1 17.9 17.7 17.4 19.2 6 2.0 0.988
New presumptive cases
Smear/culture-based algorithm
Routine data 23.2 20.9 17.0 16.8 19.7 NA* NA* 20.4 6 2.5 0.8 (2.6 to 4.3)
Model outputs 22.1 19.8 17.6 16.3 16.0 NA* NA* 19.6 6 2.1 0.581
Xpert-based algorithm
Routine data NA* NA* 21.7 15.7 18.7 15.8 16.2 17.1 6 1.9 0.0 (2.1 to 2.0)
Model outputs NA* NA* 18.3 17.5 17.0 16.7 16.8 17.1 6 0.5 0.975
Overall
Routine data 23.2 20.9 18.8 16.1 18.9 15.8 16.2 18.5 6 2.5 0.4 (2.3 to 3.0)
Model outputs 22.1 19.8 17.9 17.1 16.9 16.7 16.8 18.1 6 1.9 0.764
Previously treated presumptive cases
Smear/culture-based algorithm
Routine data 26.6 23.1 21.6 25.3 23.5 NA* NA* 24.4 6 1.9 0.2 (2.7 to 3.1)
Model outputs 26.5 24.1 22.1 20.3 21.3 NA* NA* 24.2 6 2.1 0.897
Xpert-based algorithm
Routine data NA* NA* 23.6 21.7 22.6 19.8 24.2 22.1 6 1.7 0.9 (0.9 to 2.9)
Model outputs NA* NA* 23.2 21.4 21.1 20.9 20.2 21.2 6 0.9 0.276
Overall
Routine data 26.6 23.1 22.5 22.8 22.7 19.8 24.2 23.2 6 2.0 0.7 (1.7 to 3.1)
Model outputs 26.5 24.1 22.6 21.1 21.2 20.9 20.2 22.4 6 2.1 0.535
*The smear/culture-based algorithm was not in use in the TB programme during T6 and T7; and the Xpert-based algorithm was not in use during T1 and T2.
TB¼ tuberculosis; SD¼ standard deviation; CI¼ confidence interval; NA¼ not applicable.
Table 1 Definitions used throughout the study
Presumptive case Defined as an individual with pre-treatment sputum samples submitted for diagnostic purposes
TB prevalence among presumptive cases The proportion of true TB cases among presumptive cases. For model purposes, this is defined as
culture-positive cases
TB case An individual with one or more smears positive and/or culture positive for M. tuberculosis and/or
M. tuberculosis detected on Xpert (includes true-positive cases and false-positive cases)
New presumptive cases An individual with no previous anti-tuberculosis treatment or ,4 weeks of previous anti-
tuberculosis treatment
Previously treated presumptive cases An individual with .4 weeks of previous anti-tuberculosis treatment
TB testing protocol The sequence of tests required in each diagnostic algorithm
TB diagnostic yield The number of TB cases diagnosed (based on the full TB testing protocol performed) expressed
as a proportion of presumptive cases tested
TB diagnostic yield ¼ (True positive þ false positive)/Presumptive cases
False-positive The proportion of individuals with culture-negative TB who are incorrectly diagnosed with TB
False-negative The proportion of individuals with culture-positive TB in whom a TB diagnosis is missed
True-positive The proportion of individuals with culture-positive TB who are diagnosed with TB
TB¼ tuberculosis.
384 The International Journal of Tuberculosis and Lung Disease
37
Stellenbosch University  https://scholar.sun.ac.za
Against Tuberculosis and Lung Disease, Paris, France
(59/10). A waiver for informed consent was granted
for use of routine data. The City Health Directorate,
Western Cape Health Department, Cape Town, and
the National Health Laboratory Services, Pretoria,
South Africa, granted permission to use routine
health data.
RESULTS
Model validation
The mean differences between observed yield from
routine data and model outputs over the seven time
points is shown in Figure 1 and Table 2. The TB yield
from the model closely approximated that from
routine data for both diagnostic algorithms. The
mean model yield was 0.1% (P¼ 0.928) lower than
observed values in the smear/culture-based algorithm
and 0.1% (P ¼ 0.874) higher in the Xpert-based
algorithm overall (Figure 1; Table 2).
Simulated scenarios: comparing the smear/culture and
Xpert-based algorithms
Figure 2 and Table 3 summarise the model outputs
from the scenarios comparing the TB diagnostic yield
from the smear/culture and Xpert-based algorithms.
In Scenario A (detail in Appendix Table A.6), with
85% adherence to the diagnostic algorithms and
where 50% of presumptive cases knew their HIV
status, the overall TB diagnostic yield was 15.8% in
the smear/culture-based algorithm compared to
17.9% in the Xpert-based algorithm (relative differ-
ence 13.3%), with respectively 3.3% and 2.1% of
presumptive cases having a missed TB diagnosis. A
lower proportion of cases were falsely diagnosed with
TB in the smear/culture-based algorithm (0.8%) than
in the Xpert-based algorithm (1.6%).
When the estimated TB prevalence among
presumptive cases was increased by 10% (absolute)
(Scenario B) (Appendix Table A.7), the yield was
24.0% and 26.7% in the respective algorithms.
The relative increase in yield between algorithms
was 11.3%. The proportion of missed cases was
respectively 5.1% and 3.1%.
When Scenario A was adjusted so that the
proportions of smear-negative and Xpert-negative
cases who received a culture test were set to reflect the
values found in routine practice (Scenario C), the
Table 3 Model outputs from the scenarios comparing TB diagnostic yield (%) between algorithms and sensitivity of input
parameters
Smear/culture-based
algorithm
Xpert-based
algorithm
Change in yield
between algorithms
(relative % difference)
Routine and modelled data across all time periods (i.e., smear/culture T1–T5 and Xpert T3–T7)
Diagnostic yield from routine data 20.9 17.9 3.0 (14.4)
Model with routine data as input parameters 20.8 18.0 2.8 (13.5)
Modelled scenarios: all input parameters
identical between algorithms
True TB Not TB Yield True TB Not TB Yield
Scenario A: 85% adherence to algorithm and 50% of presumptive cases know their HIV status*
TB detected 15.0 0.8 15.8 16.3 1.6 17.9 2.1 (13.3)
TB not detected 3.3 80.9 2.1 80.0
Scenario B: increase estimated TB prevalence among presumptive cases by 10%
TB detected 23.3 0.7 24.0 25.3 1.5 26.7 2.7 (11.3)
TB not detected 5.1 70.9 3.1 70.2
Scenario C: increase additional culture testing for smear or Xpert-negative presumptive cases to that found in routine practice†
TB detected 16.0 0.8 16.8 16.4 1.7 18.1 1.3 (7.7)
TB not detected 2.3 80.9 1.9 80.0
Scenario D: increased proportion (85%) of presumptive cases know their HIV status
TB detected 15.6 0.8 16.4 16.7 1.7 18.4 2.0 (12.2)
TB not detected 2.6 81.0 1.5 80.0
Scenario E: 100% adherence to algorithms; 50% know their HIV status
TB detected 15.3 0.8 16.1 16.5 1.8 18.3 2.2 (13.7)
TB not detected 3.0 80.9 1.8 79.9
Scenario F: 100% adherence to algorithms; 100% know their HIV status
TB detected 16.1 0.7 16.8 17.1 1.9 19.0 2.2 (13.1)
TB not detected 2.1 81.1 1.1 79.9
Scenario G: remove culture as part of the sequence of tests required in each diagnostic algorithm
TB detected 12.9 0.8 13.7 16.5 1.8 18.3 4.6 (33.6)
TB not detected 5.4 80.9 1.8 80.0
Scenario H: lower the sensitivity of smear microscopy by 10%
TB detected 13.9 0.8 14.7 16.3 1.6 17.9 3.2 (21.8)
TB not detected 4.4 80.9 2.1 80.0
* In Scenario A, 85% of cases in each algorithm received the initial tests as required and 85% of smear- or Xpert-negative cases who were HIV-infected underwent
culture; 50% of presumptive cases knew their HIV status. The same values for TB prevalence (18.8%), proportions of HIV, HIVþ (status known and undiagnosed),
new and previously treated cases were used in each algorithm. All scenario changes are in relation to Scenario A. Yield¼ TB detected (true TBþ not TB).
† In Scenario C, culture in smear/culture-based algorithm increased new HIV (0–30%), HIVþ (85–92%), previously treated HIV (0–10%) HIVþ (85–95%); Xpert-
based algorithm: new HIV (0–5%), HIVþ (85–92%), previously treated HIV (0–10%), HIVþ (85–95%).
TB¼ tuberculosis; HIV¼ human immunodeficiency virus;¼ negative;þ¼ positive.
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overall yield was 16.8% in the smear/culture-based
algorithm compared to 18.1% in the Xpert-based
algorithm, a relative increase of 7.7%. The propor-
tion of missed cases was 2.3% and 1.9% in the
respective algorithms (Appendix Table A.8). In
comparison to Scenario A, the relative increase in
TB yield was 6.3% in the smear/culture-based
algorithm and 1.1% in the Xpert-based algorithm
in Scenario C.
If HIV testing among presumptive TB cases was
increased and 85% knew their HIV status (Scenario
D) (Appendix Table A.9), the overall yield was 16.4%
in the smear/culture-based algorithm compared to
18.4% in the Xpert-based algorithm (relative differ-
ence 12.2%), with 2.6% and 1.5% missed cases in
the respective algorithms. In comparison to Scenario
A, an increase in HIV testing resulted in a relative
increase of 3.8% and 2.8% in TB yield in the
respective algorithms.
If adherence to the testing protocol in each
algorithm was increased to 100% but only 50% of
presumptive TB cases knew their HIV status (Scenar-
io E) (Appendix Table A.10), the TB yield was 16.1%
in the smear/culture-based compared to 18.3% in the
Xpert-based algorithm, with a relative increase of
10.9%. The proportion of missed cases was respec-
tively 3.0% and 1.8%. In comparison to Scenario A,
the relative increase in TB yield was 1.9% in the
smear/culture-based algorithm compared to 2.2% in
the Xpert-based algorithm.
If adherence to the testing protocol in each
algorithm was increased to 100% and 100% of
presumptive TB cases knew their HIV status
(Scenario F) (Appendix Table A.11), the TB yield
was 16.8% in the smear/culture-based compared to
19.0% in the Xpert-based algorithm, with a relative
increase of 13.1% between algorithms. The propor-
tion of missed cases was respectively 2.1% and
1.1%. In comparison to Scenario A, the relative
increase in TB yield was 6.3% in the smear/culture-
based algorithm compared to 6.1% in the Xpert-
based algorithm.
Removing culture as part of the testing protocol
from both algorithms (Scenario G) (Appendix Table
A.12) resulted in a TB yield of 13.7% and 18.3% in
the respective algorithms. The relative increase in
yield between algorithms was 33.6%. The propor-
tion of missed cases was 5.4% in the smear/culture
algorithm compared to 1.8% in the Xpert algo-
rithm.
If we assume the sensitivity of smear microscopy to
be 10% lower than that estimated in our model
(Scenario H) (Appendix Table A.13), the yield in the
smear/culture algorithm would be 14.7% (missed
cases 4.4%), with a relative increase in yield with the
Xpert algorithm of 21.8%.
DISCUSSION
A strength of this study was the availability of
detailed routine data and information collected on
health and laboratory processes, which allowed us to
develop a precise operational model to assess the
impact of different diagnostic algorithms in Cape
Town. The model input parameters were mostly
based on these detailed routine data, and only a few
assumptions were made. We assumed that prevalence
among presumptive cases was higher among HIV-
positive presumptive cases than among HIV-negative
cases,18,19 and among previously treated than among
new cases;20 we assumed a decrease in TB prevalence
among presumptive cases over time based on the
empiric yield data, which showed a decrease in yield
over time despite similar proportions of the popula-
tion being tested.16 The latter assumption is support-
ed by national data that showed a decrease in the
number of laboratory-confirmed cases since 2011
(nationally and across the Western Cape Province).21
The availability of routine TB NHLS data collected
through the PROVE IT study allowed us to validate
the model by comparing TB yield observed in routine
practice to model outputs using input parameters
from seven different time points during the period
when PHC facilities changed from the smear/culture
algorithm to the Xpert algorithm. This comparison
built confidence in the outputs from the model and
confirmed that the outputs were credible. Overall
model outputs closely resembled the TB yield
observed in Cape Town over the seven time points,
with a mean difference of 0.1% (P¼ 0.951) between
routine data and the model outputs.
A direct comparison of TB yield in the Xpert and
smear/culture-based algorithms in routine practice is
difficult due to the variability in the population
characteristic at each time point and different levels
of adherence to testing protocols. When the Xpert-
based algorithm was newly introduced, it took staff a
period of time to adapt their clinical practice and
become familiar with the new protocols. The global
stock-out of the Xpert test during the study period
also played a role in the extent to which testing
protocols were followed. The operational model
allows a direct comparison between the two algo-
rithms with identical population characteristics and
adherence to testing protocols. To understand the
mechanisms and the extent to which they influenced
TB yield in our setting, we used the validated model
to compare various scenarios.
In Scenario A, with 85% adherence to algorithm
and 50% of presumptive cases knowing their HIV
status, the yield in the Xpert-based algorithm was
higher than in the smear/culture-based algorithm,
with a relative increase of 13.3%. Although the TB
diagnostic yield was higher in the Xpert-based
algorithm, the increase was lower than the predicted
386 The International Journal of Tuberculosis and Lung Disease
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increase with full roll-out of Xpert in South Africa10
and reported by other studies.11,12
Scenarios B and C provide insights into the findings
on TB yield from our empirical study. The TB yield in
the smear/culture-based algorithm in Scenario B,
where TB prevalence was 10% higher than in
Scenario A, was 25% higher than in the Xpert-based
algorithm in Scenario A, demonstrating the impact of
a decline in prevalence among presumptive TB cases
on TB yield. This helps explain findings from the
empirical study that reported yields of 20.9% in the
smear/culture-based and 17.9% in the Xpert-based
algorithm.16 It is likely that the change in prevalence
in our setting during the study period was lower than
the 10% value tested in the model.
Our model showed the impact of additional culture
testing on reducing the difference in TB yield between
algorithms. When the proportions of smear- and
Xpert-negative cases who received culture tests were
increased to reflect those found in routine practice
(Scenario C), the relative increase in yield between the
smear/culture and Xpert-based algorithms was re-
duced to 7.7%. This was attributable to a higher
proportion of smear-negative than Xpert-negative
cases undergoing culture. A cluster-randomised study
in four other provinces also found that culture was
more likely to be undertaken for smear-negative
(32%) than Xpert-negative (14%) HIV-infected
cases.22 It was proposed that a greater belief in the
efficacy of the Xpert test contributed to this.
Scenarios D to F provide insights into the potential
benefits of interventions that strengthen the health
system. Increasing the proportion of presumptive
cases who knew their HIV status from 50% to 85%
had a small influence on TB yield: the yield increased
by 3.8% in the smear/culture-based algorithm, and
by 2.8% in the Xpert-based algorithm in relative
terms from Scenario A. It is interesting to note the
modest benefits, considering the effort required to
increase HIV testing of presumptive cases to this
extent.
In Scenario E for the Xpert-based algorithm,
increasing adherence to the algorithm to 100%, but
with only 50% of presumptive TB cases knowing
their HIV status, produced a 2.2% relative increase in
yield compared to Scenario A. Increasing adherence
to 100% and with 100% knowing their HIV status
resulted in a relative increase in yield of only 6.1% in
the Xpert-based algorithm in Scenario F compared to
Scenario A. In addition to this disappointingly small
benefit, 100% adherence is not realistic in routine
practice due to the failure to request the correct test
(due to new or locum staff who are unfamiliar with
Xpert and costs concerns, for example), the avail-
ability of the Xpert test due to maintenance on Xpert
machines or stock-outs and clinical decisions over-
riding the use of the testing algorithm. It is important
to note that we started on a baseline of 85%
adherence to the algorithms and with 50% knowing
their HIV status; the increases in yield would be
greater if these baseline values were lower. In a future
study, we will model the effect of a more sensitive test
than Xpert to assess the extent to which this can
increase TB diagnostic yield.
We compared two scenarios that are pertinent to
other settings. In Scenario G, where culture was
removed from the algorithms, there was a 33.6%
relative difference in TB yield between the smear/
culture and the Xpert-based algorithm. The diagnos-
tic benefits of Xpert are thus likely to be greater in
areas that do not use or have very limited use of
culture. The performance of smear microscopy in our
central laboratory may also be much higher than
reported by peripheral microscopy units. This is
possibly due to greater proficiency and technical
aspects in the central laboratory. It has been shown
that an increase in yield for smear microscopy could
be achieved by chemical treatment, centrifugation
and fluorescence microscopy,23–25 as used in our
laboratory. If we did not have these benefits and
smear microscopy sensitivity was 10% lower, the
relative increase in TB yield in the Xpert-based
algorithm would have been 21.8% compared to that
in the smear/culture-based algorithm.
Limitations
We did not have data on TB prevalence for
presumptive cases. This was estimated with a range
of values tested in the model. The model was
validated against data from Cape Town, a well-
resourced urban setting where there is extensive use
of culture in both algorithms. This may limit the
generalisability of the findings to other settings.
As complete data are rarely available for any
modelling study, assumptions are required for some
input parameters. A model is also, by definition, a
simplification of real-life processes. In this study, our
model was validated by running the model with input
parameters based on routine data for seven individual
time points and comparing the output from the model
against corresponding routine data (Figure 1; Table
2). Cost implications, treatment delay and rifampicin
resistance were not addressed in the current study and
will be reported in future studies.
CONCLUSION
We have developed and validated an operational
model that can be used to directly compare the TB
diagnostic yield between different algorithms, i.e., a
smear/culture-based and an Xpert-based algorithm.
Our model accounted for the variability found in
routine practice and made it possible to eliminate the
effect of a difference in population characteristics and
adherence to testing protocols within algorithms on
the TB diagnostic yield.
Modelling TB diagnostic algorithms 387
40
Stellenbosch University  https://scholar.sun.ac.za
We were able to show that extensive use of culture
in the smear/culture-based algorithm and decline in
TB prevalence are the main factors likely to have
contributed to our not finding an increased TB yield
in the Xpert-based algorithm in our empiric study.
The Xpert-based algorithm is likely to yield greater
diagnostic benefits in areas without culture or with
less sensitive TB microscopy.
We have demonstrated the benefits of using an
operational model to determine the effect of scaling
up a new diagnostic algorithm and investigate the
mechanistic reasons that influence the yield of a new
TB diagnostic algorithm. We would therefore recom-
mend that policy makers use operational modelling to
make appropriate decisions before new diagnostic
algorithms are scaled up. The model could provide
evidence as to how the greatest benefits could be
obtained by using a new diagnostic test within a TB
diagnostic algorithm and in a specific setting.
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APPENDIX
Modelling as a framework to help with decision
making is an attractive and viable option to guide
policy makers in implementing new diagnostic tools
and diagnostic algorithms. Two modelling approach-
es previously used in tuberculosis (TB) control are
transmission (epidemiological) modelling and opera-
tional modelling.1 Transmission modelling can be
used to predict the long-term impact of interventions
on the community by projecting TB incidence,
prevalence and mortality. Operational modelling, on
the other hand, can be used to project the impact of
interventions on health system costs and infrastruc-
ture, as well as patient access and outcomes.
Operational modelling can also be useful in identify-
ing gaps within a health system and to identify ways
to address the gaps within the health system.2 An
operational model is a simplified representation of
complex real-life processes. The data sources usually
used to drive operational models are derived from
published literature (i.e., meta-analyses, randomised
control trials, cohort studies, global reports, unpub-
lished literature, expert opinion, field data), and from
assumptions. Models are therefore only as good as
the level of detail available to develop the logic of the
model and the availability and accuracy of the data to
drive the model.3
In industrial and commercial settings, operational
models are widely used to plan and assess the
performance and efficiency of processes.4 Operation-
al models have also increasingly been used to improve
performance of the health sector.5,6 The use of
operational models in health systems is common in
high-income countries, but not in middle- to low-
income countries at this stage. Many operational
models use a discrete event simulation approach,
where the system modelled is first defined in terms of
its most important elements, including the items or
people processed through the facility, resources,
activities, rules and the process flow. The required
outputs of the model are defined (e.g., productivity,
costs, identification of bottlenecks, capacity and
sensitivity to changes), along with the key input
parameters to be investigated. Once the system is
defined and appropriate parameter inputs are as-
signed (e.g., the number of items entering the system,
the quantity of resources and the time for completing
particular activities), then simulations can be run to
assess the relative effect of different input assump-
tions on the modelled outputs.7
Model development
TheWitness package, a discrete event and continuous
process simulator,8 was used to develop a compre-
hensive model to represent the diagnosis of pulmo-
nary TB (PTB) in Cape Town, South Africa. The
model incorporated the TB diagnostic algorithms
(Figure A.1), as well as patient pathways and sample
flow (Figure A.2) from specimen collection, through
laboratory test procedures, to a result being provided
to the patient and treatment initiation.
The main elements in the model (Table A.1) were
entities (representing patients, sputum samples),
activities (representing patient reception, sputum
collection from the patient, sample transport, sample
registration at the laboratory, sample preparation and
test procedures, review and return of results to
primary health care [PHC] facilities), queues (repre-
senting delays before each activity, e.g., patient
waiting in reception prior to clinical evaluation and
sputum collection, batching and other processes in
Figure A.1 TB diagnostic algorithms. The simplified sequence of diagnostic tests in each algorithm and the action taken based on
test results is shown. TB¼ tuberculosis; MDR-TB¼multidrug-resistant TB; LPA¼ line-probe assay; MTB¼Mycobacterium tuberculosis;
RIF¼ rifampicin; HIV¼ human immunodeficiency virus; DST¼ drug susceptibility testing.
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the laboratory) and resources (representing health
facility and laboratory staff and equipment).
The model structure follows the patient and sample
pathways (Figure A.2), with the flow of entities
between activities and queues dictated by rules, which
are dependent on attributes for entities (patient or
sample).
Input parameters
A detailed list of the input parameters, including
processing times, patient and sample data as well as
test sensitivity and specificity, is shown in Table A.2.
Input data sources
Health system and laboratory processes were mapped
in three ways: through key informant interviews,
through the review of standard operating procedures
and through detailed observation and timing of clinic
and laboratory processes, all undertaken as part of
the PROVE IT study.
Characteristics of presumptive cases were derived
from electronic laboratory TB test data received from
the National Health Laboratory Services (NHLS)
Data Warehouse. Data included demographic infor-
mation, treatment history (new or previously treated
cases) human immunodeficiency virus (HIV) status
(HIV-negative, HIV-positive, status unknown), test
type (smear, culture or XpertwMTB/RIF), test results
and date when sputum was collected, tested and
results available.
As there were no unique identifiers in the NHLS
data to link results belonging to an individual,
matching was performed on personal identifying
information (first name, family name, date of birth
and facility folder number). After record matching,
all personal identifying information was removed.
These data were used to assess adherence to testing
protocols in each algorithm and to calculate diagnos-
tic yield (the proportion of presumptive cases
diagnosed as TB).
Data on the sensitivity and specificity of tests were
obtained from systematic reviews and published
literature.9–11 We did not have data on the proportion
of true TB cases among presumptive cases (TB
prevalence), and we tested a range of prevalence
values, assuming that prevalence was lower among
HIV-negative than among HIV-positive,12,13 and
among new than among previously treated presump-
tive cases14; the outputs in comparison to observed
TB yield values from routine data were then assessed
(see below).15
Model outputs
The output from the model indicated the proportion
of cases diagnosed as TB (TB yield, i.e., true-positive
and false-positive cases) and the proportion of cases
missed (false-negative) using the diagnostic algorithm
in different scenarios.
Model calibration and validation
To have confidence in the model and the outputs
produced, the model was verified and validated.16
Figure A.2 A representation of the diagnostic pathway for the diagnosis of TB in Cape Town, South Africa.* * See Table A.2. TB¼
tuberculosis; LPA¼ lineprobe assay; DST¼ drug susceptibility testing; NHLS¼ National Health Laboratory Services.
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Model verification to ensure that the coding and logic
of the model and its execution were correct was
performed through incremental model building and
carefully scrutinising the structure and logic of the
model at each stage. The distribution of input
parameters was assessed against outputs to make
sure that the model assigned patient categories
correctly.
The model was validated using input parameters
from routine data and by comparing TB yield from
model outputs to routine data.15 As part of the
PROVE IT Study, NHLS data from presumptive
cases had previously been collected and analysed to
compare TB yield in the smear/culture-based
algorithm to that in the Xpert-based algorithm
over seven time periods (T1–T7), during which the
PHC changed from the former algorithm to the
latter.15 The model used probability distributions
derived from this analysis to assign patients to
categories: diagnostic algorithm used, HIV status
(known HIV-positive, undiagnosed HIV and HIV-
negative) and treatment history (new or previously
treated).
Data on HIV status were only available for time
points T6 and T7 (50% knew their HIV status), and
similar proportions were assumed for T1–T5. The
extent to which testing protocols was followed in each
diagnostic algorithm was derived from these data. As
we did not have data on TB prevalence among
presumptive cases, a range of values were tested. We
made the assumption that prevalence among presump-
tive cases was higher among HIV-positive presumptive
cases than among HIV-negative cases,12,13 and among
previously treated than among new cases.14 We
Table A.1 The key elements used in the model developed for this study
Model element type Representation of
Entities Patients, presumptive cases reporting to a TB diagnostic centre (clinic)
for TB diagnosis
Sputum sample
Attributes Number of sputum samples required
Number of sputum samples collected
Previous history of anti-tuberculosis treatment (new, previous TB)
HIV status (HIV, HIVþ, HIVþ with status not known)
Test result
Activities Clinic
Reception
TB room
Sputum collection
Patient return home
Courier, transport of samples from clinic to central laboratory
Laboratory
Sample sorting/reception
Smear
Preparation
Microscopy
Review result
Fax result
Culture
Preparation
MGIT
ZN smear
Fax result
Xpert
Preparation
Xpert test
Review results
Fax result
Queues Clinic
Waiting room at reception
Waiting for sputum collection
Patient
Wait for result or provide further sputum samples
Laboratory
Sample waiting for preparation
Sample waiting for testing/batching
Microscopy
Culture
Xpert
Result waiting for review
Result waiting to be faxed
TB ¼ tuberculosis; HIV ¼ human immunodeficiency virus; ¼ negative; þ¼ positive; MGIT ¼Mycobacteria Growth
Indicator Tube; ZN¼ Ziehl-Neelsen.
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Table A.2 Main input parameters for operational model*
Input parameter Description Values Source
Processing times
TB diagnostic and
treatment facility
processing times
Duration of activities
within the diagnostic
centre for reception,
sputum collection and
returning results
Not defined for current model
Laboratory process
times
Duration of and
batching process
for microscopy,
culture and drug
susceptibility
testing. Preparation
and processing
times for Xpert
Sample collection times
by courier
First sputum delivery: between 2 and 3 pm Interviews with NHLS
staff, review of SOPs
and direct
observations of
laboratory procedures
Sample sorting time 25 min in batches of 96
Xpert preparation time 50 min in batches of 16
Xpert test time 1 h 50 min
Smear preparation time 2 h for 96 samples
Microscopy reading 1 h per batch of 96
Culture preparation 2 h per batch of 750
Culture test time 5–36 days
Patient data
Number of new
patients seeking
diagnosis
Number and arrival
rate of individuals
seeking diagnosis
Number of presumptive
cases per day
Uniform distribution: NHLS data warehouse
and sampled from a
uniform distribution
Minimum ¼ 11
Maximum ¼ 690
Mean ¼ 55
Arrival time of
patients4
The time during the day
that the patient arrives
at the diagnostic
centre
5 days: Monday to Friday Sampled from user-
defined distribution
starting at the
opening time of the
health facility with all
patients arriving by
closing time.
8 am to 5 pm
Working 540 min per day
Return probability5 The probability that an
individual returns to
the diagnostic centre
for the next stage of
the diagnostic process
Not defined for current model Published literature18,19
HIV status of
presumptive cases6
Proportion of
presumptive cases
who are identified as
HIVþ
New presumptive cases ¼ 18% Estimated from NHLS
Data Warehouse data
for 2013
Previous history of TB ¼ 35%
History of previous TB
treatment for
presumptive cases7
Proportion of
presumptive cases
with previous TB
treatment
Average over all observed time points ¼ 24%
(breakdown by time point in Table A.3)
Estimated from NHLS
Data Warehouse data
and stepped wedge
analysis15; 90% of
presumptive cases
with missing previous
TB treatment status
were assumed to be
new cases
Proportion of
presumptive cases
with diagnostic test
performed8
Average over all
observed time
points (breakdown
by time point in
Table A.3)
Smear/culture algorithm: New cases Previous history of TB Estimated from NHLS
Data Warehouse data
and stepped wedge
analysis15
Two smears 84% 82%
Smear-negative with
culture
36% 85%
Xpert algorithm:
Xpert 77% 65%
Xpert-negative with
culture
18% 41%
Diagnostic test accuracy
Accuracy of smear
microscopy9
Sensitivity and specificity
of LED fluorescence
microscopy
Two sputum samples Published literature9,10
HIV: sensitivity 75%, specificity 99%
HIVþ: sensitivity 65%, specificity 99%
Accuracy of Xpert10 Sensitivity and specificity
of Xpert in identifying
TB from sputum
samples
HIV: sensitivity 89%, specificity 98% Published literature11
HIVþ: sensitivity 80%, specificity 98%
Proportion of tests by
test type that give
no result11
Level of retesting
required for smear,
culture or Xpert
2% Estimated from NHLS
Data Warehouse data
and stepped wedge
analysis15
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assumed a decrease in TB prevalence among presump-
tive cases based on the routine yield data, which
showed a decrease in yield over time despite a similar
proportion of the population being tested.15 This is
supported by national data that show a reduction in
the number of laboratory-confirmed cases since 2011
(nationally and across the Western Cape Province).17
A summary of the population characteristics used for
model validation by time period is provided in Table
A.3.
The availability of TB test data collected through
the PROVE IT study allowed us to validate the model
by comparing TB yield observed in routine practice to
model outputs using the input parameters from seven
different time points during the period when PHC
facilities changed from the smear/culture algorithm to
Table A.2 (continued)
Input parameter Description Values Source
Number of sputum tests
required per patient
with suspected TB12
The number of sputum
samples required for
each diagnostic
algorithm
Two sputum samples South African National
TB Guidelines20
* See Figure A.2.
TB¼ tuberculosis; NHLS¼National Health Laboratory Services; SOPs¼ standard operating procedures; HIV¼human immunodeficiency virus;þ¼positive; LED¼
light-emitting diode;¼ negative.
Table A.3 Population characteristics used for model validation by time period (%)
T1* T2* T3* T4* T5* T6* T7*
History of previous anti-tuberculosis treatment
Proportion of previously treated cases 29 24 24 25 25 24 19
HIV status
New presumptive cases
HIV-positive 36 36 36 36 36 36 36
HIV-negative 64 64 64 64 64 64 64
Previously treated presumptive cases
HIV-positive 53 53 53 53 53 53 53
HIV-negative 47 47 47 47 47 47 47
Proportion who know their HIV status
Estimated TB prevalence among presumptive cases
New presumptive cases
HIV-positive 26 23 21 19 19 18 17.8
HIV-negative 25 22 19 18 17.8 17 17
Previously treated presumptive cases
HIV-positive 27 24 23 21.5 21.5 21 20.8
HIV-negative 26 23 22 20 19.8 19.8 19.5
Proportion of presumptive cases tested using algorithm
Smear/culture-based 100 100 57 30 19 0 0
Xpert-based 0 0 43 70 81 100 100
Adherence to smear/culture-based algorithm
New presumptive cases with two smears 85 85 85 85 85 — —
Previously treated presumptive cases with culture 88 91 90 92 75 — —
Adherence to Xpert-based algorithm
All presumptive cases with Xpert test done — — 57 67 63 75 80
Proportion of patients who were smear or Xpert-negative with culture
Smear/culture-based algorithm
New presumptive cases
HIV-positive 92 92 92 92 92 92 92
HIV-negative 30 30 30 30 30 30 30
Previously treated presumptive cases
HIV-positive 95 95 95 95 95 95 95
HIV-negative 10 10 10 10 10 10 10
Xpert-based algorithm
New presumptive cases
HIV-positive 92 92 92 92 92 92 92
HIV-negative 2 2 2 2 2 2 2
Previously treated presumptive cases
HIV-positive 95 95 95 95 95 95 95
HIV-negative 10 10 10 10 10 10 10
*T1–T7 reflect the time points evaluated as part of a non-randomised stepped-wedge evaluation of TB yield with a transition from a smear/culture to an Xpert-
based algorithm in Cape Town.15 At T1 and T2, all facilities used the smear/culture-based algorithm; this decreased to 65% of facilities at T3, 38% at T4 and 23%
at T5. At T6 and T7, all facilities used the Xpert-based algorithm: T1, November 2010; T2, May 2011; T3, November 2011; T4, May 2012; T5, November 2012, T6,
May 2013; T7, November 2013. Values are derived from routine data.15
HIV¼ human immunodeficiency virus; TB¼ tuberculosis.
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the Xpert algorithm. This comparison built confi-
dence in the outputs from the model, and confirmed
that the outputs were credible. Overall model outputs
closely resembled TB yield observed in Cape Town
over the seven time points, with a mean difference of
0.0% (P ¼ 0.988) between the routine data and the
model outputs (Table 2).
Model sensitivity analysis
We selected five parameters to test the sensitivity of
our results to uncertainty in the parameter values.
The parameters evaluated were the estimated TB
prevalence among presumptive cases, the proportion
of presumptive cases with previous anti-tuberculosis
treatment, the test sensitivity of smear microscopy
and Xpert, the proportion of adherence to testing
algorithms and the extent of use of culture. These
parameters were selected because they have a direct
impact on the probability of being correctly tested
with TB, and therefore an impact on the primary
outputs, i.e., diagnosed as TB (TB yield), missed cases
(false-negative) and unnecessarily treated cases (false-
positive).
This analysis is summarised in Tables A.14 and
A.15 as well as in Figures A.3 and A.4. The analysis
shows that TB diagnostic yield is sensitive to TB
prevalence among presumptive cases and, to a lesser
extent, to test sensitivity and previous history of TB.
The proportion of HIV-positive cases among pre-
sumptive cases had more of an effect on the Xpert-
based algorithm, with a decrease in yield as the
proportion of HIV-positive cases increased.
Table A.4 Input parameters used in base-case (Scenario A)
comparing the smear/culture and Xpert-based algorithms (%)*
History of previous anti-tuberculosis treatment 25
HIV status
New presumptive cases
HIV-positive 36
HIV-negative 64
Previously treated presumptive cases
HIV-positive 53
HIV-negative 47
Proportion who know their HIV status 50
Estimated TB prevalence among presumptive cases
New presumptive cases
HIV-positive 17.8
HIV-negative 17
Previously treated presumptive cases
HIV-positive 20.8
HIV-negative 19.5
Adherence to smear/culture-based algorithm
New presumptive cases with two smears 85
Previously treated presumptive cases with culture 85
Adherence to Xpert-based algorithm
All presumptive cases with Xpert test done 85
Proportion smear or Xpert-negative with culture testing
Smear/culture-based algorithm
New presumptive cases
HIV-positive 85
HIV-negative 0
Previously treated presumptive cases
HIV-positive 85
HIV-negative 0
Xpert-based algorithm
New presumptive cases
HIV-positive 85
HIV-negative 0
Previously treated presumptive cases
HIV-positive 85
HIV-negative 0
* Input parameters used in all scenarios except where specific parameters are
changed for a scenario (Table A.6).
HIV¼ human immunodeficiency virus; TB¼ tuberculosis.
Table A.5 Input parameters used in other simulated scenarios comparing the smear/culture and Xpert-based algorithms (%)
Smear/culture-based algorithm Xpert-based algorithm
Scenario B: increase estimated TB prevalence among presumptive cases by 10%
Scenario A Scenario B Scenario A Scenario B
New presumptive cases
HIV-negative 17 27 17 27
HIV-positive 17.8 27.8 17.8 27.8
Previously treated presumptive cases
HIV-negative 19.5 29.5 19.5 29.5
HIV-positive 20.8 30.8 20.8 30.8
Scenario C: increase additional culture testing for smear or Xpert-negative presumptive cases
Scenario A Scenario C Scenario A Scenario C
New presumptive cases
HIV-negative 0 30 0 5
HIV-positive 85 92 85 92
Previously treated presumptive cases
HIV-negative 0 10 0 10
HIV-positive 85 95 85 95
Scenario D: increased proportion of presumptive cases know their HIV status
Scenario A Scenario D Scenario A Scenario D
Proportion of presumptive cases 50% 85% 50% 85%
Scenario E: adherence to algorithms
Scenario A (85%) Scenario E (100%) Scenario A (85%) Scenario E (100%)
New presumptive cases
HIV-negative 2 smear 2 smear Xpert test Xpert test
HIV-positive 2 smear 2 smear Xpert test Xpert test
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Table A.5 (continued)
Smear/culture-based algorithm Xpert-based algorithm
Previously treated presumptive cases
HIV-negative Culture test Culture test Xpert test Xpert test
HIV-positive Culture test Culture test Xpert test Xpert test
As part of follow-up testing if smear or Xpert is negative
New presumptive cases
HIV-negative 0 0 0 0
HIV-positive 85 100 85 100
Previously treated presumptive cases
HIV-negative 0 0 0 0
HIV-positive 85 100 85 100
Scenario F: increased proportion of presumptive cases know their HIV status (100%) and adherence to algorithm (100%)
Scenario A Scenario F Scenario A Scenario F
Proportion of presumptive cases 50% 100% 50% 100%
Scenario A (85%) Scenario F (100%) Scenario A (85%) Scenario F (100%)
New presumptive cases
HIV-negative 2 smear 2 smear Xpert test Xpert test
HIV-positive 2 smear 2 smear Xpert test Xpert test
Previously treated presumptive cases
HIV-negative Culture test Culture test Xpert test Xpert test
HIV-positive Culture test Culture test Xpert test Xpert test
As part of follow-up testing if smear or Xpert is negative
New presumptive cases
HIV-negative 0 0 0 0
HIV-positive 85 100 85 100
Previously treated presumptive cases
HIV-negative 0 0 0 0
HIV-positive 85 100 85 100
Scenario G: remove culture test as part of the sequence of tests required in each diagnostic algorithm
Scenario A Scenario G Scenario A Scenario G
New presumptive cases
HIV-negative 0 0 0 0
HIV-positive 0 0 0 0
Previously treated presumptive cases
HIV-negative 85 0 0 0
HIV-positive 85 0 0 0
As part of follow-up testing if smear or Xpert test is negative
New presumptive cases
HIV-negative 0 0 0 0
HIV-positive 85 0 85 0
Previously treated presumptive cases
HIV-negative 0 0 0 0
HIV-positive 85 0 85 0
Scenario H: lower test sensitivity of smear microscopy by 10%
Scenario A Scenario H
HIV-negative 75 65
HIV-positive 65 55
TB¼ tuberculosis; HIV¼ human immunodeficiency virus.
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Table A.6 Scenario A: comparison of smear/culture and Xpert-based algorithm model outputs (with 85% adherence to algorithms)*
Smear/culture-based algorithm Xpert-based algorithm
Change in yield between algorithms
% difference P value
HIV HIVþ Overall HIV HIVþ Overall HIV HIVþ Overall
All presumptive cases
Yield† 14.8 17.3 15.8 17.1 19.2 17.9 2.3 (P , 0.001) 1.9 (P , 0.001) 2.1 (P , 0.001)
FP† 0.9 1.0 0.9 1.9 2.2 2.0 1 1.2 1.1
FN† 20.7 14.4 18.0 12.6 9.5 11.3 8.1 4.9 6.7
New presumptive cases
Yield† 13.6 15.2 14.2 16.5 17.9 17.0 2.9 (P , 0.001) 2.7 (P , 0.001) 2.8 (P , 0.001)
FP† 0.9 0.9 0.9 2.0 2.1 2.0 1.1 1.2 1.1
FN† 25.3 21.3 23.8 13.4 11.5 12.7 11.9 9.8 11.1
Previously treated presumptive cases
Yield† 19.5 21.5 20.6 19.1 21.7 20.5 0.4 (P ¼ 0.476) 0.2 (P ¼ 0.644) 0.0 (P ¼ 0.894)
FP† 0.9 1.0 0.9 1.8 2.3 2.1 0.9 1.3 1.2
FN† 3.9 2.2 3.0 9.5 6.1 7.6 5.6 3.9 4.6
* In Scenario A, 85% of cases in each algorithm received the initial tests as required and 85% of smear- or Xpert-negative cases who were HIV-infected underwent
culture; 50% of presumptive cases knew their HIV status. The same values for TB prevalence, proportions of HIV, HIVþ (status known and undiagnosed), and new
and previously treated cases were used in each algorithm.
† TB diagnostic yield (yield)¼ (TPþ FP)/presumptive cases; TP¼ correctly diagnosed with TB/culture-positive TB cases; FP¼ incorrectly diagnosed with TB/culture-
negative TB cases; FN¼ incorrectly NOT diagnosed with TB (missed)/culture-positive TB cases.
HIV¼ human immunodeficiency virus;¼ negative;þ¼ positive; FP¼ false-positive; FN¼ false-negative; TB¼ tuberculosis; TP¼ true-positive.
Table A.7 Scenario B: increase in estimated TB prevalence among presumptive cases by 10%*
Smear/culture-based algorithm
% (95%CI)
Xpert-based algorithm
% (95%CI)
Change in yield between algorithms
% difference P value
HIV HIVþ Overall HIV HIVþ Overall HIV HIVþ Overall
All presumptive cases
Yield† 22.7 26.0 24.0 25.7 28.1 26.7 3.0 (P , 0.001) 2.1(P , 0.001) 2.7 (P , 0.001)
FP† 1.0 1.0 1.0 1.9 2.2 2.0 0.9 1.2 1
FN† 20.5 13.9 17.8 12.1 9.6 11.0 8.4 4.3 6.8
New presumptive cases
Yield† 21.1 23.4 21.9 25.1 26.6 25.6 4.0 (P , 0.001) 3.2 (P , 0.001) 3.7 (P , 0.001)
FP† 1.0 1.1 1.0 2.0 2.2 2.0 1 1.1 1
FN† 25.0 20.3 23.3 12.9 11.7 12.5 12.1 8.6 10.8
Previously treated presumptive cases
Yield† 29.2 31.4 30.4 28.3 31.2 29.9 0.9 (P ¼ 0.125) 0.2 (P ¼ 0.771) 0.1 (P ¼ 0.212)
FP† 0.9 0.9 0.9 1.8 2.2 2.0 0.9 1.3 1.1
FN† 3.6 2.4 3.0 8.8 5.8 7.1 5.2 3.4 4.1
* In Scenario B, the estimated TB prevalence among presumptive case was increased by 10; 50% of presumptive cases knew their HIV status. The same values for
proportions of HIV, HIVþ (status known and undiagnosed), and new and previously treated cases were used in each algorithm.
† TB diagnostic yield (yield)¼ (TPþ FP)/presumptive cases; TP¼ correctly diagnosed with TB/culture-positive TB cases; FP¼ incorrectly diagnosed with TB/culture-
negative TB cases; FN¼ incorrectly NOT diagnosed with TB (missed)/culture-positive TB cases.
TB¼ tuberculosis; CI¼confidence interval; HIV¼human immunodeficiency virus;¼negative;þ¼positive; FP¼ false-positive; FN¼ false-negative; TP¼ true-positive.
Table A.8 Scenario C: increased proportion of smear- or Xpert-negative presumptive cases with additional culture*
Smear/culture-based algorithm
% (95%CI)
Xpert-based algorithm
% (95%CI)
Change in yield between algorithms
% difference P value
HIV HIVþ Overall HIV HIVþ Overall HIV HIVþ Overall
All presumptive cases
Yield† 15.9 18.2 16.8 17.2 19.3 18.1 1.3 (P , 0.001) 1.2 (P , 0.001) 1.3 (P , 0.001)
FP† 0.9 1.0 0.9 2.0 2.2 2.1 1.1 1.2 1.2
FN† 14.5 9.8 12.5 11.9 8.8 10.6 2.6 1 1.9
New presumptive cases
Yield† 15.0 16.4 15.5 16.7 18.1 17.2 1.7 (P , 0.001) 1.6 (P , 0.001) 1.7 (P , 0.001)
FP† 0.9 0.9 0.9 2.0 2.1 2.0 1.1 1.2 1.1
FN† 17.5 14.5 16.4 12.7 10.8 12.0 4.8 3.7 4.4
Previously treated presumptive cases
Yield† 19.6 21.6 20.7 19.4 21.9 20.7 0.2 (P ¼ 0.632) 0.3 (P ¼ 0.543) 0.0 (P ¼ 0.895)
FP† 0.9 1.0 0.9 1.9 2.4 2.1 1 1.4 1.2
FN† 3.5 1.6 2.4 8.7 5.2 6.8 5.2 3.6 4.4
* In Scenario C, 85% of cases in each algorithm underwent the initial tests as required; 50% of presumptive cases knew their HIV status. Additional culture was
based on values found in routine practice for each patient category (smear/culture algorithm by 14.3%, Xpert algorithm by 8%). The same values for TB
prevalence, proportions of HIV–, HIVþ (status known and undiagnosed), and new and previously treated cases were used in each algorithm.
†TB diagnostic yield (yield)¼ (TPþ FP)/presumptive cases; TP¼ correctly diagnosed with TB/culture-positive TB cases; FP¼ incorrectly diagnosed with TB/culture-
negative TB cases; FN¼ incorrectly NOT diagnosed with TB (missed)/culture-positive TB cases.
CI¼confidence interval; HIV¼human immunodeficiency virus;¼negative;þ¼positive; FP¼ false-positive; FN¼ false-negative; TB¼ tuberculosis; TP¼ true-positive.
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Table A.9 Scenario D: increased proportion (85%) of presumptive cases who know their HIV status*
Smear/culture-based algorithm Xpert-based algorithm
Change in yield between algorithms
% difference P value
HIV HIVþ Overall HIV HIVþ Overall HIV HIVþ Overall
All presumptive cases
Yield† 14.8 18.7 16.4 17.1 20.5 18.4 2.3 (P , 0.001) 1.8 (P , 0.001) 2.1 (P , 0.001)
FP† 0.9 0.9 0.9 1.9 2.4 2.1 1 1.5 1.2
FN† 20.7 5.9 14.4 12.6 2.7 8.4 8.1 3.2 6
New presumptive cases
Yield† 13.6 17.1 14.9 16.5 19.2 17.5 2.9 (P , 0.001) 2.2 (P , 0.001) 2.6 (P , 0.001)
FP† 0.9 0.9 0.9 2.0 2.4 2.1 1.1 1.5 1.2
FN† 25.3 8.9 19.3 13.4 3.4 9.7 11.9 5.5 9.6
Previously treated presumptive cases
Yield† 19.5 22.0 20.8 19.1 23.0 21.2 0.4 (P ¼ 0.476) 1.0 (P ¼ 0.043) 0.0 (P ¼ 0.297)
FP† 0.9 0.9 0.9 1.8 2.4 2.1 0.9 1.5 1.2
FN† 3.9 0.7 2.1 9.5 1.5 5.1 5.6 0.8 3
*Scenario D, 85% of cases in each algorithm underwent the initial tests as required and 85% of smear- or Xpert-negative cases that were HIV-infected underwent
culture; 85% of presumptive cases knew their HIV status. The same values for TB prevalence, proportions of HIV–, HIVþ (status known and undiagnosed), and new
and previously treated cases were used in each algorithm.
†TB diagnostic yield (yield)¼ (TPþ FP)/presumptive cases; TP¼ correctly diagnosed with TB/culture-positive TB cases; FP¼ incorrectly diagnosed with TB/culture-
negative TB cases; FN¼ incorrectly NOT diagnosed with TB (missed)/culture-positive TB cases.
HIV¼ human immunodeficiency virus;¼ negative;þ¼ positive; FP¼ false-positive; FN¼ false-negative; TB¼ tuberculosis; TP¼ true-positive.
Table A.10 Scenario E: increased adherence to smear/culture and Xpert algorithm to 100%*
Smear/culture-based algorithm
% (95%CI)
Xpert-based algorithm
% (95%CI)
Change in yield between algorithms
% difference P value
HIV HIVþ Overall HIV HIVþ Overall HIV HIVþ Overall
All presumptive cases
Yield† 14.9 17.7 16.1 17.5 19.5 18.3 2.5 (P , 0.001) 1.8 (P , 0.001) 2.2 (P , 0.001)
FP† 0.9 1.0 0.9 2.1 2.4 2.2 1.2 1.4 1.3
FN† 19.8 12.1 16.5 10.9 9.0 10.1 8.9 3.1 6.4
New presumptive cases
Yield† 13.6 15.6 14.4 17.1 18.4 17.6 3.5 (P , 0.001) 2.7 (P , 0.001) 3.2 (P , 0.001)
FP† 0.9 0.9 0.9 2.1 2.4 2.2 1.2 1.5 1.3
FN† 25.3 19.0 22.9 11.0 10.5 10.8 14.3 8.5 12.1
Previously treated presumptive cases
Yield† 20.3 21.9 21.2 19.0 21.8 20.5 1.3 (P ¼ 0.013) 0.2 (P ¼ 0.744) 0.7 (P ¼ 0.057)
FP† 0.9 1.0 0.9 1.9 2.5 2.2 1 1.5 1.3
FN† 0.0 0.0 0.0 10.6 6.2 8.2 10.6 6.2 8.2
*In Scenario E, adherence to the full range of tests required in each algorithm was set at 100% from 85%; 50% of presumptive cases knew their HIV status. The
same values for TB prevalence, proportions of HIV–, HIVþ (status known and undiagnosed), and new and previously treated cases were used in each algorithm.
†TB diagnostic yield (yield)¼ (TPþ FP)/presumptive cases; TP¼ correctly diagnosed with TB/culture-positive TB cases; FP¼ incorrectly diagnosed with TB/culture-
negative TB cases; FN¼ incorrectly NOT diagnosed with TB (missed)/culture-positive TB cases.
CI¼confidence interval; HIV¼human immunodeficiency virus;¼negative;þ¼positive; FP¼ false-positive; FN¼ false-negative; TB¼ tuberculosis; TP¼ true-positive.
Table A.11 Scenario F: increased proportion of presumptive cases who know their HIV status to 100% and adherence to algorithms
to 100%*
Smear/culture-based algorithm
% (95%CI)
Xpert-based algorithm
% (95%CI)
Change in yield between algorithms
% difference P value
HIV HIVþ Overall HIV HIVþ Overall HIV HIVþ Overall
All presumptive cases
Yield† 14.9 19.7 16.8 17.5 21.2 19.0 2.5 (P , 0.001) 1.5 (P , 0.001) 2.1 (P , 0.001)
FP† 0.9 0.8 0.9 2.1 2.7 2.3 1.2 1.9 1.4
FN† 19.8 0.0 11.5 10.9 0.0 6.3 8.9 0 5.2
New presumptive cases
Yield† 13.6 18.5 15.4 17.1 20.1 18.2 3.5 (P , 0.001) 1.5 (P , 0.001) 2.8 (P , 0.001)
FP† 0.9 0.9 0.9 2.1 2.8 2.3 1.2 1.9 1.4
FN† 25.3 0.0 16.0 11.0 0.0 7.0 14.3 0 9
Previously treated presumptive cases
Yield† 20.3 22.0 21.2 19.0 23.5 21.4 1.3 (P ¼ 0.013) 1.5 (P ¼ 0.004) 0.2 (P ¼ 0.623)
FP† 0.9 0.8 0.8 1.9 2.6 2.3 1 1.8 1.5
FN† 0.0 0.0 0.0 10.6 0.0 4.7 10.6 0 4.7
*In Scenario F, increase in the percentage of presumptive cases who knew their HIV status from 50% to 100% and adherence to the full range of tests required in
each algorithm to 100% from 85%. The same values for TB prevalence, proportions of HIV, HIVþ (status known and undiagnosed), and new and previously
treated cases were used in each algorithm.
†TB diagnostic yield (yield)¼ (TPþ FP)/presumptive cases; TP¼ correctly diagnosed with TB/culture-positive TB cases; FP¼ incorrectly diagnosed with TB/culture-
negative TB cases; FN¼ incorrectly NOT diagnosed with TB (missed)/culture-positive TB cases.
CI¼confidence interval; HIV¼human immunodeficiency virus;¼negative;þ¼positive; FP¼ false-positive; FN¼ false-negative; TB¼ tuberculosis; TP¼ true-positive.
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Table A.12 Scenario G: remove culture test as part of the sequence of tests required in smear/culture and Xpert algorithms*
Smear/culture-based algorithm
% (95%CI)
Xpert-based algorithm
% (95%CI)
Change in yield between algorithms
% difference P value
HIV HIVþ Overall HIV HIVþ Overall HIV HIVþ Overall
All presumptive cases
Yield† 14.0 13.3 13.7 17.5 19.5 18.3 3.5 (P , 0.001) 6.2 (P , 0.001) 4.6 (P , 0.001)
FP† 0.9 1.0 0.9 2.1 2.4 2.2 1.2 1.4 1.3
FN† 25.3 35.2 29.4 10.9 9.0 10.1 14.4 26.2 19.3
New presumptive cases
Yield† 13.6 12.5 13.2 17.1 18.4 17.5 3.5 (P , 0.001) 5.9 (P , 0.001) 4.3 (P , 0.001)
FP† 0.9 0.9 0.9 2.1 2.4 2.2 1.2 1.5 1.3
FN† 25.3 36.1 29.3 11.0 20.3 10.5 14.3 15.8 18.8
Previously treated presumptive cases
Yield† 15.4 14.8 15.1 19.0 21.8 20.5 3.6 (P , 0.001) 6.9 (P , 0.001) 5.4 (P , 0.001)
FP† 0.9 1.0 0.9 1.9 2.5 2.2 1 1.5 1.3
FN† 25.2 33.6 29.9 10.6 6.2 8.2 14.6 27.4 21.7
*In Scenario G, culture testing was removed as part of the sequence of tests required in each algorithm; 50% of presumptive cases knew their HIV status. The same
values for TB prevalence, proportions of HIV, HIVþ (status known and undiagnosed), and new and previously treated cases were used in each algorithm.
†TB diagnostic yield (yield)¼ (TPþ FP)/presumptive cases; TP¼ correctly diagnosed with TB/culture-positive TB cases; FP¼ incorrectly diagnosed with TB/culture-
negative TB cases; FN¼ incorrectly NOT diagnosed with TB (missed)/culture-positive TB cases.
CI¼ confidence interval; HIV¼ human immunodeficiency virus;¼ negative;þ¼ positive; FP¼ false-positive; FN¼ false-negative; TB¼ tuberculosis; TP¼ true-
positive.
Table A.13 Scenario H: lower test sensitivity of smear microscopy by 10% in smear/culture algorithm*
Smear/culture-based algorithm
% (95%CI)
Xpert-based algorithm
% (95%CI)
Change in yield between algorithms
% difference P value
HIV HIVþ Overall HIV HIVþ Overall HIV HIVþ Overall
All presumptive cases
Yield† 13.4 16.6 14.7 17.1 19.1 17.9 3.6 (P , 0.001) 2.6 (P , 0.001) 3.2 (P , 0.001)
FP† 1.0 1.0 1.0 1.9 2.2 2.0 0.9 1.2 1
FN† 28.6 18.0 24.1 12.6 9.5 11.3 16 8.5 12.8
New presumptive cases
Yield† 12.0 14.2 12.8 16.5 17.9 17.0 4.6 (P , 0.001) 3.7 (P , 0.001) 4.2 (P , 0.001)
FP† 1.0 1.1 1.0 2.0 2.1 2.0 1 1 1
FN† 35.1 26.8 32.0 13.4 11.5 12.7 21.7 15.3 19.3
Previously treated presumptive cases
Yield† 19.2 21.4 20.4 19.1 21.7 20.5 0.1 (P ¼ 0.881) 0.3 (P ¼ 0.493) 0.1 (P ¼ 0.681)
FP† 0.9 0.9 0.9 1.8 2.3 2.1 0.9 1.4 1.2
FN† 5.4 2.7 3.9 9.5 6.1 7.6 4.1 3.4 3.7
* In Scenario H, the test sensitivity of smear microscopy was reduced by 10%. The Xpert algorithm is set as per Scenario A; 50% of presumptive cases knew their
HIV status. The same values for TB prevalence, proportions of HIV, HIVþ (status known and undiagnosed), and new and previously treated cases were used in each
algorithm.
† TB diagnostic yield (yield)¼ (TPþ FP)/presumptive cases; TP¼ correctly diagnosed with TB/culture-positive TB cases; FP¼ incorrectly diagnosed with TB/culture-
negative TB cases; FN¼ incorrectly NOT diagnosed with TB (missed)/culture-positive TB cases.
CI¼ confidence interval; HIV¼ human immunodeficiency virus;¼ negative;þ¼ positive; FP¼ false-positive; FN¼ false-negative; TB¼ tuberculosis; TP¼ true-
positive.
Table A.14 Summary of input and output parameters for model sensitivity analysis*
Base value High value Low value
Estimated TB prevalence among presumptive cases
Input 18.9 28.9 8.9
Output
Smear/culture-based algorithm
Yield 15.8 24.0 7.6
FP 0.9 1.0 1.0
FN 17.6 17.4 16.9
Xpert-based algorithm
Yield 17.5 26.1 8.7
FP 1.9 1.9 1.9
FN 12.5 12.5 12.4
Proportion of presumptive cases with previous anti-tuberculosis treatment
Input 25 50 15
Output
Smear/culture-based algorithm
Yield 15.8 17.3 15.2
FP 0.9 1.0 1.0
FN 17.6 11.7 19.3
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Table A.14 (continued)
Base value High value Low value
Xpert-based algorithm
Yield 17.5 18.2 17.0
FP 1.9 2.0 1.9
FN 12.5 11.1 13.1
Test sensitivity of smear microscopy and Xpert
Input
Smear microscopy (two samples)
HIV-negative 75 85 65
HIV-positive 65 75 55
Xpert
HIV-negative 89 94 81
HIV-positive 80 88 67
Output
Smear/culture-based algorithm
Yield 15.8 17.0 14.7
FP 0.9 1.0 1.0
FN 17.6 11.4 23.6
Xpert-based algorithm
Yield 17.5 18.1 16.5
FP 1.9 1.9 1.9
FN 12.5 9.3 17.9
* TB diagnostic yield (yield)¼ (TPþFP)/presumptive cases; TP¼correctly diagnosed with TB/culture-positive TB cases; FP
¼ incorrectly diagnosed with TB/culture-negative TB cases; FN¼ incorrectly NOT diagnosed with TB (missed)/culture-
positive TB cases.
TB¼ tuberculosis; FP¼ false-positive; FN¼ false-negative; HIV¼ human immunodeficiency virus; TP¼ true-positive.
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Table A.15 Proportion of culture as part of the sequence of tests required in each diagnostic algorithm and 100% adherence to
algorithms*
Smear/culture-based algorithm Xpert-based algorithm
Base 0% culture Base 0% culture
Use of culture
Input
As part of the initial sequence of tests
New presumptive cases
HIV-negative 0 0 0 0
HIV-positive 0 0 0 0
Previously treated presumptive cases
HIV-negative 85 0 0 0
HIV-positive 85 0 0 0
As part of follow-up testing if smear or Xpert test is negative
New presumptive cases
HIV-negative 0 0 0 0
HIV-positive 85 0 85 0
Previously treated presumptive cases
HIV-negative 0 0 0 0
HIV-positive 85 0 85 0
Output
Yield 15.8 13.7 17.5 17.2
FP 0.9 0.9 1.9 2.0
FN 17.6 29.4 12.5 14.7
Adherence to algorithms
Input
As part of the initial sequence of tests
85% adherence 100% adherence 85% adherence 100% adherence
New presumptive cases
HIV-negative 2 smears 2 smears Xpert test Xpert test
HIV-positive 2 smears 2 smears Xpert test Xpert test
Previously treated presumptive cases
HIV-negative Culture test Culture test Xpert test Xpert test
HIV-positive Culture test Culture test Xpert test Xpert test
As part of followup testing if smear or Xpert test is negative
Base 0% culture Base 0% culture
New presumptive cases
HIV-negative 0 0 0 0
HIV-positive 85 100 85 100
Previously treated presumptive cases
HIV-negative 0 0 0 0
HIV-positive 85 100 85 100
Output
85% adherence 100% adherence 85% adherence 100% adherence
Yield 15.8 16.1 17.5 18.3
FP 0.9 0.9 1.9 2.2
FN 17.6 16.5 12.5 10.1
* TB diagnostic yield (yield)¼ (TPþ FP)/presumptive cases; TP¼ correctly diagnosed with TB/culture-positive TB cases; FP¼ incorrectly diagnosed with TB/culture-
negative TB cases; FN¼ incorrectly NOT diagnosed with TB (missed)/culture-positive TB cases.
HIV¼ human immunodeficiency virus; FP¼ false-positive; FN¼ false-negative; TB¼ tuberculosis; TP¼ true-positive.
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R E S U M E
CONT EX T E : Le Cap, Afrique du Sud.
OB J E C T I F : Comparer le rendement diagnostique des
algorithmes de frottis/culture et d’Xpertw MTB/RIF et
e´tudier les me´canismes influenc¸ant le rendement de la
tuberculose (TB).
M E´ THODE : Nous avons e´labore´ et valide´ un mode`le
ope´rationnel du processus de diagnostic de la TB,
d’abord avec l’algorithme de frottis/culture et ensuite
avec l’algorithme de l’Xpert. Nous avons mode´lise´ les
sce´narios en variant la pre´valence de la TB, l’adhe´sion
aux algorithmes de diagnostic et le statut du virus de
l’immunode´ficience humaine. Ceci a permis de faire des
comparaisons directes du rendement diagnostique dans
les deux algorithmes.
R E´ S U LTAT S : Les donne´es de routine ont montre´ que le
rendement diagnostique avait diminue´ pendant la
pe´riode de lancement de l’algorithme Xpert par
rapport a` la pe´riode ou` l’algorithme frottis/culture
e´tait en place. Cependant, le rendement de la
mode´lisation dans des conditions identiques a mis en
e´vidence une augmentation de 13,3% du rendement
diagnostique de l’algorithme Xpert compare´ au frottis/
culture. Le mode`le a de´montre´ que l’utilisation extensive
de la culture dans l’algorithme frottis/culture et le de´clin
de la pre´valence de la TB e´taient les principaux facteurs
contribuant a` ne pas trouver d’augmentation du
rendement diagnostique dans les donne´es de routine.
CONC LU S I ON : Nous avons de´montre´ les be´ne´fices
d’un mode`le ope´rationnel afin de de´terminer l’effet de
l’expansion d’un nouvel algorithme de diagnostic et de
recommander que les de´cideurs politiques utilisent la
mode´lisation ope´rationnelle pour prendre des de´cisions
approprie´es avant que de nouveaux algorithmes de
diagnostic ne soient e´tendus.
R E S UM E N
MARCO DE R E F E R EN C I A: La Ciudad del Cabo en
Sura´frica.
OB J E T I VO: Comparar el desempen˜o de un algoritmo
diagno´stico basado en la baciloscopia y el cultivo y un
algoritmo con la prueba Xpertw MTB/RIF e investigar
los mecanismos que influyen en su eficacia.
M E´ TODOS: Se creo´ un modelo operativo del proceso
diagno´stico de la tuberculosis (TB) y se evaluo´
inicialmente con el algoritmo de la baciloscopia y el
cultivo y luego con el algoritmo que incluı´a la prueba
Xpert. Se simularon modelos con diferentes hipo´tesis de
prevalencia de TB, adhesio´n a los algoritmos y situacio´n
frente a la infeccio´n por el virus de la inmunodeficiencia
humana. Estos modelos permitieron una comparacio´n
directa del rendimiento diagno´stico de ambos
algoritmos.
R E S U LTA D O S: Los datos de la pra´ctica corriente
pusieron de manifiesto que el rendimiento diagno´stico
disminuyo´ durante el perı´odo de despliegue del
algoritmo con la prueba Xpert en comparacio´n con el
rendimiento que se lograba cuando se aplicaba el
algoritmo de la baciloscopia y el cultivo. Sin embargo,
al utilizar la modelizacio´n en ide´nticas condiciones, se
obtuvo un aumento de 13,3% del rendimiento
diagno´stico del algoritmo con la prueba Xpert en
comparacio´n con el algoritmo de la baciloscopia y el
cultivo. La modelizacio´n revelo´ que un uso extenso del
cultivo en el algoritmo de la baciloscopia y el cultivo y la
disminucio´n de la prevalencia de TB fueron los
principales factores que explicaban el hecho de no
haber logrado un mejor rendimiento diagno´stico en los
datos de la pra´ctica corriente con la prueba Xpert.
CONC LU S I O´ N: En el presente estudio se demuestra la
utilidad de un modelo operativo disen˜ado con el
propo´sito de determinar el efecto de la ampliacio´n de
escala de un nuevo algoritmo diagno´stico y se
recomienda que las instancias normativas apliquen la
modelizacio´n operativa a fin de adoptar las decisiones
apropiadas, antes de ampliar la escala de nuevos
algoritmos diagno´sticos.
xiv The International Journal of Tuberculosis and Lung Disease
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Chapter 3: Improving rifampicin resistant tuberculosis 
diagnosis with Xpert® MTB/RIF: modelling interventions and 
costs 
 
Accepted: The International Journal of Tuberculosis and Lung Disease, 2017-10-06. 
Reprinted with permission of the International Union Against Tuberculosis and Lung 
Disease. Copyright © The Union. 
 
Summary: In this chapter, I model interventions to improve the diagnosis of RMP-R 
TB in terms of the number of RMP-R TB cases diagnosed and cost. I developed and 
validated an operational model using routine data from the empirical study 
representing TB and RMP-R TB diagnostic algorithms as implemented in Cape Town. 
I modelled the RMP-R TB cases detected and missed in the smear/culture and Xpert-
based algorithms using identical input parameters (population characteristics and 
100% adherence to diagnostic algorithms) for both algorithms. I then modelled 
interventions in the Xpert-based algorithm by varying adherence to the Xpert-based 
algorithm and varying the proportion who know their HIV status during TB diagnosis. 
The model indicated a small increase in the number of TB cases detected (5.1%) with 
the real benefit of the Xpert-based algorithm the 102.6% increase in the number of 
RMP-R TB cases detected with only a 7.4% increase in the cost per RMP-R TB case 
detected between the smear/culture and Xpert-based algorithm. When adherence to 
the Xpert-based algorithm was increased from 50% to 100%, the number of RMP-R 
TB cases detected increased by 63.4%. Increasing the proportion who know their HIV 
status in the Xpert-based algorithm from 60% to 100% resulted in only a 4.6% increase 
in RMP-R TB cases detected. The Xpert-based algorithm is efficient in detecting RMP-
R TB as the increase in costs is offset by the increase in the number of cases detected. 
Adherence to the Xpert-based algorithm is important to ensure all presumptive TB 
cases receive the benefit of simultaneous TB and RMP-R testing. 
My contributions: In this chapter, I did the development and validation of the model. 
I conducted the overall data management and data analysis as well as conceived, 
designed and performed the experiments of running the different scenarios in the 
model. I wrote the manuscript and submitted the final manuscript for publication to the 
peer-reviewed journal.  
Co-author contribution: Pren Naidoo, Ivor Langley and Nulda Beyers contributed 
with conceiving and designing experiments. The co-authors reviewed the draft 
manuscript and approved the final draft manuscript for submission.    
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Setting 
Cape Town, South Africa 
Objective 
To model RMP-R diagnosis and laboratory costs in smear/culture and Xpert-based 
algorithms and the effect of varying adherence and HIV testing in the Xpert-based 
algorithm. 
Methods 
We used a validated operational model (100,000 population) and published 
laboratory cost data. We estimated the number and cost of RMP-R TB cases 
identified between a smear/culture and Xpert-based algorithm. We modelled varying 
adherence and different levels of known HIV-status to the Xpert-based algorithm. 
Results 
RMP-R TB cases identified increased from 603 with smear/culture to 1,178 with the 
Xpert-based algorithm (100% adherence - 60% knew their HIV status). The overall 
laboratory cost increased from U$1,073,858 to U$2,430,050 and the cost per RMP-
TB case identified increased from U$1,781 to U$2,063 in respective algorithms.  
When adherence to the Xpert-based algorithm was increased from 50% to 100% 
(60% knew their HIV-status), the number of RMP-R TB cases identified increased 
from 721 to 1,178. 
Conclusion 
The Xpert-based algorithm is efficient in identifying RMP-R TB as the increase in 
costs is offset by the increase in the number of cases identified. Adherence to the 
Xpert-based algorithm is important to ensure all presumptive TB cases receive the 
benefit of simultaneous TB and RMP-R testing. 
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3.1 Introduction  
Globally the multidrug-resistant tuberculosis (MDR-TB) crisis is continuing. The 
burden of MDR-TB is decreasing more slowly than the overall burden of tuberculosis 
(TB) and in some countries the MDR-TB burden is on the increase.1 The World 
Health Organisation (WHO) collectively defines cases of MDR-TB (defined as 
resistance to rifampicin and isoniazid) and rifampicin-resistant (RMP-R) TB as 
MDR/RMP-R TB with the recommendation to start all these cases on a second-line 
MDR-TB regimen.1 
The gaps between the estimated number of  incident MDR/RMP-R TB cases, the 
number diagnosed and the number notified are still of major concern. Globally there 
were 3.4 million bacteriologically confirmed TB cases notified in 2015 of which only 
30% were reported to have had a drug susceptibility test (DST) for rifampicin. In 
2015, 132,120 cases of MDR/RMP-R TB were detected and notified globally which 
amounts to only 40% of the estimated 340,000 MDR/RMP-R TB cases that could 
have been detected had DST been provided to all pulmonary TB patients notified in 
2015.1  
In South Africa, there were a total of 294,603 TB cases notified in 2015 of whom 
196,783 (66.8%) were tested for RMP resistance. Of the 19,613 MDR/RMP-R TB 
cases diagnosed only 12,527 were reported to have started treatment.1 
The WHO endorsed the use of Xpert® MTB/RIF (Xpert) (Cepheid, Sunnyvale, CA, 
USA)  in 20102 after which South Africa implemented Xpert in 2011 as a 
replacement test for smear microscopy for all presumptive TB cases. The 
introduction of the more sensitive Xpert test2,3 offered improved TB case detection 
with the added benefit of simultaneous screening for RMP-R. The Xpert test makes it 
possible for a RMP-R TB result to be available in the laboratory within a few hours 
rather than in 2 to 6 weeks as would be the case with culture-based testing.4 
However, studies have reported variable adherence to the Xpert-based algorithm. A 
nationwide retrospective cohort study in South Africa assessing second-line 
treatment initiation reported that in 2013, after full national rollout of Xpert, only 59% 
of RMP-R TB cases received an initial Xpert test and 63% of RMP-R TB cases 
diagnosed started treatment.5 
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The PROVE IT (Policy Relevant Outcomes from Validating Evidence on ImpacT) 
Study evaluating the impact of Xpert  in Cape Town, South Africa, compared the 
proportion of RMP-R TB cases diagnosed pre-treatment in the smear/culture-based 
and Xpert-based algorithms.6 This study found that the proportion of TB cases with 
DST undertaken pre-treatment increased from 42.7% in the smear/culture-based 
algorithm to 78.9% in the Xpert-based algorithm. The proportion of TB cases with 
RMP-R diagnosed was 5.5% and 7.7% respectively - a 33.3% increase in RMP-R 
TB cases. A laboratory costing study in PROVE IT, reported a 42% increase in 
overall TB diagnostic costs and a 157% increase in the cost per TB case diagnosed 
with the transition from a smear/culture to the Xpert-based algorithm with a similar 
cost per MDR/RMP-R TB case diagnosed of US$190.14 and US$183.86 
respectively.7 Underlying differences in the populations tested (prevalence of TB, 
HIV coinfection and drug resistance, TB cases with a previously history of TB 
treatment) and adherence to the algorithms may have contributed to these findings 
and was a limitation in both studies.   
This study used an operational model to compare the number and proportion of 
RMP-R TB cases identified, and the cost per RMP-R TB case identified between a 
smear/culture and an Xpert-based algorithm. Since adherence to the Xpert-based 
algorithm in South Africa has been sub-optimal, we evaluated the effect of increased 
adherence to the algorithm and increased HIV testing amongst presumptive TB 
cases (which influences the ability to diagnose Xpert-negative TB cases) on the 
number and proportion of RMP-R TB cases identified. 
3.2 Methods 
3.2.1 Definitions 
Presumptive case: We defined a presumptive TB case in the model as an individual 
who had pre-treatment sputum specimens collected for TB diagnostic purposes. 
TB case: We defined a TB case in the model as an individual with culture positive TB, 
irrespective of how the individual was ultimately identified (i.e. tested positive by either 
sputum smear microscopy or culture or Xpert). False positive TB cases (true negative 
TB cases in the population as defined by culture, with a positive test result by either 
sputum smear microscopy or Xpert) identified in the model were excluded.   
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RMP-R TB case: We defined a RMP-R TB case in the model as a TB case with 
rifampicin resistance. False positive RMP-R TB cases (true negative RMP-R TB cases 
in the population as defined by culture and conventional DST, with a positive test by 
either LPA or Xpert) were excluded.  
Adherence to algorithm: We defined adherence to an algorithm as the proportion of 
presumptive TB cases that received the full sequence of test as stipulated by the 
diagnostic algorithm (Figure 1).8 
3.2.2 Setting and timeframe 
The study is set in Cape Town, one of the large cities in South Africa, with a 
population of 3.7 million in 2011 (National Census 2011). MDR/RMP-R case 
notification among TB cases increased from 3.6% (1,020/28,644) in 2011 to 4.4% 
(1,134/25,846) in 2013 (Routine TB Programme Data, Cape Town Health 
Directorate, April 2016).  
In Cape Town, free TB diagnostic services are provided at 142 primary health care 
(PHC) facilities in eight health sub-districts. All TB diagnostic tests are performed at 
a central laboratory, National Health Laboratory Services (NHLS), with all sputum 
specimens collected for TB testing at PHC facilities couriered to NHLS on a daily 
basis for testing and results returned to facilities via courier and fax. 
Up until August 2011 a smear/culture-based algorithm was in place in Cape Town 
and from August 2011 an Xpert-based algorithm was introduced with Xpert replacing 
smear microscopy as a 1st-line test (Figure 1). The rollout of the Xpert-based 
algorithm was completed by February 2013 (with 5 Xpert GX XVI modules placed at 
the laboratory7). 
3.2.3 Model development 
We developed and validated an operational model using routine National Health 
Laboratory data collected for the period 2010 to 2013 in Cape Town, including the 
period when Xpert was rolled out.9  The Witness package10, a discrete event and 
continuous process simulator, was used to develop a comprehensive model to 
represent the diagnosis of pulmonary TB and RMP-R TB in Cape Town. The model 
incorporated the TB diagnostic algorithms (Figure 1) and specimen flow from 
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specimen collection, through laboratory test procedures, to a test result being 
available at the laboratory. The model was developed for both the previous 
smear/culture-based and current Xpert-based algorithms as stipulated by the South 
African National TB programme.8  
Further details regarding model development, validation as well as model sensitivity 
analysis was previously published.9 
3.2.4 Model inputs  
As part of the PROVE IT (Policy Relevant Outcomes from Validating Evidence on 
ImpacT) Study conducted in Cape Town, routine TB and MDR/RMP-R TB treatment 
data as well as NHLS data from presumptive TB cases had previously been 
collected and analysed to compare TB yield11 and RMP-R TB yield6 in the 
smear/culture and the Xpert-based algorithms. Input parameters for the model used 
probability distributions derived from these analyses (Table 2). We used identical 
input parameters to model the number and proportion of RMP-R TB cases identified 
amongst 100,000 presumptive TB cases screened in the smear/culture and Xpert-
based algorithms.  
Laboratory cost data per test in each algorithm were obtained from a costing 
evaluation undertaken at the high throughput central laboratory (NHLS) in Cape 
Town (Table 1).7 Costs were calculated for sputum smear microscopy, culture, line 
probe assay (LPA) and Xpert and used to estimate total TB diagnostic costs in each 
algorithm (all expressed in 2013 values).  
In the Xpert-based algorithm, we modelled scenarios with varying levels of 
adherence to the algorithm (at increments of 10% from 50% to 100%) and varying 
the proportion of presumptive TB cases that knew their HIV status (at 60%, 80% and 
100%) since routine NHLS data showed that 50% of presumptive TB cases knew 
their HIV status in 2013.9,11  
3.2.5 Model outputs and analysis 
We firstly modelled the RMP-R TB cases identified and missed in the smear/culture 
and Xpert-based algorithms. We report the RMP-R cases identified as a number and 
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as a percentage of TB cases identified among the 100,000 presumptive TB cases 
evaluated.  
The overall laboratory TB diagnostic costs per algorithm were calculated using 
model outputs on the number of tests undertaken and cost per test from the costing 
study (Table 1).7  We calculated the cost per RMP-R TB case identified in both 
algorithms by dividing the total TB diagnostic costs by the number of RMP-R TB 
cases identified.  We calculated the cost per additional RMP-R TB case identified in 
the Xpert-based algorithm by dividing the difference in total diagnostic costs by the 
difference in the number of RMP-R TB cases identified between the algorithms. 
In order to evaluate the effect of varying adherence levels to the Xpert-based 
algorithm and varying proportion of HIV testing in the Xpert-based algorithm we 
compared the number and proportion of RMP-R TB cases identified and missed in 
each scenario. 
3.3 Ethics statement 
The Health Research Ethics Committee at Stellenbosch University (IRB0005239) 
(N10/09/308) and Ethics Advisory Group at The International Union Against 
Tuberculosis and Lung Disease (59/10) approved the study. The City of Cape Town 
Health Directorate, Western Cape Health Department and National Health 
Laboratory Service granted permission to use routine health data. 
3.4 Results 
3.4.1 Model outputs for the smear/culture and Xpert-based algorithms at 100% 
adherence to algorithms 
3.4.1.1 RMP-R TB cases identified  
The model indicated that if 60% of presumptive cases knew their HIV status, 603 
RMP-R cases (3.9% of 15,475 TB cases) were identified in the smear/culture 
compared to 1,178 RMP-R cases (7.2% of 16,332 TB cases) identified in the Xpert-
based algorithm.  
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When 100% of presumptive cases knew their HIV status, 608 RMP-R cases (3.8% of 
16,144 TB cases) were identified in the smear/culture compared to 1,232 RMP-R 
cases (7.3% of 16,968 TB cases) in the Xpert-based algorithm (Table 3). 
3.4.1.2 RMP-R TB cases missed 
In the scenario where 60% of presumptive cases knew their HIV status, a total of 
795 (56.9%) RMP-R cases were missed in the smear/culture-based algorithm: 231 
(16.5%) had a false negative TB test, 13 (0.9%) had a false negative RMP-R result 
and 551 (39.4%) had no DST done pre-treatment. In the Xpert-based algorithm a 
total of 220 (15.7%) RMP-R cases were missed: 144 (10.3%) had a false negative 
TB test, 76 (5.4%) had a false negative RMP-R result and all presumptive cases 
were screened for RMP resistance pre-treatment (Table 3). 
When 100% of presumptive cases knew their HIV status, a total of 790 (56.5%) 
RMP-R cases were missed in the smear/culture-based algorithm: 226 (16.2%) had a 
false negative TB test, 13 (0.9%) had a false negative RMP-R result and 551 
(39.4%) had no DST done pre-treatment. In the Xpert-based algorithm a total of 166 
(11.9%) RMP-R cases were missed: 88 (6.3%) had a false negative TB test, 78 
(5.6%) had a false negative RMP-R result and all presumptive cases were screened 
for RMP resistance pre-treatment (Table 3).  
3.4.1.3 Laboratory costs  
In the scenario where 60% of presumptive TB cases knew their HIV status the 
overall laboratory TB diagnostic cost was U$1,073,858 in the smear/culture and 
U$2,430,050 in the Xpert-based algorithm. The cost per RMP-R TB case identified 
was U$1,781 in the smear/culture compared to U$2,063 in the Xpert-based 
algorithm. If 100% of presumptive TB cases knew their HIV status the overall 
laboratory TB diagnostic costs were U$1,240,777 and U$2,700,384 respectively and 
the costs per RMP-R TB case identified were U$2,041 and U$2,192 respectively.  
The cost per additional RMP-R TB cases identified in the Xpert compared to 
smear/culture-based algorithm was US$2,359 and US$2,339 in scenarios when 60% 
and 100% respectively knew their HIV status (Table 3).  
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3.4.2 Model outputs for an Xpert-based algorithm with varying adherence to the 
algorithm  
3.4.2.1 RMP-R TB cases identified  
In scenarios where 60% of presumptive cases knew their HIV status and with 50% 
adherence to the algorithm, 721 RMP-R cases (4.7% of 15,398 TB cases) were 
identified, increasing to 1,178 (7.2% of 16,332 TB cases) RMP-R cases identified 
with 100% adherence to the algorithm.  
In scenarios where 100% of presumptive cases knew their HIV status and with 50% 
adherence to the algorithm, 742 RMP-R cases (4.7% of 15,892 TB cases) were 
identified, increasing to 1,232 (7.3% of 16,968 TB cases) RMP-R cases with 100% 
adherence to the algorithm (Table 4, Figure 2 and 3). 
3.4.2.2 RMP-R TB cases missed  
In a scenario when 60% of presumptive cases knew their HIV status and with 50% 
adherence in the Xpert-based algorithm, 677 (48.4%) RMP-R cases were missed: 
240 (17.2%) had a false negative TB test, 40 (2.9%) had a false negative RMP-R 
result and 397 (28.4%) had no DST done pre-treatment. When adherence increased 
to 100%, 220 (15.7%) RMP-R cases were missed: 144 (10.3%) had a false negative 
TB test, 76 (5.4%) had a false negative RMP-R result and all cases had a DST done 
pre-treatment (Table 4, Figures 3). 
3.4.3 Model outputs for an Xpert-based algorithm with varying proportion of 
presumptive cases that knew their HIV status 
3.4.3.1 RMP-R TB cases identified  
In scenarios where we set adherence to the algorithm at 50% and varied the 
proportion of presumptive cases who knew their HIV status, 721 RMP-R cases 
(4.7% of 15,398 TB cases) were identified when 60% of presumptive TB cases knew 
their HIV-status increasing to 742 RMP-R cases (4.7% of 15,892 TB cases) when 
100% knew their HIV status.  
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When we set adherence at 100% 1,178 RMP-R cases (7.2% of 16,332 TB cases) 
were identified when 60% knew their HIV status increasing to 1,232 RMP-R cases 
(7.3% of 16,968 TB cases) when 100% knew their HIV status (Table 4, Figures 2 
and 3). 
3.4.3.2 RMP-R TB cases missed  
In a scenario when 60% of presumptive cases knew their HIV status and with 50% 
adherence in the Xpert-based algorithm, 677 (48.4%) RMP-R cases were missed: 
240 (17.2%) had a false negative TB test, 40 (2.9%) a false negative RMP-R result 
and 397 (28.4%) had no DST done pre-treatment. When 100% knew their HIV status 
656 (46.9%) RMP-R cases were missed: 217 (15.5%) had a false negative TB test, 
42 (3.0%) had a false negative RMP-R result and 397 (28.4%) were not screened for 
RMP-R pre-treatment (Table 4, Figures 3). 
3.5 Discussion 
In many countries, including South Africa, DST was historically limited to 
presumptive TB cases with a history of previous TB treatment as these cases have a 
higher risk than new cases of developing MDR-TB.12–14 Therefore, in the 
smear/culture-based algorithm DST was limited to those with a history of previous 
TB treatment, MDR-TB contacts or those in congregate settings. It was assumed 
that the small number of new TB case with MDR-TB missed pre-treatment would 
start 1st-line TB treatment and would eventually be diagnosed with MDR-TB when 
1st-line treatment failed. In contrast, with the Xpert-based algorithm all presumptive 
TB cases receive an Xpert test and are simultaneously screened for RMP-R.  
The PROVE IT Study which used a non-randomised stepped-wedge design to 
compare TB yield between the smear/culture and Xpert-based algorithms found no 
difference in TB yield between algorithms11. Possible factors contributing to this 
finding included the following: (1) a decline in TB prevalence over time; (2) higher 
than expected use of culture in the smear/culture-based algorithm; (3) limited use of 
culture for HIV-infected Xpert-negative cases; (4) and poor adherence to the Xpert-
based algorithm. Despite this, the PROVE IT study found a 54% increase in the 
number of RMP-R TB cases diagnosed pre-treatment (from 269 to 415)6, which may 
be an underestimate of the benefit of the Xpert-based algorithm on RMP-R TB 
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diagnosis. The model allowed us to address these issues and enabled comparison 
of the two algorithms with similar adherence and identical population characteristics.  
The model showed small differences in the number of TB cases identified (Table 3) 
between the smear/culture and Xpert-based algorithms (a 5.5% and 5.1% increase 
in TB yield when 60% and 100% of presumptive cases respectively knew their HIV 
status). The real benefit of the Xpert-based algorithm was the 95.4% and 102.6% 
increase in the number of RMP-R TB cases identified when 60% and 100% of 
presumptive cases respectively knew their HIV status. The overall laboratory costs 
between algorithms increased by 126.3% and 117.6% when 60% and 100% of 
presumptive cases respectively knew their HIV status. These costs were off-set by 
the increase in the number of RMP-R TB cases identified, resulting only in a 15.8% 
and 7.4% increase respectively in the cost per RMP-R TB case identified in the 
Xpert-based algorithm.  
In the Xpert-based algorithm, cases not tested by Xpert were tested by the previous 
smear/culture-based algorithm. When adherence to the Xpert-based algorithm was 
increased from 50% to 100%, the number of RMP-R TB cases identified increased 
by 63.4% if 60% of presumptive TB cases knew their HIV-status (Table 4). This 
illustrates the importance of simultaneous screening for TB and RMP-R, as occurs 
with adherence to the Xpert-based algorithm.      
Increasing the proportion of presumptive TB cases who knew their HIV status had 
very little effect on the number of RMP-R TB cases identified in the Xpert-based 
algorithm. When the proportion was increased from 60% to 100%, the number of 
RMP-R TB identified increased by 2.9% and 4.6% at 50% and 100% adherence 
respectively. However, HIV-testing of presumptive TB cases does have other clinical 
importance, for example access to antiretroviral therapy.  
3.5.1 Strengths and limitations 
The strengths of the current study are that we used a validated model, based on real 
data on testing and diagnosis, to estimate the number and cost per RMP-R TB cases 
identified in the smear/culture and Xpert-based algorithms. Our study provides a 
better estimate of these as the PROVE IT  laboratory costing and RMP-R TB yield 
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studies included false-positive TB and RMP-R TB cases and the population tested in 
the Xpert and smear/culture eras may have had  different characteristics.6,7,11  
The model was validated against data from Cape Town, a well-resourced urban 
setting where there was extensive use of culture. This may limit the generalisability 
of our findings to other settings.  
3.6 Conclusion 
The model showed a substantial increase in the number of RMP-R TB cases 
identified with a transition from a smear/culture to an Xpert-based algorithm even 
though the increase in the number of TB cases identified was small. The Xpert-
based algorithm was relatively efficient in diagnosing RMP-R TB cases as the overall 
increase in laboratory costs was offset by the increased number of RMP-R TB cases 
identified. Our model highlights the importance of adherence to the Xpert-based 
algorithm in order to ensure that all presumptive TB cases receive an Xpert test and 
are simultaneously tested for TB and RMP-R.  
The value of this operational model is that future new diagnostic tests and their use 
in a TB diagnostic algorithm, within an operational setting, can be evaluated.   
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Table 1: Test costs for sputum smear microscopy, culture, line probe assay and Xpert in the 
smear/culture and Xpert-based algorithms* (Reprinted with permission of the International Union 
Against Tuberculosis and Lung Disease. Copyright © The Union)7 
 Smear 
microscopy 
(Bleach 
treated) 
US$ 
Smear 
microscopy & 
culture 
US$ 
Culture 
confirmation 
US$ 
MTBDRplus 
line-probe 
assay 
US$ 
Xpert 
US$ 
Smear/culture-based algorithm 
Building space 0.02 0.14 0.05 0.15 - 
Equipment 0.11 0.72 0.02 0.17 - 
Consumables 0.36 3.87 0.84 12.67 - 
Staff 0.55 2.21 0.57 1.34 - 
Overheads# 1.80 1.80 0.00 1.80 - 
Cost per test 2.85 8.75 1.49 16.12 - 
Xpert-based algorithm 
Building space 0.02 0.14 0.05 0.15 0.06 
Equipment 0.13 0.74 0.02 0.18 0.40 
Consumables 0.36 3.87 0.84 12.67 14.62 
Staff 0.55 2.21 0.57 1.34 1.32 
Overheads# 2.64 2.64 0.00 2.64 2.64 
Cost per test 3.70 9.62 1.49 16.98 19.03 
*Test costs are for the central National Health Laboratory only. All costs are expressed in 2013 CPI-
adjusted values. Overhead costs included costs for buildings, equipment, consumables and staff 
involved in specimen sorting and registration, results processing, procurement, stores, training, 
supervision and management. Specimen transport, electricity, water, sanitation, municipal and 
biohazardous waste disposal, cleaning and janitorial services, security services and telephone and 
Internet costs were also included. In each scenario tested, we determined the number of tests 
performed per algorithm, applied the above costs and calculated the cost per TB and RMP-R TB case 
identified. 
 
  
71
Stellenbosch University  https://scholar.sun.ac.za
Table 2: Input parameters used for the smear/culture and Xpert-based algorithms 
 Input values (%) 
 
New 
presumptive 
cases 
Previously 
treated 
presumptive 
cases 
 75 25 
HIV status 
HIV-positive 36 54 
HIV-negative 64 46 
Best estimated TB prevalence amongst presumptive cases 18 21 
Estimated proportion of RMP-R cases amongst TB cases 6 12 
Accuracy of fluorescence 
light-emitting diode (LED) 
smear microscopy15,16 (1 
specimen) 
 
Sensitivity 
HIV-positive 55 
HIV-negative 60 
Specificity 
HIV-positive 99 
HIV-negative 99 
Accuracy of fluorescence 
light-emitting diode (LED) 
smear microscopy15,16 (2 
specimens) 
 
Sensitivity 
HIV-positive 65 
HIV-negative 75 
Specificity 
HIV-positive 99 
HIV-negative 99 
Accuracy of Xpert MTB/RIF 
for TB17 
Sensitivity 
HIV-positive 80 
HIV-negative 89 
Specificity 
HIV-positive 98 
HIV-negative 98 
Accuracy of GenoType® 
MTBDRplus LPA for RMP-R 
TB18 
 
Sensitivity HIV-positive 98 
Specificity HIV-positive 98 
Accuracy of Xpert MTB/RIF 
for RMP-R TB17 
Sensitivity HIV-positive 94 
Specificity HIV-positive 98 
NHLS data from presumptive cases had been analysed previously as part of the PROVE IT (Policy 
Relevant Outcomes from Validating Evidence on ImpacT) study. Input parameters derived from these 
analyses were used as probability distributions for the model.6,9,11 Test sensitivity and specificity is 
provided relative to culture and phenotypic culture-based DST.  
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Table 3: The number and percentage of TB and RMP-R TB cases identified in a smear/culture 
compared to an Xpert-based algorithm and laboratory diagnostic cost for both algorithms 
  
Smear/Culture-based algorithm 
n (%) 
Xpert-based algorithm 
n (%) 
Relative % 
difference in Xpert 
compared to 
smear/culture-
based algorithm 
% knew their HIV status* % knew their HIV status* % knew their HIV status* 
60 80 100 60 80 100 60 80 100 
TB cases 
identified 
15,475 
(15.5) 
15,810 
(15.8) 
16,144 
(16.1) 
16,332 
(16.3) 
16,670 
(16.7) 
16,968 
(17.0) 5.5 5.4 5.1 
RMP-R TB 
cases 
identified 
603 
(3.9) 
607 
(3.8) 
608 
(3.8) 
1,178 
(7.2) 
1,201 
(7.2) 
1,232 
(7.3) 95.4 97.9 102.6 
RMP-R TB cases missed and the reasons why they were missed (% of total RMP-R TB cases) 
False 
negative TB 
test 
231 
(16.5) 
227 
(16.2) 
226 
(16.2) 
144 
(10.3) 
120 
(8.6) 
88 
(6.3) 
  
False 
negative 
RMP-R 
result 
13 
(0.9) 
13 
(0.9) 
13 
(0.9) 
76 
(5.4) 
77 
(5.5) 
78 
(5.6) 
No DST 
done 
551 
(39.4) 
551 
(39.4) 
551 
(39.4) 0 0 0 
Laboratory diagnostic cost 
Total TB 
diagnostic 
costs 
1,073,858 1,159,092 1,240,777 2,430,050 2,567,444 2,700,384 126.3 121.5 117.6 
Cost per 
RMP-R TB 
case 
identified 
1,781 1,910 2,041 2,063 2,138 2,192 15.8 12.0 7.4 
Cost per 
additional 
RMP-R TB 
case 
identified 
 2,359 2,371 2,339  
Amongst the population of 100,000 presumptive TB cases there were 18,155 true TB cases and 
1,398 true RMP-R TB cases. Adherence to algorithms at 100%. All costs are expressed in 2013 CPI-
adjusted values and in US$. 
* Proportion of presumptive TB cases that knew their HIV status. 
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Table 4: The number and percentage of TB and RMP-R TB cases identified in an Xpert-based 
algorithm with varying adherence to the algorithm and proportion that knew their HIV status 
 Adherence to the Xpert-based algorithm 
50% 60% 70% 80% 90% 100% 
TB cases identified 
60% knew their HIV 
status 
15,398 
(15.4) 
15,610 
(15.6) 
15,926 
(15.9) 
16,116 
(16.1) 
16,243 
(16.2) 
16,332 
(16.3) 
80% knew their HIV 
status 
15,659 
(15.7) 
15,916 
(15.9) 
16,226 
(16.2) 
16,415 
(16.4) 
16,568 
(16.6) 
16,670 
(16.7) 
100% knew their HIV 
status 
15,892 
(15.9) 
16,213 
(16.2) 
16,531 
(16.5) 
16,719 
(16.7) 
16,869 
(16.9) 
16,968 
(17.0) 
RMP-R TB cases identified 
60% knew their HIV 
status 
721 
(4.7) 
855 
(5.5) 
963 
(6.0) 
1,034 
(6.4) 
1,122 
(6.9) 
1,178 
(7.2) 
80% knew their HIV 
status 
730 
(4.7) 
869 
(5.5) 
979 
(6.0) 
1,051 
(6.4) 
1,146 
(6.9) 
1,201 
(7.2) 
100% knew their HIV 
status 
742 
(4.7) 
884 
(5.5) 
996 
(6.0) 
1,074 
(6.4) 
1,166 
(6.9) 
1,232 
(7.3) 
RMP-R TB cases missed and the reasons why they were missed (% of total RMP-R TB cases) 
False negative TB test 
60% knew their HIV 
status 
240 
(17.2) 
184 
(13.2) 
174 
(12.4) 
165 
(11.8) 
138 
(9.9) 
144 
(10.3) 
80% knew their HIV 
status 
228 
(16.3) 
172 
(12.3) 
159 
(11.4) 
146 
(10.4) 
116 
(8.3) 
120 
(8.6) 
100% knew their HIV 
status 
217 
(15.5) 
156 
(11.2) 
141 
(10.1) 
122 
(8.7) 
97 
(6.9) 
88 
(6.3) 
False negative RMP-R result 
60% knew their HIV 
status 
40 
(2.9) 
52 
(3.7) 
59 
(4.2) 
65 
(4.6) 
76 
(5.4) 
76 
(5.4) 
80% knew their HIV 
status 
43 
(3.1) 
50 
(3.6) 
58 
(4.1) 
67 
(4.8) 
74 
(5.3) 
77 
(5.5) 
100% knew their HIV 
status 
42 
(3.0) 
51 
(3.6) 
59 
(4.2) 
68 
(4.9) 
73 
(5.2) 
78 
(5.6) 
No DST done 
60% knew their HIV 
status 
397 
(28.4) 
307 
(22.0) 
202 
(14.4) 
134 
(9.6) 
62 
(4.4) 0 
80% knew their HIV 
status 
397 
(28.4) 
307 
(22.0) 
202 
(14.4) 
134 
(9.6) 
62 
(4.4) 0 
100% knew their HIV 
status 
397 
(28.4) 
307 
(22.0) 
202 
(14.4) 
134 
(9.6) 
62 
(4.4) 0 
Amongst the population of 100,000 presumptive TB cases there were 18,155 true TB cases and 
1,398 true RMP-R TB cases. 
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Figure 1: TB diagnostic algorithms as stipulated by the South African National TB program.8 The 
simplified sequence of diagnostic tests in each algorithm and the action taken based on test results 
are shown.  
With the Xpert-based algorithm, two spot specimens were collected and the first was tested with 
Xpert. If TB was detected, the second specimen underwent smear and if RMP-R was detected, a 
culture and LPA test was undertaken. The second specimen underwent culture and LPA if the Xpert 
test was negative and the individual was HIV-infected. 
With the smear/culture-based algorithm, all presumptive TB cases were required to submit two spot 
sputum specimens an hour apart to be tested with fluorescence smear microscopy. The second 
specimen underwent culture testing (BACTEC™ MGIT™ 960; BD, Spark, MD, USA) if the individual 
had a history of previous TB treatment, was from a congregate setting or had an MDR-TB contact. If 
culture-positive, a DST using GenoType® MTBDRplus LPA was undertaken. All new, smear-negative 
HIV-infected individuals required a culture test to diagnose paucibacillary TB, however a DST was not 
required pre-treatment. 
In both algorithms, new and previously treated cases in which first line TB treatment regimens failed 
had specimens submitted for culture and LPA during the course of treatment. 
Abbreviations: TB - tuberculosis; HIV – human immunodeficiency virus; MTB – mycobacterium 
tuberculosis; RIF – rifampicin; DST - drug susceptibility test; LPA - line-probe assay. 
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 Figure 2: The number of TB cases identified in an Xpert-based algorithm with varying adherence to 
the algorithm and proportion that knew their HIV status. TB = tuberculosis; HIV = human 
immunodeficiency virus. 
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 Figure 3: Number of RMP-R TB cases identified and missed in an Xpert-based algorithm with varying 
adherence to the algorithm and proportion that knew their HIV status. RMP-R TB = rifampicin 
resistant tuberculosis; HIV = human immunodeficiency virus 
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Chapter 4: High laboratory cost predicted per tuberculosis case 
diagnosed with increased case finding without a triage strategy 
 
Published: Dunbar R, Naidoo P, Beyers N, Langley I. High laboratory cost predicted 
per tuberculosis case diagnosed with increased case finding without a triage strategy. 
Int J Tuberc Lung Dis. 2017 Sep 1;21(9):1026–34. 
Reprinted with permission of the International Union Against Tuberculosis and Lung 
Disease. Copyright © The Union. 
 
Summary: In this chapter, I model strategies to reduce the cost per TB case detected. 
I use a validated operational model representing TB diagnosis in Cape Town for both 
the smear/culture and Xpert-based algorithms and published laboratory cost data. I 
modelled the effect of varying the prevalence of TB among presumptive cases; 
decreased (as would occur if case-finding was scaled-up) and increased (as would 
occur if a triage screening test was used). I also reduced the price per Xpert cartridge 
by 10%, 25% and 50% and assessed the effect on cost per TB case detected. 
The model indicated that with a TB prevalence among presumptive cases of 18.3% 
(best estimate from empirical analysis) the cost per TB case detected increased by 
142% between the smear/culture and Xpert-based algorithm with only an 8.7% 
increase in TB cases detected. If the TB prevalence among presumptive cases was 
10.6% and with a 50% reduction in the price of Xpert cartridges, the cost per TB case 
detected is still high, at US$142. With a further increase (relative to the estimated 
18.3%) in TB prevalence among presumptive cases tested to between 25.9% – 30.8% 
and the price of the Xpert cartridge reduced by 50%, the cost per TB case detected 
would range from US$50 to US$59 (comparable to the US$48.77 found in routine 
practice with smear/culture). Unless triage strategies are identified, the cost per TB 
case detected with increased case-finding will not be sustainable, even if Xpert 
cartridge prices are reduced. 
 
 
My contributions: In this chapter, I conducted the overall data management and data 
analysis as well as conceived, designed and performed the experiments of running 
the different scenarios in the model. I wrote the manuscript and submitted the final 
manuscript for publication to the peer-reviewed journal.  
Co-author contribution: Pren Naidoo, Ivor Langley and Nulda Beyers contributed 
with conceiving and designing experiments. The co-authors reviewed the draft 
manuscript and approved the final draft manuscript for submission.    
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High laboratory cost predicted per tuberculosis case diagnosed
with increased case finding without a triage strategy
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S UMMA R Y
S E T T I NG : Cape Town, South Africa.
OB J E C T I V E : To model the effects of increased case
finding and triage strategies on laboratory costs per
tuberculosis (TB) case diagnosed.
METHODS : We used a validated operational model and
published laboratory cost data. We modelled the effect
of varying the proportion with TB among presumptive
cases and Xpert cartridge price reductions on cost per
TB case and per additional TB case diagnosed in the
Xpert-based vs. smear/culture-based algorithms.
R E SU LT S : In our current scenario (18.3% with TB
among presumptive cases), the proportion of cases
diagnosed increased by 8.7% (16.7% vs. 15.0%), and
the cost per case diagnosed increased by 142% (US$121
vs. US$50). The cost per additional case diagnosed was
US$986. This would increase to US$1619 if the
proportion with TB among presumptive cases was
10.6%. At 25.9–30.8% of TB prevalence among
presumptive cases and a 50% reduction in Xpert
cartridge price, the cost per TB case diagnosed would
range from US$50 to US$59 (comparable to the
US$48.77 found in routine practice with smear/culture).
CONC LU S I ON : The operational model illustrates the
effect of increased case finding on laboratory costs per
TB case diagnosed. Unless triage strategies are identi-
fied, the approach will not be sustainable, even if Xpert
cartridge prices are reduced.
K E Y WORD S : TB diagnostic; diagnostic cost; opera-
tional modelling; simulation
DESPITE A 22% REDUCTION in the number of
deaths in the last 15 years, tuberculosis (TB) remained
one of the top 10 causes of death worldwide in 2015.
Although the global TB incidence rate declined by
1.4% per year in this period, 10.4 million incident
cases were reported globally in 2015.1 There are still
major gaps in TB case finding and diagnosis, with the
World Health Organization (WHO) estimating that
one third of incident TB cases are either missed
through current TB screening and diagnostic efforts
or are not notified.2
As part of the End TB Strategy, three people-
centred targets were introduced, which consist of
reaching 90% of all people who need anti-tubercu-
losis treatment, including 90% of people in key
populations and achieving at least 90% treatment
success rates. The strategy recommends that countries
set an operational target of reaching at least 90% of
people in key populations through improved access to
services, systematic screening, where required, and
new case-finding methods, and of providing all
people in need with effective and affordable treat-
ment.1,3
The South African Department of Health plans to
substantially scale up case-finding efforts based on
the End TB Strategy. This has cost implications, as the
cost per presumptive TB case tested and diagnosed
with TB is higher with Xpertw MTB/RIF (Cepheid,
Sunnyvale, CA, USA), which was introduced in 2013,
than with the previous smear/culture-based algo-
rithm. Two studies in South Africa reported a cost per
Xpert test performed of US$25.90 (in 2010 $US)4 and
US$14.93 (in 2012 $US) compared with respectively
US$1.58 and US$3.40 for smear.5 A study conducted
in Cape Town, South Africa, found that the cost per
TB case diagnosed increased by 157%, from
US$48.77 in the previous smear/culture-based algo-
rithm to US$125.32 in the newly introduced Xpert-
based algorithm.6 A study conducted in India,
evaluating the costs of various pulmonary TB
diagnostic strategies, found that the strategy with
Xpert as the first-line test had the highest cost per TB
case diagnosed.7
Correspondence to: Rory Dunbar, Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of
Medicine and Health Sciences, Stellenbosch University, Francie Van Zijl Dr, Tygerberg Hospital, Cape Town 7505, South
Africa. e-mail: rdun@sun.ac.za
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The scale-up of case-finding efforts and the
introduction of alternative case-finding strategies,
such as improved sensitivity and specificity of pre-
screening strategies8 or a triage-screening test,9,10 will
have an effect on the proportion of TB prevalence
among presumptive cases. As case-finding efforts are
scaled up and more people are screened for TB, the
proportion with TB among those tested is likely to
decline, and the cost per TB case diagnosed will
consequently increase. There is little evidence at
present on what the proportion of TB among
presumptive cases should be to optimise the cost of
diagnosing a case of TB.
The aim of the present study was to use an
operational model to simulate the effect of a decrease
(scale-up of case finding) and an increase (triage
screening test) in the proportion of TB cases among
presumptive cases tested on laboratory cost 1) per TB
case diagnosed and 2) per additional TB case
diagnosed in the Xpert-based compared with the
smear/culture-based algorithm. We also assessed the
effect on laboratory costs if the Xpert cartridge price
was reduced.
METHODS
Setting
The operational model was developed for the TB
diagnostic algorithms implemented in Cape Town,
one of the largest cities in South Africa, with a
population of 3 740 025 in 2011 (National Census
2011). In 2011, 28 644 TB cases were reported (case
notification rate 752 per 100 000 population), and
among the 97% of cases tested for human immuno-
deficiency virus (HIV), 47% of TB cases were co-
infected with HIV (Source: Routine TB Programme
Data, Cape Town Health Directorate, Cape Town,
South Africa, April 2016).
Municipal and provincial health authorities pro-
vided TB diagnostic services at 142 primary health
care (PHC) facilities. All sputum samples collected for
TB testing at PHC facilities were couriered to the
central National Health Laboratory Services (NHLS)
on a daily basis for testing, and results were returned
to the facilities via courier and fax.
A smear/culture-based algorithm (Figure 1) was
used in all facilities until August 2011; all presump-
tive cases were required to submit two spot sputum
samples 1 h apart. Previously treated presumptive
cases as well as new smear-negative cases co-infected
with HIV underwent culture using BACTECe
MGITe 960 (BD, Sparks, MD, USA).
Between August 2011 and February 2013, an
Xpert-based algorithm (Figure 1) was phased in, with
Xpert replacing smear microscopy for all presumptive
cases; after February 2013, all facilities used the
Xpert-based algorithm. The first of two sputum
samples submitted was tested using Xpert. In HIV-
infected cases who were Xpert-negative, the second
sample underwent culture.
Definitions
Presumptive case: for this model, presumptive cases
were those who accessed the PHC facilities and had
sputum samples collected for TB testing.
TB case: a TB case was defined in the model as an
individual with culture-positive TB, irrespective of
how the individual was ultimately diagnosed (i.e., test
positive on sputum smear microscopy, culture or
Xpert). False-positive cases were thus excluded.
Model development
A comprehensive operational model representing TB
diagnosis in Cape Town PHC facilities has been
developed using the Witness package (Lanner, Red-
ditch, UK), a discrete event and continuous process
simulator.12 The model was validated for both the
historic smear/culture and newly introduced Xpert-
based algorithm using routine programmatic data,13
and the findings were published.14 The model
incorporated patient pathways and sample flow from
specimen collection and laboratory test procedures to
Figure 1 TB diagnostic algorithms. Diagnostic algorithms as stipulated by the South African National TB programme.11 The
simplified sequence of diagnostic tests in each algorithm and the action taken based on test results is shown. TB¼ tuberculosis;þ¼
positive;¼ negative; HIV¼ human immunodeficiency virus; RMP¼ rifampicin.
Modelling the cost of TB cases diagnosed 1027
80
Stellenbosch University  https://scholar.sun.ac.za
a result being provided to the patient and treatment
being initiated at the PHC facility.
Laboratory cost data
Laboratory cost data per test in each algorithm were
obtained from a costing evaluation undertaken at the
high-throughput central laboratory (NHLS) in Cape
Town.6 An ingredients-based costing approach was
used, with test cost based on building cost per m2,
equipment, consumables, staff and overheads (Table
1).6 Costs were calculated only for sputum smear
microscopy, culture and Xpert, and were used to
estimate diagnostic costs in each algorithm as
appropriate. The cost of drug susceptibility testing
was not considered in the current model.
Model inputs
For direct comparisons of cost per TB case diagnosed
between algorithms, we modelled both algorithms
with identical input parameters for the proportion
with TB among the presumptive cases being tested,
HIV status, history of previous anti-tuberculosis
treatment and adherence to testing protocols.14 The
model input parameters used for both the smear/
culture and Xpert-based algorithms are summarised
in Table 2.
Simulated scenarios
We modelled scenarios in which we reduced and
increased the proportion with TB among presumptive
cases being tested. From our previous analysis, the
most likely estimate for the proportion with TB
among presumptive cases tested was 18.3%, which
we selected as our starting point.14 We varied the
proportion to a low of 3.0% (scenarios 6–11) and a
high of 30.8% (scenarios 1–5). We also assessed the
effect on cost per TB case diagnosed if the price per
Xpert cartridge was reduced by 10%, 25% and 50%.
Table 1 Test costs for sputum smear microscopy, culture and
XpertW MTB/RIF by algorithm.* (Reprinted with permission of
the International Union Against Tuberculosis and Lung Disease.
Copyright Q The Union)6
Smear
microscopy
(bleach-treated)
US$
Smear
microscopy
and culture
US$
Culture
confirmation
US$
Xpert
US$
Smear/culture-based algorithm
Building space 0.02 0.14 0.05 —
Equipment 0.11 0.72 0.02 —
Consumables 0.36 3.87 0.84 —
Staff 0.55 2.21 0.57 —
Overheads† 1.80 1.80 0.00 —
Cost per test 2.85 8.75 1.49 —
Xpert-based algorithm
Building space 0.02 0.14 0.05 0.06
Equipment 0.13 0.74 0.02 0.40
Consumables 0.36 3.87 0.84 14.62
Staff 0.55 2.21 0.57 1.32
Overheads† 2.64 2.64 0.00 2.64
Cost per test 3.70 9.62 1.49 19.03
* Test costs are for the central National Health Laboratory only. All costs are
expressed in 2013 CPI-adjusted values.
† Includes costs for buildings, equipment, consumables and the staff involved
in specimen sorting and registration, results processing, procurement, stores,
training, supervision and management. Specimen transport, electricity, water,
sanitation, municipal and biohazardous waste disposal, cleaning and janitorial
services, security services and telephone and internet costs were also included.
In each scenario tested, we determined the number of tests performed per
algorithm, applied the above costs and calculated the cost per tuberculosis
case diagnosed.
CPI¼Consumer Price Index.
Table 2 Input parameters used comparing the smear/culture
and XpertW MTB/RIF based algorithms
Input
values %
History of previous anti-tuberculosis treatment 25
HIV status*
New presumptive cases
HIV-positive 36
HIV-negative 64
Previously treated presumptive cases
HIV-positive 53
HIV-negative 47
Proportion knowing their HIV status 50
Best estimated proportion of TB cases among
presumptive cases
18.3†
Adherence to a smear/culture-based algorithm
New presumptive cases with 2 smears 85
Previously treated presumptive cases with culture 85
Adherence to the Xpert-based algorithm
All presumptive cases with the Xpert test performed 85
Proportion smear or Xpert-negative with culture
Smear/culture-based algorithm
New presumptive cases
HIV-positive 85
HIV-negative 0
Previously treated presumptive cases
HIV-positive 85
HIV-negative 0
Xpert-based algorithm
New presumptive cases
HIV-positive 85
HIV-negative 0
Previously treated presumptive cases
HIV-positive 85
HIV-negative 0
Accuracy of smear microscopy15,16
Sensitivity
HIV-positive 65
HIV-negative 75
Specificity
HIV-positive 99
HIV-negative 99
Accuracy of Xpert17
Sensitivity
HIV-positive 80
HIV-negative 89
Specificity
HIV-positive 98
HIV-negative 98
*Data on HIV status were only recorded for 2013, and showed that 50% of
presumptive cases knew their HIV status; similar proportions were assumed
for the model.12–14
† Best estimated proportion of TB cases among presumptive cases.12–14 As
part of the PROVE IT Study, NHLS data from presumptive cases had previously
been collected and analysed to compare TB yield in the smear/culture-based
algorithm to that in the Xpert-based algorithm. Input parameters for the
model used probability distributions derived from this analysis.
HIV ¼ human immunodeficiency virus; TB ¼ tuberculosis; PROVE IT ¼ Policy
Relevant Outcomes from Validating Evidence on ImpacT evaluation; NHLS ¼
National Health Laboratory Services.
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Model outputs and analysis
Outputs from the model on the number of tests
performed per algorithm and the number of TB cases
diagnosed under different scenarios and cost per test
from our costing study6 were summarised in Micro-
soft Excele (Microsoft Corp, Redmond, WA). They
were used to calculate overall diagnostic costs per
algorithm, cost per TB case diagnosed and cost per
additional TB case diagnosed in the Xpert-based
algorithm compared with that in the smear/culture-
based algorithm. We used the validated model to
predict the costs per TB case diagnosed under various
conditions.
Ethics statement
The Health Research Ethics Committee at Stellen-
bosch University, Tygerberg, South Africa
(IRB0005239) (N10/09/308) and the Ethics Advisory
Group of the International Union Against Tubercu-
losis and Lung Disease, Paris, France (59/10) ap-
proved the study protocol. The City of Cape Town
Health Directorate, the Western Cape Health De-
partment and NHLS granted permission to use
routine health data.
RESULTS
At our published best estimate of 18.3%13,14 TB
prevalence among presumptive cases, the proportion
diagnosed with TB increased from 15.0% in the
smear/culture-based algorithm to 16.3% in the
Xpert-based algorithm, a relative increase of 8.7%.
The cost per TB case diagnosed increased from US$50
in the smear/culture-based algorithm to US$121 in
the Xpert-based algorithm, a relative increase in cost
of 142% (Table 3, Figure 2). The cost per additional
TB case diagnosed in the Xpert-based algorithm
compared with that in the smear/culture-based
algorithm was US$986 (Table 3, Figure 3).
The effect of varying the proportion with TB among
presumptive cases tested
When the proportion with TB among presumptive
cases tested was lowered to 3.0% (scenario 11) or
increased to 30.8% (scenario 1) in the model, the
proportion of TB cases diagnosed ranged from 2.5%
to 25.3% in the smear/culture-based algorithm and
from 2.7% to 27.4% in the Xpert-based algorithm.
The cost per TB case diagnosed ranged from
US$299 to US$30 in the smear/culture algorithm
and from US$727 to US$73 in the Xpert-based
algorithm (Table 3, Figure 2). At the lowest propor-
tion of TB among presumptive cases tested (3.0%;
scenario 11), the cost per additional TB case
diagnosed was US$9245, and at the highest TB
proportion (30.8%; scenario 1), the cost per addi-
tional TB case diagnosed was US$603 in the Xpert-
based algorithm compared to the smear/culture-based
algorithm (Table 3, Figure 3).
The effect of Xpert cartridge price
At the current best-estimated proportion of 18.3%
with TB among presumptive cases tested, the cost per
TB case diagnosed would be respectively US$114,
US$102 and US$83 in the Xpert-based algorithm if
the price of the Xpert cartridge was reduced by 10%,
25% and 50% (Table 4, Figure 2). The cost per
additional TB case diagnosed in the Xpert-based
algorithm compared with that in the smear/culture
algorithm would be US$886, US$737 and US$489 at
these respective reductions in cartridge price (Table 4,
Figure 3).
The effect of varying both TB prevalence among
presumptive cases and the Xpert cartridge price
At 3.0% (scenario 11) TB prevalence among pre-
sumptive cases, the cost per TB case diagnosed in the
Xpert-based algorithm was respectively US$682,
US$613 and US$499 if the price of the Xpert
cartridge was reduced by 10%, 25% and 50%. At
30.8% (scenario 1) TB prevalence among presump-
tive cases (scenario 1), the cost per TB case diagnosed
was respectively US$68, US$61 and US$50 if the
price of the Xpert cartridge was reduced by 10%,
25% and 50% (Table 4, Figure 2).
The cost per additional TB case diagnosed in the
Xpert-based algorithm compared with that in the
smear/culture algorithm was respectively US$8290,
US$6857 and US$4470 at 3.0% (scenario 11) of
presumptive cases tested having TB and if the price of
the Xpert cartridge was reduced by 10%, 25% and
50%. At 30.8% (scenario 1) TB prevalence among
presumptive cases, the cost per additional TB case
diagnosed in the Xpert-based algorithm compared
with that in the smear/culture algorithm was respec-
tively US$543, US$454 and US$304 if the price of the
Xpert cartridge was reduced by 10%, 25% and 50%
(Table 4, Figure 3).
DISCUSSION
It was hoped that with the roll-out of Xpert as a
replacement for smear microscopy the proportion of
TB cases diagnosed would increase due to the higher
test sensitivity of Xpert.17–19 A population-level
decision model study estimated that with full Xpert
coverage, the total TB diagnostic cost for South
Africa would increase annually by 53–57%/year, with
the increase in cost offset by a 30–37% increase in TB
cases diagnosed.20
The results from our operational model and
laboratory and cost data collected for 142 PHC
facilities show, however, that at the current best
estimate of 18.3% TB prevalence among presumptive
cases, there was a 142% relative increase in cost per
Modelling the cost of TB cases diagnosed 1029
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TB case diagnosed in the Xpert-based algorithm
compared with that in the smear/culture-based
algorithm, with a relative increase in the number of
TB cases diagnosed of only 8.7%. The increase in the
cost per TB case diagnosed was slightly lower in our
study than the 157% reported in a study conducted in
Cape Town using routine laboratory data. The Cape
Town study, however, reported a temporal decline in
TB diagnostic yield from 20.4% to 16.6% for the
period 2010–2013, due to a possible decline in TB
Figure 2 Diagnostic yield and cost per TB case diagnosed as proportion of TB among
presumptive cases is varied and Xpert costs are reduced. All costs per TB case diagnosed are
expressed in 2013 CPI-adjusted values. ‘Current’ costs are at levels reported from the laboratory
cost study.6 Xpert cartridge prices were reduced by 10%, 25% and 50%. The primary y-axis shows
current costs in each algorithm and the cost per TB case diagnosed as the proportion with TB
among presumptive cases tested is increased at different Xpert cartridge prices (with reductions of
10%, 25% and 50%). The secondary y-axis shows the proportion of TB cases diagnosed as the
proportion with TB among presumptive cases tested is increased in the smear/culture and the
Xpert-based algorithms. TB¼ tuberculosis; CPI¼Consumer Price Index. This image can be viewed
online in colour at http://www.ingentaconnect.com/content/iuatld/ijtld/2017/00000021/
00000009/art00014
Figure 3 Cost per additional TB case diagnosed in the Xpert-based algorithm compared to the
smear/culture-based algorithm as proportion with TB among presumptive cases tested is varied
and Xpert prices are reduced. All costs per TB case diagnosed are expressed in 2013 CPI-adjusted
values. ‘Current’ cost is reported from the laboratory cost study.6 Xpert cartridge prices were
reduced by 10%, 25% and 50%. TB¼ tuberculosis; CPI¼Consumer Price Index. This image can be
viewed online in colour at http://www.ingentaconnect.com/content/iuatld/ijtld/2017/00000021/
00000009/art00014
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prevalence attributed to the rapid scale-up of
antiretroviral treatment, and costs were partially
influenced by this.13 An advantage of our model is
that we were able to compare outputs when input
parameters between algorithms were similar.
The cost per TB case diagnosed is directly
influenced by the proportion of TB prevalence among
presumptive cases. As case-finding efforts are scaled
up and the number of individuals tested for TB
increases, the proportion with TB among those tested
will decrease, and therefore the cost per TB case
diagnosed will increase. This increase in cost has
serious implications for South Africa’s efforts to
increase case finding, and alternative strategies would
need to be considered to reduce costs.
One approach to reduce the cost per TB case
diagnosed would be to increase the proportion with
TB among the presumptive cases being tested. This
could be accomplished by implementing an improved
triage or testing strategy.9 A study using a decision
analytical model showed that with a hypothetical
triage test with sensitivity equivalent to that of the
Xpert test, 75% specificity and cost of US$5 per test
would reduce the total diagnostic cost by 39% in
South Africa.21 No triage test is currently available,
and this has been identified as one of the priorities in
the development of new diagnostics for TB.22 It has
been shown that pre-screening with smear microsco-
py could reduce the cost per TB case diagnosed by
more than 20%.8
A further approach to reduce the cost would be a
reduction in the price of the Xpert cartridge. Our
model shows that with a 50% reduction in the price
of Xpert cartridges and with the proportion with TB
among presumptive cases tested at 3%, the cost per
TB case diagnosed would be US$499, which is
extremely high. At a more realistic proportion of
10.6% TB prevalence among presumptive cases and a
50% reduction in the price of Xpert cartridges, the
cost per TB case diagnosed is still high, at US$142.
The best approach to improve affordability would
therefore be a combination of increasing the propor-
tion with TB among presumptive cases tested using
either a triage test or other pre-screening strategies,
and a reduction in the price of Xpert cartridges. Our
model shows that if the proportion with TB among
presumptive cases tested was 25.9–30.8% and the
price of the Xpert cartridge reduced by 50%, the cost
per TB case diagnosed would range from US$50 to
US$59, a level that is comparable with the cost per TB
case diagnosed in the smear/culture-based algorithm
(US$48.77) found in a laboratory costing study.6
Strengths and limitations
The strengths of the current study are that we used a
validated model, based on real data on testing and
diagnosis, to estimate the cost per TB case diagnosed
in the smear/culture and Xpert-based algorithms. Our
study provides a better estimate of the cost per TB
case diagnosed. The previous laboratory costing
study included false-positive cases in the cost calcu-
lation. Our model suggests that the proportion of
false-positive cases is lower in the Xpert-based than in
the smear/culture-based algorithm.14
The model was validated using routine program-
matic data from Cape Town, a well-resourced urban
setting where culture is extensively used. This may
limit the generalisation of findings to other settings.
We did not consider the costs for diagnosis of
multidrug-resistant TB and the added benefit of the
Table 4 Cost per TB case diagnosed and cost per additional TB case diagnosed in the Xpert-
based algorithm with a reduction in Xpert cartridge price and with varying proportions of
presumptive cases tested having TB
TB cases among
presumptive cases
%
Xpert-based algorithm
cost per TB case diagnosed
US$*
Cost per additional
TB case diagnosed
US$*†
Reduction in Xpert cartridge price
10% 25% 50% 10% 25% 50%
Scenario 1 30.8 68 61 50 543 454 304
Scenario 2 28.4 74 66 54 580 484 324
Scenario 3 25.9 80 72 59 624 520 347
Scenario 4 23.3 89 80 66 691 576 383
Scenario 5 20.8 100 90 74 774 644 428
Best estimate‡ 18.3 114 102 83 886 737 489
Scenario 6 15.8 131 118 96 1057 879 581
Scenario 7 13.2 157 141 115 1239 1029 678
Scenario 8 10.6 194 174 142 1453 1206 793
Scenario 9 8.0 255 229 187 2078 1722 1128
Scenario 10 5.5 374 336 274 3712 3074 2009
Scenario 11 3.0 682 613 499 8290 6857 4470
*All costs are expressed in 2013 CPI-adjusted values.
† Cost per additional TB case diagnosed in the Xpert-based algorithm compared to in the smear/culture-based
algorithm.
‡ Best current estimate of proportion with TB among presumptive cases tested.13,14
TB¼ tuberculosis; CPI¼Consumer Price Index.
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Xpert test in identifying rifampicin resistance at
screening; this will be reported in a future study.
The impact of new TB diagnostic algorithms on
patient costs is extremely important and was not
considered in this study; however, patient costs from
the broader PROVE-IT (Policy Relevant Outcomes
from Validating Evidence on ImpacT) study have
been published.23
Recommendations
We recommend that alternative, more cost-effective,
strategies be implemented in settings where the
proportion with TB among presumptive cases tested
is low or declining over time, as would occur with
increased case-finding efforts. Recommended strate-
gies would include better pre-screening or a triage
screening test to increase the proportion with TB
among presumptive cases tested with Xpert. Substan-
tial further reductions in the price of Xpert cartridges
are also recommended to make using Xpert afford-
able in low-resource settings. Further operational
research is required to determine the most effective
triage strategies to make Xpert more sustainable and
affordable.
CONCLUSION
An analysis of routine laboratory data has shown
that, in our setting, the introduction of Xpert as a
replacement test for smear microscopy has resulted in
a much higher cost per TB case diagnosed.6 The high
cost is not offset by a substantially higher number of
TB cases diagnosed despite the increased sensitivity of
the Xpert test.13
The operational model illustrates the effect of
increased case-finding efforts on laboratory costs per
TB case diagnosed. It is clear that unless alternative
triage strategies are identified, the approach will not
be sustainable, even if Xpert cartridge prices are
reduced. Additional studies are required to assess the
cost-effectiveness of alternative strategies and their
impact on TB transmission.
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R E S U M E
CONT EX T E : Le Cap, Afrique du Sud.
OB J E C T I F : Mode´liser les effets de strate´gies accrues de
recherche des cas et de triage sur les couˆts de laboratoire
par cas de tuberculose (TB) diagnostique´.
M E´ T H O D E S : Nous avons utilise´ une mode`le
ope´rationnel valide´ et publie´ les donne´es de couˆt de
laboratoire. Nous avons mode´lise´ l’effet de la variation
de la proportion de patients avec TB parmi les cas
pre´sume´s et des re´ductions de prix des cartouches
d’Xpert sur le couˆt par cas de TB et par cas
supple´mentaire de TB diagnostique´ dans les
algorithmes base´s sur l’Xpert par rapport a` ceux base´s
sur le frottis/la culture.
R E´ S U LTAT S : Dans notre sce´nario actuel (18,3%
atteints de TB parmi les cas pre´sume´s), la proportion
de cas diagnostique´s a augmente´ de 8,7% (16,7% contre
15,0%) et le couˆt par cas diagnostique´ a augmente´ de
142% (121 $US contre 50 $US). Le couˆt par cas
supple´mentaire diagnostique´ a e´te´ de 986 $US. Ceci
augmenterait a` 1619 $US si la proportion de patients
avec TB parmi les cas pre´sume´s e´tait de 10,6%. Avec
entre 25,9% et 30,8% de patients avec TB parmi les cas
pre´sume´s et avec 50% de re´duction du prix des
cartouches d’Xpert, le couˆt par cas de TB diagnostique´
se situerait entre 50 $US et 59 $US (comparable aux
48,77 $US trouve´s en pratique de routine avec frottis/
culture).
CONC LU S I ON : Le mode`le ope´rationnel illustre l’effet
de l’augmentation de la recherche des cas sur les couˆts de
laboratoire par cas de TB diagnostique´. A moins
d’identifier des strate´gies de triage, l’approche ne sera
pas pe´rennisable, meˆme si le prix des cartouches d’Xpert
est re´duit.
R E S UM E N
MA R C O D E R E F E R E N C I A: Ciudad del Cabo en
Sura´frica.
O B J E T I V O: Modelizar los efectos que ejercen las
estrategias de aumento de la bu´squeda de casos y de
preseleccio´n de los pacientes, en los costos de
laboratorio por cada caso de tuberculosis (TB)
diagnosticado.
M E´ TODOS: Se aplico´ un modelo operativo validado y
datos publicados sobre los costos de laboratorio. Se llevo´
a cabo una modelizacio´n del efecto de la modificacio´n en
la proporcio´n de casos de TB diagnosticados en las
personas con presuncio´n clı´nica de la enfermedad y de la
disminucio´n del precio del cartucho utilizado en la
prueba Xpert, en los costos por caso de TB y por caso
adicional de TB diagnosticados con los algoritmos
fundados en la prueba Xpert en comparacio´n con los
algoritmos basados en la baciloscopia y el cultivo.
R E SU LTADOS: En la hipo´tesis adoptada (18,3% casos
de TB en las personas con presuncio´n clı´nica), la
proporcio´n de casos diagnosticados aumento´ un 8,7%
(16,7% contra 15,0%) y el costo por caso diagnosticado
aumento´ un 142% (121 USD contra 50 USD). El costo
por caso adicional diagnosticado fue 986 USD. El costo
aumentarı´a a 1619 USD cuando la proporcio´n de casos
con TB es 10,6%. Si la proporcio´n es de 25,9% a 30,8%
de casos de TB en las personas con presuncio´n clı´nica,
con una reduccio´n de 50% del precio del cartucho
Xpert, el costo por caso de TB diagnosticado osciları´a
entre 50 USD y 59 USD (equivalente al costo observado
de 48,77 USD en la pra´ctica corriente con la
baciloscopia y el cultivo).
CONC LU S I O´ N: El presente modelo operativo explica el
efecto de un aumento de la bu´squeda de casos sobre los
costos de laboratorio por caso de TB diagnosticado. A
menos que se definan estrategias de preseleccio´n de los
pacientes la estrategia no es sostenible, incluso cuando se
considera una disminucio´n del precio del cartucho de la
prueba Xpert.
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Chapter 5: Modelling the impact of Xpert® MTB/RIF Ultra as a 
replacement test for Xpert® MTB/RIF 
 
Unpublished. Plan to submit November 2017. 
 
Summary: In this chapter, I model the effect of introducing a more sensitive molecular 
diagnostic test, Xpert MTB/RIF Ultra (Ultra), on the number of TB and RMP-R TB 
cases detected. I used an operational model representing the diagnosis of pulmonary 
TB and RMP-R TB in Cape Town for the Xpert MTB/RIF (Xpert) based algorithm. I 
modelled scenarios comparing the effect of TB and RMP-R TB detection if Ultra 
replaced Xpert. All scenarios used identical population characteristics and 100% 
adherence to the diagnostic algorithms to compare the Xpert-based and Ultra-based 
algorithms. I also modelled scenarios with 60% and 100% of presumptive TB cases 
knowing their HIV status. 
The model indicated a 3.4% (60% know their HIV status) and 0.9% (100% know their 
HIV status) increase in the number of TB cases detected between the Xpert-based 
and Ultra-based algorithm. However, the number of false positive TB cases detected 
would increase by 167%. The model indicated a 3.5% (60% know their HIV status) 
and 0.8% (100% know their HIV status) increase in the number of RMP-R TB cases 
detected. In our model for Cape Town, Ultra has small benefits over that of Xpert for 
both the number of TB and RMP-R TB cases detected and therefore the cost of 
introducing Ultra would be an important consideration in the decision to implement 
Ultra. In settings with high proportions of presumptive TB cases with a history of 
previous TB treatment, the introduction of Ultra poses potential health system and 
patient related challenges. 
 
 
 
My contributions: In this chapter, I adapted the previously developed and validated 
operational model to compare the Xpert-based algorithm with the Ultra-based 
algorithm. I conducted the overall data management and data analysis for this chapter 
as well as conceived, designed and performed the experiments of running the different 
scenarios in the model. I also wrote this chapter.  
Co-author contribution: Pren Naidoo, Ivor Langley and Nulda Beyers contributed 
with conceiving and designing experiments. The co-authors reviewed the draft chapter 
and approved the final draft chapter published in this dissertation. 
89
Stellenbosch University  https://scholar.sun.ac.za
Modelling the impact of Xpert® MTB/RIF Ultra as a replacement 
test for Xpert® MTB/RIF 
5.1 Introduction 
Although tuberculosis (TB) is a curable disease, it remains a global health challenge. 
In 2015, the World health Organisation (WHO) estimated that there were 10.4 million 
incident TB cases globally; 1.2 million (11%) were human immunodeficiency virus 
(HIV) co-infected cases. There were 1.4 million estimated TB deaths among HIV-
negative TB cases in 2015, and an additional 0.4 million deaths amongst HIV-positive 
TB cases.1 
Some of the key drivers of the TB epidemic are HIV (HIV-positive individuals at a 20 
to 37-fold increased risk of developing TB2) and under-diagnosis or late diagnosis of 
TB and rifampicin resistant (RMP-R) TB, which results in deaths amongst TB cases3,4 
and transmission to other individuals.5 
Of the 3.4 million bacteriologically confirmed TB cases notified globally in 2015, only 
30% were reported to have had a drug susceptibility test (DST) for rifampicin.1 If all 
pulmonary TB patients notified in 2015 had a DST done, an estimated 340,000 RMP-
R TB cases could have been identified. Due to poor DST coverage only 132,120 RMP-
R TB cases were detected and notified globally.  
In 2010, the WHO endorsed the use of Xpert® MTB/RIF (Cepheid, Sunnyvale, CA, 
USA) (Xpert) and recommended its use as the initial diagnostic test in individuals 
presumed to have RMP-R TB or HIV co-infected TB cases6 and expanded the 
recommendation in 2014 to include all presumptive TB cases.7 Xpert simultaneously 
detects Mycobacterium tuberculosis (MTB) and rifampicin resistance on a single 
specimen. Xpert was rolled out in over 120 countries by 2016, with varied 
implementation strategies followed by different countries.8  
A Cochrane Review reported that Xpert, as an initial test replacing smear microscopy, 
had a pooled sensitivity of 89% (95% CI 83% to 92%) and specificity of 98% (95% CI 
97% to 99%) for detecting MTB and sensitivity was 94% (95% CI 87% to 97%) and 
specificity was 98% (95% CI 97% to 99%) for RMP-R.9 In HIV-positive individuals, 
Xpert has a sensitivity for detecting MTB of 80% (95% CI 67% to 88%). This lower 
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sensitivity in HIV-positive individuals is a serious limitation, especially in settings such 
as South Africa where the HIV prevalence is high (18.9 [16.6 - 21.0] of the adult 
population (aged 15 to 49) were estimated to be HIV-positive in 2016).10  
In order to address some of the limitations of Xpert (low sensitivity for detecting MTB 
especially in HIV-positive and imperfect detection of RMP-R TB) a new test, Xpert 
MTB/RIF Ultra (Ultra), has been developed.11 A prospective multicentre (10 sites 
across 8 countries) diagnostic accuracy study was conducted to assess  performance 
in geographically diverse, high-burden settings.12 The study compared the 
performance of Ultra for detection of MTB and RMP-R in adults suspected of having 
pulmonary TB against the performance of Xpert, with culture and phenotypic drug 
susceptibility as the reference standard. Ultra had a higher sensitivity, in particular 
among smear-negative culture-positive specimens from HIV-positive individuals, and 
lower specificity for detecting MTB (Table 1).  
If Ultra was to replace Xpert for the diagnosis of TB, the higher sensitivity will 
potentially result in more true cases of TB being diagnosed, while the lower specificity 
will potentially result in more false positive cases being diagnosed. The decision of 
whether or not to implement a new test with higher sensitivity and lower specificity will 
be dependent on the setting in which Ultra is implemented (for example, HIV 
prevalence, previous history of TB treatment and TB prevalence). 
The aim of this study was to use an operational model to compare the detection of TB 
and RMP-R TB cases between the current Xpert-based algorithm and a potential new 
Ultra-based algorithm.  
5.2 Methods 
5.2.1 Definitions used in the model 
Presumptive case: A presumptive TB case is an individual who had pre-treatment 
sputum specimen collected for TB diagnostic purposes. 
TB case: A TB case is an individual with culture positive TB, irrespective of how the 
individual was ultimately identified (i.e. tested positive by either sputum smear 
microscopy or culture or Xpert or Ultra).   
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True positive: A presumptive case with culture positive TB that is correctly detected 
with TB by the test in use. 
False positive: A presumptive case without TB (culture negative) that is incorrectly 
detected with TB by the test in use. 
False negative: A presumptive case with culture positive TB in whom TB is not 
detected 
RMP-R TB case: A RMP-R TB case is a TB case with true rifampicin resistance.  
Adherence to algorithms: We defined adherence to an algorithm as the proportion 
of presumptive TB cases that received the full sequence of tests as stipulated by the 
diagnostic algorithm (Figure 1).13 
TB yield: The proportion of the presumptive TB cases correctly diagnosed with TB 
(i.e. includes only true positive cases). 
5.2.2 Setting and timeframe 
The study uses data from Cape Town, one of the largest cities in South Africa, with a 
population of 3.7 million in 2011 (National Census 2011). In Cape Town, free TB 
diagnostic services are provided at 142 primary health care (PHC) facilities in eight 
health sub-districts. All TB diagnostic tests are performed at a central National Health 
Laboratory Service (NHLS), with all sputum specimens collected for TB testing at PHC 
facilities couriered to NHLS on a daily basis for testing and results returned to facilities 
via courier and fax. Results can also be accessed electronically. 
South Africa was an early adopter of Xpert and shortly after the WHO policy statement 
in 20106, South Africa introduced Xpert as a replacement test for smear microscopy 
for all presumptive TB cases. The rollout of Xpert started in Cape Town in August 
2011, with full rollout completed in February 2013. The implementation of the Xpert-
based algorithm was slightly different in Cape Town compared to the rest of South 
Africa, with two spot specimen required in Cape Town compared to one spot specimen 
in the rest of South Africa.  
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This study used the Xpert-based algorithm as implemented in Cape Town. With the 
Xpert-based algorithm, the first specimen collected was tested with Xpert and if TB 
was detected the second specimen underwent fluorescence light-emitting diode (LED) 
smear microscopy for acid-fast bacilli. If Xpert detected RMP-R, a culture and 
GenoType® MTBDRplus (Hain LifeScience GmbH, Nehren, Germany) line-probe 
assay (LPA) test was undertaken. If Xpert was negative and the individual was HIV-
positive, the second specimen underwent culture and LPA. 
5.2.3 Model development 
We used an operational model previously developed and validated using routine 
National Health Laboratory Service (NHLS) data collected for the period 2010 to 2013 
in Cape Town for the detection of TB and RMP-R TB.14–16 The operational model was 
developed using the Witness package17, a discrete event and continuous process 
simulator and incorporated specimen flow from specimen collection, through 
laboratory test procedures, to a result being provided to the patient. The original 
operational model was developed to compare the previously used smear/culture-
based algorithm and currently used Xpert-based algorithm, as stipulated by the South 
African National TB programme and as implemented in Cape Town.13 For the current 
study, we used the Xpert-based algorithm in the model to compare Xpert to Ultra and 
replaced Xpert for Ultra in the new Ultra-based algorithm (Figure 1). 
5.2.4 Model inputs 
Routine TB treatment and NHLS data for all presumptive TB cases had previously 
been collected and analysed as part of the PROVE IT (Policy Relevant Outcomes from 
Validating Evidence on ImpacT) study. The PROVE IT study included a comparison 
of TB yield16 and RMP-R TB14 yield between the previously used smear/culture-based 
algorithm and the newly introduced Xpert-based algorithm. For the current study, we 
used probability distributions derived from the PROVE IT analyses as input 
parameters for the model (Table 2).  
Test sensitivities and specificities were obtained from published literature, including 
findings reported from a multicentre non-inferiority diagnostic accuracy study 
comparing Ultra to Xpert.12,18,19 The sensitivity and specificity for detecting TB with 
Xpert or Ultra was defined in the model relative to culture positive TB cases in the 
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model. The sensitivity and specificity for detecting RMP resistance with Xpert or Ultra 
was defined, in the model, relative to culture positive TB cases with RMP resistance 
(true RMP-R TB cases). 
5.2.5 Model scenarios 
We modelled scenarios comparing the TB and RMP-R TB yield among 100,000 
presumptive TB cases in the Xpert and Ultra-based algorithms. We used identical 
population characteristics and adherence to algorithms as inputs in each algorithm. All 
scenarios were modelled with a 100% adherence to the diagnostic algorithms and with 
either 60% or 100% of presumptive TB cases knowing their HIV status. 
5.2.6 Model outputs and analysis 
We used the modelled scenarios to identify the number and percentage of TB and 
RMP-R TB cases detected by either the Xpert-based or Ultra-based algorithm.  
We report the number of true TB cases detected as a percentage of the 100,000 
presumptive TB cases (TB yield) based on the full testing protocol defined in each 
algorithm (Figure 1). We also report the number and percentage of presumptive TB 
cases with false positive and false negative TB test results. 
The number and percentage of RMP-R TB cases (RMP-R yield) correctly detected, 
the number of false negative and false positive RMP-R TB cases detected by either 
the Xpert-based or Ultra-based algorithm are reported as a percentage of true TB 
cases in the model.  
5.3 Ethics statement 
The Health Research Ethics Committee at Stellenbosch University (IRB0005239) 
(N10/09/308) and Ethics Advisory Group at The International Union Against 
Tuberculosis and Lung Disease (59/10) approved the study. The City of Cape Town 
Health Directorate, Western Cape Health Department and National Health Laboratory 
Service granted permission to use the routine health data in the validation of the 
model. 
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5.4 Results 
5.4.1 TB cases detected  
Model outputs comparing TB cases detected in the Xpert-based and Ultra-based 
algorithms for 100,000 presumptive TB cases are summarised in table 3. In the 
scenario where 60% of presumptive cases know their HIV status, the model identified 
16,248 (16.2%) true TB cases in the Xpert-based algorithm and 16,797 (16.8%) in the 
Ultra-based algorithm, a 3.4% difference in the number of cases identified. If 100% of 
presumptive cases know their HIV status, the model identified 17,012 (17.0%) in the 
Xpert-based algorithm and 17,160 (17.2%) in the Ultra-based algorithm, a 0.9% 
difference the number of cases identified. 
In a scenario where 60% of presumptive cases know their HIV status, there were 1,907 
(1.9%) false negative tests (missed TB cases) in the Xpert-based algorithm compared 
to 1,358 (1.4%) in the Ultra-based algorithm, a 28.8% reduction in the number of TB 
cases missed. When 100% of presumptive cases know their HIV status, there were 
1,143 (1.1%) false negative tests in the Xpert-based algorithm and 995 (1.0%) in the 
Ultra-based algorithm, a 12.9% reduction in the number of TB cases missed.  
In a scenario where 100% of presumptive cases know their HIV status, the model 
identified 1,576 (1.6%) false positive TB cases in the Xpert-based algorithm and 4,201 
(4.2%) in the Ultra-based algorithm, an increase of 166.6%. 
5.4.2 RMP-R TB cases detected 
The model outputs for detecting RMP-R TB cases are summarised in Table 4. In a 
scenario where 60% of presumptive cases know their HIV status, the model indicated 
that 1,186 (6.5%) TB cases would be detected with RMP-R in the Xpert-based 
algorithm compared to 1,228 (6.8%) in the Ultra-based algorithm, an increase of 3.5% 
in the number of RMP-R TB cases detected.  
When 100% of presumptive cases know their HIV status, the number of TB cases 
detected with RMP-R would be 1,263 (7.0%) in the Xpert-based algorithm and 1,253 
(6.9%) in the Ultra-based algorithm, a decrease of 0.8%. 
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In a scenario when 60% of presumptive cases know their HIV status, 212 (1.2%) RMP-
R TB cases would be missed in the Xpert-based algorithm and 170 (0.9%) in the Ultra-
based algorithm, a decrease of 19.8%. In this scenario, the number of missed RMP-
R TB cases in the model comprise of 164 (77.4%) with an initial negative TB result 
and 48 (22.6%) with a false negative RMP-R TB result in the Xpert-based algorithm 
compared to 104 (61.2%) with an initial negative TB result and 66 (38.8%) with a false 
negative RMP-R TB result in the Ultra-based algorithm. 
In the scenario when 100% of presumptive cases know their HIV status, 135 (0.7%) 
RMP-R TB cases would be missed in the Xpert-based algorithm and 145 (0.8%) in the 
Ultra-based algorithm. In this scenario, the number of missed RMP-R TB cases in the 
model comprise of 87 (64.4%) with an initial negative TB result and 48 (35.6%) with a 
false negative RMP-R TB result in the Xpert-based algorithm compared to 79 (54.5%) 
with an initial negative TB result and 66 (45.5%) with a false negative RMP-R TB result 
in the Ultra-based algorithm. 
5.5 Discussion 
Increased efforts to address the ongoing TB and RMP-R TB diagnostic challenges 
have resulted in the development of new molecular  tests. Xpert MTB/RIF, one of these 
new tests, was endorsed by the WHO in 20106,7. South Africa adopted Xpert early and 
started implementing an Xpert-based algorithm in 2011. Even though Xpert has 
improved sensitivity and specificity compared to smear microscopy, Xpert still has 
some limitations, including lower sensitively among HIV-positive individuals. Previous 
studies have also reported concerns regarding false positive Xpert results, especially 
amongst those with a history of previous TB treatment.6,20,21 In order to address some 
of these limitation, Ultra was developed. However, even though Ultra has a higher 
sensitively for the detection of TB than Xpert, specificity is lower.11  
We used a previously developed and validated operational model to assess the 
potential impact of introducing Ultra as a replacement for Xpert in the current Xpert-
based algorithm. 
The model indicated that if Ultra replaced Xpert and when 60% of presumptive TB 
cases know their HIV status, there would be only a small (3.4%) increase in the 
number of TB cases detected. This is slightly less than the modelled 4.7% increase in 
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the number of TB cases detected in the Xpert-based algorithm if the proportion of 
presumptive TB cases who know their HIV status increased from 60% to 100%. When 
100% of presumptive cases know their HIV-status in both the Xpert and the Ultra 
algorithms, the difference in TB yield between algorithms was low at 0.9%. 
However, despite the relatively small increase in the number of TB cases detected by 
Ultra, the model indicated that when 100% of presumptive TB cases know their HIV 
status, the number with a false positive test result would increase massively by 167% 
with the Ultra-based algorithm. This is due to the lower specificity of Ultra compared 
to that of Xpert, especially for those with a history of previous TB treatment. Previous 
studies have already highlighted the concern of false positive test results with 
Xpert.6,20,21 The model indicated that this will be an even bigger problem if Ultra was 
implemented, especially in settings such as Cape Town where a high proportion 
(24%)16 of presumptive TB cases have a history of previous TB treatment.22 This 
presents a challenge for the health system: although more true TB cases are likely to 
be identified and treated with Ultra, the number of unnecessarily treated individuals is 
also likely to increase. It will be necessary for policy makers to consider the trade-off 
between high sensitivity and low specificity and whether identifying more cases is 
more important than unnecessarily treating people who do not have TB.  
While the number of TB cases missed decreased by 28.8% with the Ultra-based 
compared to the Xpert-based algorithm when 60% of presumptive TB cases know 
their HIV status, this decrease was only 12.9% when 100% of presumptive TB cases 
know their HIV status. This is due to more Xpert-negative HIV-positive cases receiving 
a culture test, which reduces the benefits gained from Ultra’s higher sensitivity.  
The model indicated a small benefit for the detection of RMP-R TB cases. There was 
only a 6.5% increase in detecting RMP-R TB cases in the Ultra-based algorithm. This 
increase in RMP-R TB cases is due to more TB cases detected with Ultra. The number 
of RMP-R TB cases missed decreased by 24.8% with the Ultra-based algorithm. This 
decrease is due to the higher specificity of Ultra in detecting TB cases resulting in 
fewer false negative TB results and therefore fever RMP-R TB cases missed. Both 
Xpert and Ultra only produce a RMP-R result if the test in positive for TB.  
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These model outputs were based on population characteristics and the diagnostic 
algorithm in Cape Town where we have a high TB incidence, a high HIV prevalence 
and a high proportion of previously treated presumptive TB cases. Different results 
might be obtained under different epidemiological conditions and it is possible that 
these results will be different, with lower false positive tests in areas with lower TB 
incidence and lower proportions of retreatment cases. The WHO reported that in low 
TB burden settings, false positive results were not a major concern.11 
5.5.1 Strengths and limitation 
The strengths of the current study are that we used a previously developed, validated 
and published operational model, based on operational data on testing and diagnosis, 
to estimate the number of TB and RMP-R TB cases identified in an Xpert-based 
algorithms and extrapolated this to the Ultra-based algorithm. The model compared 
the two algorithms using identical population characteristics and adherence to 
algorithms. We compared the algorithms taking the full sequence of tests in each 
algorithm into consideration (as they would be used in routine practice), and not only 
the performance of the individual Xpert or Ultra tests. 
The Xpert model was validated against data from Cape Town, a well-resourced urban 
setting with a well functioning centralised laboratory and the availability of culture 
testing. This may limit the generalisability of our findings to other settings. We did not 
consider alternative diagnostic algorithms to that of the currently used Xpert-based 
algorithm in Cape Town. For the current comparison, we assumed Ultra would be 
introduced as a direct replacement for Xpert (Figure 1). We did not consider cost to 
the health system, cost to the patient, time to treatment initiation and initial loss to 
follow-up for TB or RMP-R TB. This will be included in future analyses and 
publications. 
5.6 Conclusion 
Our model suggests that Ultra will have small benefits over that of Xpert for both the 
number of TB and RMP-R TB cases detected in our setting and therefore the cost of 
introducing Ultra would be an important consideration in the decision to implement 
Ultra. This benefit is reduced as more presumptive TB cases know their HIV status, 
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as more HIV-positive presumptive TB cases with initial negative Xpert would go on to 
have a culture test and if culture-positive a LPA.  
The implementation of Ultra would however result in an almost 3-fold increase in the 
number of false positive TB cases identified. In certain settings, especially those with 
high proportions of previously treated TB cases, the introduction of Ultra poses serious 
challenges: would health services be willing to treat 2,625 individuals unnecessarily, 
in order to identify 549 more TB cases? 
Alternative strategies, such as alternative diagnostic algorithms, will have to be 
considered to find a balance between increased detection of TB cases and 
unnecessarily starting patients on TB treatment due to false positive results. Further 
operational research is required to evaluate the full effect of introducing Ultra in 
different settings with different population characteristics and existing or new 
diagnostic algorithms.   
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Table 1: Reported sensitivity and specificity of Xpert MTB/RIF and Xpert TB/RIF Ultra for detecting 
mycobacterium tuberculosis and rifampicin resistant from a multicentre study.12 
 MTB Sensitivity 
(95% CI) 
Pooled* HIV- HIV+ 
Xpert 82.9% (78.8% – 86.4%) 
89.3% 
(83.1% - 93.7%) 
75.5% 
(65.8% - 83.6%) 
Ultra 87.8% (84.8% - 90.9%) 
90.6% 
(84.7% - 94.8%) 
87.8% 
(79.6% - 93.5%) 
 
 
MTB Specificity 
(95% CI) 
Pooled* No history of TB treatment History of previous TB treatment 
Xpert 98.0% (96.8% - 98.8%) 
98.4% 
(97.0% - 99.2%) 
96.9% 
(93.7% - 98.7%) 
Ultra 94.8% (93.0% - 96.2%) 
95.9% 
(94.1% - 97.4%) 
91.5% 
(87.1% - 94.8%) 
 
 RMP sensitivity (95% CI) 
RMP specificity 
(95% CI) 
 Xpert 
95.5% 
(90.9% - 98.2%) 
97.9% 
(95.7% - 99.1%) 
Ultra 94.8% (90.1% - 97.7%) 
98.2% 
(96.1% - 99.3%) 
Xpert and Ultra sensitivities and specificities were extracted from findings reported from a multicentre 
non-inferiority diagnostic accuracy study conducted by FIND (Campus Biotech, Geneva, 
Switzerland).12 
* Pooled estimate include patient with unknown HIV status. 
MTB = mycobacterium tuberculosis; CI = confidence interval; HIV = Human Immunodeficiency Virus; 
RMP = rifampicin. 
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Table 2: Input parameters used for the Xpert-based and Ultra-based algorithms 
 Input values (%) 
 
New 
presumptive 
cases 
Previously 
treated 
presumptive 
cases 
 75 25 
HIV status 
HIV-positive 36 54 
HIV-negative 64 46 
Best estimated TB prevalence amongst presumptive cases 18 21 
Estimated proportion of RMP-R cases amongst TB cases 6 12 
Accuracy of fluorescence 
light-emitting diode smear 
microscopy18,19 (1 specimen) 
 
Sensitivity 
HIV-positive 55 
HIV-negative 60 
Specificity 
HIV-positive 99 
HIV-negative 99 
Accuracy of fluorescence 
light-emitting diode smear 
microscopy18,19 (2 
specimens) 
 
Sensitivity 
HIV-positive 65 
HIV-negative 75 
Specificity 
HIV-positive 99 
HIV-negative 99 
Accuracy of Xpert MTB/RIF 
for TB12 
Sensitivity 
HIV-positive 75.5 
HIV-negative 89.3 
Specificity 98.4 96.9 
Accuracy of Ultra MTB/RIF 
for TB12 
Sensitivity 
HIV-positive 87.8 
HIV-negative 90.6 
Specificity 
HIV-positive 
95.9 91.5 
HIV-negative 
Accuracy of GenoType® 
MTBDRplus LPA for RMP-R 
TB18,19 
 
Sensitivity HIV-positive 98 
Specificity HIV-positive 98 
Accuracy of Xpert MTB/RIF 
for RMP-R TB12 
Sensitivity 95.5 
Specificity 97.9 
Accuracy of Ultra MTB/RIF 
for RMP-R TB12 
Sensitivity 94.8 
Specificity 98.2 
HIV = Human Immunodeficiency Virus; TB = tuberculosis; RMP-R = rifampicin resistant; LPA = line 
probe assay. 
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Table 3: Model output comparing the detection of TB in the Xpert-based and Ultra-based algorithms 
and the influence of increased HIV testing among 100,000 presumptive cases 
  
Xpert-based 
algorithm 
n 
(%) 
Ultra-based 
algorithm 
n  
(%) 
Difference in number of 
cases between 
algorithms 
(% difference) 
60% of presumptive 
cases know their HIV 
status 
TB cases 
identified 
16,248 
(16.2) 
16,797 
(16.8) 
549 
(3.4) 
False positive TB 
test 
1,576 
(1.6) 
4,201 
(4.2) 
2625 
(166.6) 
False negative TB 
test 
1,907 
(1.9) 
1,358 
(1.4) 
-549 
(-28.8) 
  
100% of presumptive 
cases know their HIV 
status 
TB cases 
identified 
17,012 
(17.0) 
17,160 
(17.2) 
148 
(0.9) 
False positive TB 
test 
1,576 
(1.6) 
4,201 
(4.2) 
2625 
(166.6) 
False negative TB 
test 
1,143 
(1.1) 
995 
(1.0) 
-148 
(-12.9) 
Amongst the 100,000 presumptive TB cases, there were 18,155 true TB cases. Adherence to 
algorithms was set at 100% for all scenarios. 
HIV = Human Immunodeficiency Virus; TB = tuberculosis. 
 
 
  
105
Stellenbosch University  https://scholar.sun.ac.za
Table 4: Model output comparing the detection of rifampicin resistant tuberculosis between the Xpert-
based and Ultra-based algorithms 
  
Xpert-based 
algorithm 
n 
(%) 
Ultra-based 
algorithm 
n  
(%) 
Difference in 
number of cases 
between 
algorithms 
(% difference) 
60% of presumptive 
cases know their 
HIV status 
RMP-R TB cases 
identified 
1,186 
(6.5) 
1,228 
(6.8) 
42 
(3.5) 
False positive 
RMP-R result 
326 
(1.8) 
301 
(1.7) 
-25 
(-7.7) 
RMP-TB cases 
missed 
212 
(1.2) 
170 
(0.9) 
-42 
(-19.8) 
Reasons for RMP-R TB cases missed (% of total RMP-R TB cases missed) 
False negative TB 
test 
164 
(77.4) 
104 
(61.2) 
-60 
(-36.6) 
False negative 
RMP-R result 
48 
(22.6) 
66 
(38.8) 
18 
(37.5) 
 
100% of 
presumptive cases 
know their HIV 
status 
RMP-R TB cases 
identified 
1,263 
(7.0) 
1,253 
(6.9) 
-10 
(-0.8) 
False positive 
RMP-R result 
342 
(1.9) 
310 
(1.7) 
-41 
(-12.0) 
RMP-TB cases 
missed 
135 
(0.7) 
145 
(0.8) 
10 
(7.4) 
Reasons for RMP-R TB cases missed (% of total RMP-R TB cases missed) 
False negative TB 
test 
87 
(64.4) 
79 
(54.5) 
-8 
(-9.2) 
False negative 
RMP-R result 
48 
(35.6) 
66 
(45.5) 
18 
(37.5) 
Amongst the 18,155 true TB cases there were 1,398 true RMP-R TB cases. Adherence to algorithms 
at 100%. RMP as a proportion of TB cases in model (18,155). RMP-R TB cases detected, false-
positive RMP-R and RMP-R TB cases are reported as a percentage of true TB cases in the model 
(18,155). 
HIV = Human Immunodeficiency Virus; TB = tuberculosis; RMP-R = rifampicin resistant. 
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 Presumptive TB cases
2 sputum specimens submitted
1st specimen Xpert® MTB/RIF or 
Xpert® MTB/RIF Ultra 
MTB positive 
rifampicin 
susceptible
MTB positive 
rifampicin 
resistant
MTB positive 
rifampicin 
inconclusive
MTB negative
2nd specimen
smear 
microscopy
2nd specimen
smear, culture
Culture positive
LPA for DST
If HIV-positive
2nd specimen
smear, culture 
 
Figure 1: The Xpert-based diagnostic algorithm as implemented in Cape Town.13 In the Xpert-based 
algorithm, two spot specimens were collected and the first was tested with Xpert. If TB was detected, 
the second specimen underwent smear microscopy. If RMP-R was detected, a culture (BACTEC™ 
MGIT™ 960; BD, Spark, MD, USA) and LPA (GenoType® MTBDRplus line-probe assay) test was 
undertaken. The second specimen underwent culture and LPA if the Xpert test was negative and the 
individual was HIV-positive.  
In the model, we assume that Ultra will replace Xpert without further changes to the existing 
algorithm. 
Abbreviations: TB - tuberculosis; HIV – human immunodeficiency virus; MTB – mycobacterium 
tuberculosis; RIF – rifampicin; DST - drug susceptibility test; LPA - line-probe assay. 
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Chapter 6: Discussion 
Tuberculosis (TB) and rifampicin resistant (RMP-R) TB are major concerns globally. 
In 2015, TB was still one of the top 10 causes of death worldwide and the World Health 
Organisation (WHO) estimated that one third of incident TB cases as well as many 
RMP-R TB cases were missed, partly due to ineffective diagnosis1, including the use 
of insensitive tests such as smear microscopy2–4, the low availability of culture and 
drug susceptibility test (DST) infrastructure and delays experienced with the use of 
culture and conventional DST, which on solid media takes 4-6 weeks to provide a TB 
result and an additional 2-3 weeks to provide a RMP-R result.5 Undiagnosed TB and 
RMP-R TB cases, diagnostic and treatment delays6,7 and treatment non-initiation 
among diagnosed cases8–10 (which is partly influenced by diagnostic delays) all 
contribute to the ongoing transmission of TB and RMP-R TB.  
These challenges have led to increased investment in the development and rollout of 
new, more sensitive and rapid molecular diagnostic tests for TB and RMP-R TB, with 
the expectation that these tests would lead to an increase in the number of cases 
detected and earlier diagnosis and initiation of treatment, thus reducing transmission 
and, ultimately, the burden of disease.  Some of these new diagnostic tests such as 
line probe assay (LPA) and Xpert MTB/RIF (Xpert), have already been rolled out, or 
are in the process of being rolled out, in many countries.11 There are also many other 
new diagnostic tests currently under development and testing, for example the Xpert 
TB/RIF Ultra (Cepheid, Sunnyvale, CA, USA) cartridge, Genedrive MTB/RIF (Epistem 
Ltd, Manchester, M13 9XX, UK), Signature Mapping™ for Tuberculosis Detection 
Diagnostic System (Applied Visual Sciences Inc., Virginia, US) and loop-mediated 
isothermal amplification (Eiken Chemical Company Ltd, Tokyo, Japan).12   
It is essential that during and after the rollout of a new diagnostic test, studies are 
conducted to evaluate the impact of the new diagnostic test and to identify and test 
interventions to inform the optimal use of the new test within routine operational 
settings.2  
The PROVE IT (Policy Relevant Outcomes from Validating Evidence on ImpacT) study 
evaluated the impact of the rollout of an Xpert-based algorithm within a routine 
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operational setting in Cape Town. A limitation of this observational study was that 
several confounding factors were likely to have contributed to the differences found 
between the smear/culture and Xpert-based algorithms, making interpretation of the 
impact of Xpert difficult.  These included differences in population characteristics, for 
example due to a decline in TB prevalence over time, and differences in adherence to 
the algorithms (including differences in the proportion of human immunodeficiency 
virus (HIV) positive smear- and Xpert-negative cases with culture tests). Since HIV 
data was not available consistently, the study could not fully assess the interaction of 
HIV as a co-variable.  
I developed an operation model that could account for these differences in population 
characteristics and adherence to diagnostic algorithms and to fill gaps in data that 
were not available through routine data alone. With the model, it was possible to 
directly compare model outputs for the smear/culture and Xpert-based algorithms 
whilst allowing us to account for differences in population characteristics and 
adherence to diagnostic algorithms. 
6.1 The overall aim of this dissertation 
The overall aim of this dissertation was to use an operational model to compare the 
proportion of TB and RMP-R TB cases detected (yield), the costs, the model inputs 
influencing these and the potential impact of health system strengthening interventions 
in the smear/culture and Xpert-based algorithms. I developed and validated an 
operational model for the diagnosis of TB and RMP-R TB in Cape Town using data 
collected during the PROVE IT study. I used the outputs from the model to: (1) explain 
why the expected increase in TB yield was not found in our empirical study (2) model 
the effect of interventions on the number of TB and RMP-R TB cases detected (3) 
model the impact of varying inputs on laboratory cost for TB and RMP-R TB detected 
(4) model strategies to reduce laboratory cost for TB diagnosis (5) model the effect of 
introducing a new more sensitive diagnostic test as a replacement for Xpert.  
This chapter sets out to synthesise the findings from the operational model used in 
this dissertation and to provide an overview of using an operational model to assess 
the mechanisms that influence the diagnosis of TB and RMP-R TB in an Xpert-based 
algorithm. I discuss the use of an operational model to assess interventions to improve 
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TB and RMP-R TB diagnosis and the impact on laboratory cost. The rollout of a new 
more sensitive diagnostic test (Xpert Ultra) as a replacement for Xpert is discussed. I 
address the strengths and limitations of this research and discuss what it contributes 
to the evidence base on operational modelling and the use of these models in rolling 
out new TB diagnostic tests in routine operational settings.  
6.2 Modelling TB yield in the smear/culture and Xpert-based algorithms 
The empirical study from PROVE IT reported a decrease in TB yield from 20.9% with 
the smear/culture-based algorithm compared to 17.7% in the Xpert-based algorithm. 
The decrease in TB yield was attributed to a decrease in TB prevalence. Differences 
in adherence to the diagnostic algorithms may also have contributed. In order to 
account for these differences, we modelled a scenario where the population 
characteristics and adherence to testing protocols were identical in both algorithms 
(Chapter 2).13  
In a scenario with identical population characteristics and adherence to testing 
protocols, the TB yield was 15.8% in the smear/culture-based algorithm compared to 
17.9% in the Xpert-based algorithm, an increase of 13.3%. This increase is well below 
the 30%-37% estimated by a population-level decision model in South Africa14. 
However, the increase is close to that reported from a prospective cluster-randomised 
trial conducted in a primary care clinic in Cape Town which reported an increase in TB 
yield from 17% with a smear/culture-based algorithm to 26% with an Xpert-based 
algorithm.15 
Both TB prevalence and the extent to which culture testing is undertaken for HIV-
positive smear- or Xpert-negative presumptive TB cases are important variables 
influencing TB yield.  
6.2.1 How did TB prevalence affect TB yield? 
In order to evaluate the effect of TB prevalence on TB yield, I modelled a scenario with 
a 10% increase in TB prevalence amongst presumptive cases to 28.8% from the 
baseline of 18.8% (Chapter 2).13 When I compared TB yield in the smear/culture-
based algorithm at this increased TB prevalence (28.8%) compared to TB yield in the 
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Xpert-based algorithm at the baseline TB prevalence (18.8%) as calculated from 
routine data, the model indicated a 30% decrease in TB yield, from 23.3% in the 
smear/culture-based algorithm to 16.3% in the Xpert-based algorithm.  
Even though the TB prevalence amongst presumptive case in the empirical study is 
unlikely to have declined by as much as 10% (absolute), this partly helps to explain 
findings from the empirical study and why TB yield did not increase with the rollout the 
Xpert-based algorithm.16 
6.2.2 How did culture testing affect TB yield? 
According to the diagnostic algorithms, HIV-positive presumptive TB cases with a 
smear- or Xpert-negative result require a culture test. Routine laboratory data for the 
empirical study had incomplete HIV data for presumptive TB cases. It was therefore 
not possible to assess adherence to the algorithm for HIV-positive TB cases who 
required a culture test after an initial smear-negative or Xpert-negative test result.16 I 
addressed this limitation in data by modelling a scenario to show the impact of 
additional culture testing on reducing the difference in TB yield between algorithms 
(Chapter 2).13  
When I increased the proportion of smear-negative and Xpert-negative cases who 
received culture tests in the model to similar levels to that found in routine practice in 
our setting, the difference in TB yield between algorithms was reduced to 7.7%. This 
was attributable to a higher proportion of smear-negative cases in the smear/culture-
based algorithm undergoing culture testing compared to Xpert-negative cases 
undergoing culture testing in the Xpert-based algorithm. 
A cluster-randomised trial in four provinces in South Africa also found that culture was 
more likely to be undertaken for smear-negative (32%) than Xpert-negative (14%) HIV-
positive cases.17 The authors suggested that a greater belief in the efficacy of Xpert 
may have contributed to fewer culture tests being undertaken on HIV-positive, Xpert-
negative presumptive TB cases. 
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6.3 Modelling RMP-R TB yield in the smear/culture and Xpert-based 
algorithms 
The difference in levels of adherence to DST screening between algorithms in the 
empirical PROVE IT study made interpretation of the impact of RMP-R TB diagnosis 
with the rollout of the Xpert-based algorithm difficult. The empirical study found that 
among presumptive cases diagnosed with TB, 5.5% were identified as RMP-R TB 
cases in the smear/culture-based algorithm compared to 7.7% in the Xpert-based 
algorithm, an increase of 54%.18 The empirical study reported that only 42.7% of 
presumptive cases (new cases = 31.6%; previous history of TB treatment = 68.1%) 
diagnosed with TB had a DST done in the smear/culture-based algorithm compared 
to 78.9% in the Xpert-based algorithm.18  
I modelled a scenario to compare RMP-R TB yield between algorithms with 100% 
adherence to algorithms, where 60% of presumptive TB cases know their HIV status 
in both algorithms and with identical population characteristics (TB prevalence among 
presumptive TB case = 18.1%, RMP-R prevalence = 7.7%, HIV-positive = 40%, history 
of previous TB treatment = 25%) (Chapter 3). Among the presumptive cases 
diagnosed with TB the model identified 3.9% with RMP-R TB in the smear/culture-
based algorithm compared to 7.2% in the Xpert-based algorithm, an increase of 
95.4%. This difference is attributable to the differences in DST screening strategy 
between these algorithms. In the smear/culture-based algorithm, only high MDR-TB 
risk cases are screened for RMP-R at pre-treatment compared to all presumptive TB 
cases with Xpert-based algorithm.   
In a model scenario with 100% adherence to algorithms and where 100% of 
presumptive TB cases know their HIV status, 56.5% RMP-R TB cases were missed in 
the smear/culture-based algorithm compared to 11.9% in the Xpert-based algorithm. 
In the smear/culture-based algorithm 39.4% of RMP-R TB cased were missed due to 
no DST done compared to all cases having a DST in the Xpert-based algorithm where 
testing for RMP-R and TB are done simultaneously.  
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6.4 How can modelling inform the focus of health system strengthening 
interventions? 
I modelled scenarios to provide insights into the potential benefits of interventions that 
could strengthen the health system after full rollout of the Xpert-based algorithm. 
These modelled interventions included increasing adherence to the Xpert-based 
algorithm and increasing HIV testing amongst presumptive TB cases. 
6.4.1 Adherence to diagnostic algorithms 
6.4.1.1 Effect on TB yield 
During the study period, adherence to the Xpert-based algorithm was sub-optimal due 
to the failure to request the Xpert test by staff that were unfamiliar with the algorithm, 
due to costs concerns and to clinical decisions overriding the use of the testing 
algorithm. At times the Xpert test may not have been available due to maintenance on 
Xpert machines or cartridge stock-outs.  
Increasing adherence to the Xpert-based algorithm in the model from 50% to 100% 
(when 60% of presumptive cases know their HIV status) would increase TB yield by 
only 6.1% from 15.4% to 16.3% (Chapter 3). This is a small benefit considering that 
100% adherence is not a realistic goal in routine practice.  
6.4.1.2 Effect on RMP-R TB yield 
When adherence to the Xpert-based algorithm was increased from 50% to 100% (with 
60% of presumptive cases know their HIV status), the number of RMP-R TB cases 
detected increased by 63.4% (Chapter 3). The number of RMP-R cases missed 
decreased from 48.4% to 15.7%. In the modelled scenario with 50% adherence to the 
Xpert-based algorithm, RMP-R TB cases were missed for the following reasons: 
17.2% had a false negative TB test, 2.9% had a false negative RMP-R result and 
28.4% had no DST done pre-treatment.  
In the modelled scenario with 100% adherence to the Xpert-based algorithm, when all 
cases had a DST done pre-treatment, the reasons for RMP-R cases missed were as 
follows: 10.3% had a false negative TB test and 5.4% had a false negative RMP-R. 
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This illustrates the importance of simultaneous screening for TB and RMP-R, as 
occurs with adherence to the Xpert-based algorithm. 
6.4.2 Increased HIV testing among presumptive TB cases 
6.4.2.1 Effect on TB yield 
Increasing the proportion of presumptive cases who know their HIV status from 60% 
to 100% in the model increased TB yield from 15.4% to 15.9%, an increase in TB yield 
of 3.2% (Chapter 3). This is a modest increase in TB yield, considering the effort 
required to increase HIV testing so that all presumptive TB cases have an HIV test. 
Increasing HIV testing does however have other important clinical benefits, for 
example in enabling access to antiretroviral therapy.  
6.4.2.2 Effect on RMP-R TB yield 
Increasing the proportion of presumptive TB cases who know their HIV status had very 
little effect on the number of RMP-R TB cases detected in the Xpert-based algorithm 
(Chapter 3). When the proportion was increased from 60% to 100%, the number of 
RMP-R TB cases detected increased by 2.9% (with 50% adherence to the algorithm) 
and by 4.6% (with 100% adherence to the algorithm).  
6.5 The influence of context on the impact of a new diagnostic test  
The expected impact of implementing a new diagnostic test will vary depending on the 
epidemiology of the setting where the new test is implemented.19 Similarly, the existing 
diagnostic tests and algorithms already in place as well as where the new diagnostic 
test is placed within exiting algorithms will affect the observed impact of the new 
diagnostic test. If the new test is rolled out in a setting where TB cases are already 
being detected with tests with a high sensitivity (e.g. through the use of high-quality 
diagnostics such as culture as is the case in Cape Town), the new tool will have a 
much lower impact than if it is deployed in a setting where TB cases are frequently 
missed due to low sensitivity as occurs in settings that use only smear microscopy.  
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6.5.1 Epidemiology of settings 
In order to determine the effect of a difference in TB epidemiology on TB yield, we 
modelled the effect of different TB prevalence levels amongst presumptive cases on 
TB yield (Chapter 2). In a scenario where the TB prevalence amongst presumptive 
cases was 10% lower in the smear/culture-based algorithm (18.8%) than in the Xpert-
based algorithm (28.8%), the TB yield increased from 15.8% in the smear/culture-
based algorithm to 26.7% in the Xpert-based algorithm, an increase of 69%. If we 
model a scenario with a 10% increase in TB prevalence amongst presumptive cases 
(from 18.8% to 28.8%) in the Xpert-based algorithm the TB yield increased from 17.9% 
to 26.7%, an increase of 49.2%.  
6.5.2 New diagnostic test in relation to existing diagnostic tests and algorithms  
In a scenario where culture testing was removed from the algorithms (85% adherence 
to algorithms and 50% of presumptive case know their HIV status), there was a 33.6% 
increase in TB yield between the smear/culture and the Xpert-based algorithm 
(Chapter 2). The diagnostic benefits of Xpert are thus likely to be greater in areas that 
do not use or have very limited use of culture.  
The performance of smear microscopy in our central laboratory in Cape Town may 
also be much higher than in settings where smear microscopy is done at point-of-care. 
This is possibly due to greater proficiency and technical aspects (centrifugation, 
chemical treatment, fluorescence microscopy) at the central laboratory. In a modelled 
scenario (85% adherence to algorithms and 50% of presumptive case know their HIV 
status) where the sensitivity of smear microscopy was 10% lower (70% to 60%), as 
assumed would be the cases if smear microscopy was done at point-of-care, the TB 
yield increased from 14.7% in the smear/culture-based algorithm to 17.9% in the 
Xpert-based algorithm, an increase of 21.8% (Chapter 2). 
6.6 Cost implications with the rollout of the Xpert-based algorithm 
The empirical costing study undertaken in PROVE IT showed that the laboratory cost 
per pulmonary TB case detected increase by 157%, from $48.77 in the smear/culture-
based algorithm to $125.32 in the Xpert-based algorithm.20 The cost per RMP-R TB 
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case detected (cost of TB diagnosis plus cost of RMP-R diagnosis) was similar at 
US$190.14 in the smear/culture-based algorithm and US$183.86 in the Xpert-based 
algorithm. A direct comparison in laboratory cost between the two algorithms was 
difficult to make due to the decline in TB prevalence over the study period, differences 
in adherence to the diagnostic algorithms, and possibly some wasteful testing due to 
unnecessary repeat tests requested.  
We modelled a scenario to directly compare laboratory costs between algorithms. We 
modelled both algorithms with identical input parameters for TB prevalence among the 
presumptive cases tested (18.1%), HIV status (60% knew their HIV status and 40% 
were HIV-positive), history of previous tuberculosis treatment (25%) and adherence to 
diagnostic algorithms (100%) (Chapter 3).21 The model indicated that the cost per TB 
case detected would increase by 114% for the Xpert-based algorithm compared to the 
smear-based algorithm, with only a 5.5% increase in the number of TB cases detected.  
The model indicated that even though the increase in the number of TB cases detected 
was small, the most important benefit of the Xpert-based algorithm was the 95.4% 
increase in the number of RMP-R TB cases detected with only a 15.8% increase in 
the cost per RMP-R TB (Chapter 3). The cost per additional RMP-R TB case detected 
in the Xpert-based algorithm compared to the smear/culture-based algorithm was 
U$2,359. These high costs should be weighed against potential cost savings that may 
be realised through reducing TB and RMP-R TB transmission.   
Numerous studies have indicated that the use of Xpert has come at a much higher 
cost than tests previously used for TB diagnosis. Two studies in South Africa reported 
a cost per Xpert test performed of US$25.90 (in 2010 US$)22 and US$14.93 (in 2012 
US$) compared with respectively US$1.58 and US$3.40 for smear.23 A study 
conducted in India, evaluating the costs of various pulmonary TB diagnostic strategies, 
found that the strategy with Xpert as the first-line test had the highest cost per TB case 
detected.24 These high diagnostic costs to the health system in developing countries 
are not likely to be sustainable in the long term, and alternative strategies need to be 
sought.  
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6.7 Efforts to decrease the cost per TB case detected in the Xpert-based 
algorithm as case-finding is scaled-up  
The South African Department of Health plans to substantially scale-up case-finding 
efforts to meet the End TB Strategy goals. As part of the End TB Strategy, three 
people-centred targets were introduced which consist of reaching 90% of all people 
who need anti-tuberculosis treatment, including 90% of people in key populations and 
achieving at least 90% treatment success rates. The strategy recommends that 
countries set an operational target of reaching at least 90% of people in key 
populations through improved access to services, systematic screening where 
required, new case-finding methods, and  providing all people in need with effective 
and affordable treatment.1,25 
The cost per TB case detected is directly influenced by the TB prevalence among 
presumptive cases tested for TB. As case-finding efforts are scaled-up and the number 
of individuals tested for TB increases, the proportion with TB among those tested will 
decrease, and therefore the cost per TB case detected will increase. This increase in 
cost has serious implications for South Africa’s efforts to increase case-finding, and 
alternative strategies would need to be considered to reduce costs while still finding 
cases. 
Other than reducing the price of the Xpert cartridge, a further approach to reduce the 
cost per TB case detected would be to increase TB prevalence (the proportion of 
people who have TB) among the presumptive cases tested. This could be 
accomplished by implementing an improved pre-test screening or triage strategy.26 I 
modelled scenarios in which I reduced and increased the TB prevalence among 
presumptive cases tested and assessed the effect on the cost per TB case detected 
(Chapter 4).21 I also assessed the effect on cost per TB case detected if the price per 
Xpert cartridge was reduced.  
The model indicated that the best approach to improve affordability would be a 
combined approach of increasing the TB prevalence among presumptive cases tested 
using either a triage test or other pre-screening strategies, and a reduction in the price 
of Xpert cartridges. For example, if the TB prevalence among presumptive cases was 
10.6% and with a 50% reduction in the price of Xpert cartridges, the cost per TB case 
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detected was still high, at US$142. With an increase in TB prevalence among 
presumptive cases tested to between 25.9% – 30.8% and the price of the Xpert 
cartridge reduced by 50%, the cost per TB case detected would range from US$50 to 
US$59, a level that is comparable with the cost per TB case detected in the 
smear/culture-based algorithm (US$48.77) found in the PROVE IT empirical 
laboratory costing study.20 
The model indicated that unless alternative triage strategies are identified, the 
approach of increasing case-finding will not be sustainable, even if Xpert cartridge 
prices are reduced. 
A study using a decision analytical model showed that a hypothetical triage test with 
sensitivity equivalent to that of the Xpert test, 75% specificity and cost of US$5 per 
test, would reduce the total diagnostic cost by 39% in South Africa.27 No triage test is 
currently available, and this has been identified as one of the priorities in the 
development of new diagnostics for TB.28  
It has been shown that pre-screening presumptive TB cases with smear microscopy 
with a follow-up Xpert test for all those with a smear-negative tests had a higher 
sensitivity (81.9%, 95% CI 74.9 – 87.2) than testing only with smear microscopy 
(sensitivity = 68.5%, 95% CI 60.6 – 75.4) or testing only with Xpert (sensitivity = 77.2%, 
95% CI 69.8 – 83.2). This strategy would result in a 28.7% reduction in the cost per 
TB case detected from US$516 when Xpert was used on all cases to US$401 when 
used on all smear-negative cases.29 
6.8 Modelling the rollout of future tests 
In many countries, the detection of TB is still reliant on old technology such as smear 
microscopy and culture. However, over the last decade, there has been an increase 
in the development of new diagnostic tests. A pipeline analysis of new TB diagnostic 
technologies reported that, in 2015, there were about 50 different new TB diagnostic 
technologies.12 One of these new technologies, Xpert MTB/RIF Ultra (Ultra) (Cepheid, 
Sunnyvale, CA, United States), has been developed to replace the current version of 
Xpert MTB/RIF (Xpert).30,31 The development and rollout of Xpert was a major 
improvement over previous diagnostic test, such as smear microscopy and culture, for 
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the simultaneous detection of TB and RMP-R TB. However, Xpert still had imperfect 
sensitivity especially in HIV-positive TB cases and some limitations in detecting RMP-
R TB. Ultra was developed to address these limitations and showed higher sensitivity 
and lower specificity than Xpert.30,31  
A prospective multicentre diagnostic accuracy study compared the performance of 
Ultra to that of Xpert for the detection of TB and RMP-R TB.30 This study found an 
overall 4.9% increase in sensitivity with Ultra (87.8%) compared to Xpert (82.9%). The 
increase in sensitivity was higher among HIV-positive individuals with an increase of 
12.3% (Ultra = 87.8%, Xpert = 75.5%) compared to 1.3% (Ultra = 90.6%, Xpert = 
89.3%) among HIV-negative individuals. The overall specificity was lower by 3.2% with 
Ultra (94.8%) compared to Xpert (98%). The decrease in specificity was higher among 
individuals with a previous history of TB treatment (5.4%, Ultra = 91.5%, Xpert = 
96.9%) compared to individuals with no previous history of TB treatment (2.5%, Ultra 
= 95.9%, Xpert = 98.4%). Sensitivity and specificity for detecting RMP-R TB was 
similar between Ultra (sensitivity = 94.8%, specificity 98.2%) and Xpert (sensitivity = 
95.5%, specificity 97.9%). 
The model indicated that using Ultra as a replacement for Xpert (Chapter 5) would 
only increase TB yield by 3.4% (if 60% know their HIV status). The increase in TB yield 
was even smaller (0.9%) if 100% of presumptive TB cases know their HIV status. This 
was balanced by a 167% increase in the number of false positive presumptive cases 
detected (when 100% know their HIV status). The model indicated a 3.5% (if 60% 
know their HIV status) increase in the number of RMP-R TB cases detected and a 
0.8% decrease in the number of RMP-R TB cases detected if 100% of presumptive 
TB cases know their HIV status.  
The small increase in TB and RMP-R TB yield has to be weighed against the massive 
increase in the number of false positive cases detected and unnecessarily treated. 
The increase in false positive cases, especially in settings with high proportions of 
presumptive TB cases with a history of previous TB treatment, would place a large 
burden on the health system and patients. Decision makers would have to take the 
high number of false positive cases in consideration, if Ultra replace Xpert, and find a 
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balance between increased TB case detection and unnecessarily starting patients on 
TB treatment.  
6.9 Summary: What did I find with the operational model?  
The model outputs presented in this dissertation showed that there was an increase 
in TB yield in the Xpert-based compared to a smear/culture-based algorithm, though 
this increase was not as high as expected (Chapter 2). The model indicated that a 
decrease in TB prevalence as well as different levels in adherence to the diagnostic 
algorithms were likely reasons that the empirical study did not find an increase in TB 
yield in the Xpert-based algorithm. The model also indicated that the context of the 
health system has to be taken into consideration when evaluating the impact of a new 
TB diagnostic test. In our setting, the high efficiency of the central laboratory as well 
as extensive use of culture testing for smear-negative cases in the smear/culture-
based algorithm limited the observed benefit of the Xpert-based algorithm. 
The model indicated that the real benefit of the Xpert-based algorithm is the ability of 
Xpert to simultaneous test for TB and RMP-R (Chapter 3). The small increase in TB 
yield and the high laboratory cost of the Xpert-based algorithm have to be weighed 
against the efficiency of Xpert in diagnosing RMP-R TB cases. The model did however 
indicate that this benefit in diagnosing RMP resistance is highly dependent on 
adherence to the Xpert-based algorithm. 
The high laboratory cost and high cost per TB case detected with the rollout of the 
Xpert-based algorithm is a concern. The long-term sustainability of the high cost to the 
health system is questionable, particular if TB case-finding efforts are increased. The 
model indicated that alternative, more cost-effective strategies will need to be 
implemented in settings where the TB prevalence among presumptive cases is low or 
declining (Chapter 4). We showed that a reduction in the price of Xpert cartridges 
would not be sufficient to bring the cost per TB case detected down and alternative 
strategies such as better pre-screening or a triage screening test will need to be 
implemented with increased case-finding efforts. 
The model showed that replacement of Xpert with Ultra, which has higher sensitivity 
but lower specificity for TB detection, would increase TB and RMP-R TB case 
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detection slightly (Chapter 5). However, there would be a significant increase in the 
number of false-positive TB cases detected. The small increase in the number of TB 
cases detected has to be weighed against the increased number of false positive 
cases detected and unnecessarily treated. 
6.10 Strengths and Limitations 
The model developed and used in this dissertation had several strengths, including 
the availability of detailed routine data and information on health and laboratory 
processes collected within the PROVE IT empirical study. This allowed me to develop 
a precise operational model to assess the impact of TB and RMP-R TB detection in 
terms of number of cases detected and laboratory costs. The model input parameters 
were based mostly on these detailed routine data, and only a few assumptions, based 
on literature, were made. We assumed that TB prevalence among presumptive cases 
was higher among HIV-positive presumptive cases than among HIV-negative 
cases32,33, and among previously treated than among new TB cases;14 we assumed a 
decrease in TB prevalence among presumptive TB cases over time based on the 
empiric yield data, which showed a decrease in yield over time despite similar 
proportions of the population being tested.16 
We had detailed information for both the previously used smear/culture-based 
algorithm and the newly introduced Xpert-based algorithm and therefore the model 
could be developed for both algorithms. This made a direct comparison between the 
algorithms possible taking into account differences in population characteristics and 
adherence to algorithms. A further strength of the model is the fact that we could 
validate the model against data for seven-time points, as reported by the empirical 
study, which built confidence in the outputs from the model and confirmed that the 
outputs were credible. 
Generalisability of findings from the model and the use of the model for other settings 
may be limited as the model was validated against data from a well-resourced, urban 
setting, with good health and laboratory infrastructure and therefore may not reflect 
reality in other settings, such as rural areas. The rollout of the Xpert-based algorithm 
in Cape Town was different to the Xpert-based algorithm rolled out nationally. In the 
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Cape Town Xpert-based algorithm, two sputum specimens are required compared to 
only one specimen required in the national Xpert-based algorithm. 
The highly centralised diagnostic infrastructure in Cape Town as well as the extensive 
use of culture testing may also limit generalisability of findings from the model and 
therefore make a direct comparison to countries with decentralised diagnostic 
infrastructure and no culture testing difficult.  
A limitation of the model is that we did not consider time delays in the model, such as 
the time it takes to process a sputum specimen and have a test result available. We 
did include time delays as part of the model input parameters and model logic, 
however, these were not reported as part of the model output as they did not add to 
the findings from the empirical study. 
6.11 Innovation 
This dissertation used an operational model for the detection of TB and RMP-R TB 
cases to compare diagnostic algorithms in routine operational settings. The model did 
not only evaluate the impact of a single test on the health system, but rather took the 
complete testing protocol stipulated in each algorithm into consideration. New 
diagnostic tests are implemented as part of a diagnostic algorithm and not used in 
isolation and using this approach allowed for a more realistic comparison between 
algorithms.  
It would not have been possible to develop the operational model without operational 
data being available. Whilst it would thus not have been feasible to use this model to 
inform decisions about the implementation of Xpert, it could be used to provide data 
on the benefits to be expected from health system strengthening efforts such as 
improved adherence to diagnostic algorithms and increased HIV testing amongst 
presumptive TB cases. The model provides useful data on the benefits to be expected 
if Ultra were to replace Xpert, providing a sobering picture of the potential number of 
cases treated unnecessarily, in order to detect a relatively small number of additional 
TB and RMP-R TB cases. To my knowledge an operation model has not, to date, been 
used to comprehensively evaluate diagnostics in the way that I have done in this 
dissertation. 
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6.12 What does modelling contribute to the evidence base? 
This dissertation and the modelling approach followed demonstrates that modelling is 
not just a useful tool to make future projections of burden of a disease, but could be 
used to assess the potential impact of new diagnostic tools under routine operational 
conditions and provide insights on how to increase impact.   
The operational model used in this dissertation was developed as part of the PROVE 
IT study undertaken after the rollout of Xpert in South Africa. The empirical analyses 
from PROVE IT identified inefficiencies in the health system that contributed to the 
findings on TB and RMP-R TB yield and laboratory costs when comparing algorithms. 
These need to be addressed to ensure the optimal use of Xpert, for example, ensuring 
adherence to the Xpert-based algorithm and therefore that all presumptive TB cases 
receive Xpert as a first-line test and that all HIV-positive presumptive TB cases with a 
negative Xpert result receive a culture test.  
The modelling allowed us to answer several important questions. With the model, the 
above factors to strengthen the health system for TB and RMP-R TB detection could 
be evaluated, and gaps in data (HIV status) could be addressed. This research 
contributes important evidence to decision makers as to which intervention strategies 
would result in better TB and RMP-R TB case detection as well as the impact of these 
interventions on laboratory cost.  
The effect of culture testing for HIV-positive presumptive TB cases, on TB and RMP 
detection, was however not possible in the empirical study due to the incomplete data 
available in the routine laboratory on HIV status . 
An important challenge for the health system is to ensure that everyone has access to 
health services and to new technologies, in particular the poor and marginalised 
groups.34 The model indicates that unless a concerted effort is made to use the newly 
introduced technology optimally, the investment in the new technology would not fully 
benefit the health system and patients.  
The empirical study as well as output from the model indicate that with the rollout of 
Xpert there were definite benefits, in particular an increase in the detection of RMP-R 
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TB cases. Other benefit were also identified by the empirical study such as reduced 
initial loss to follow-up and reduced treatment delay for TB cases, reduced delays to 
MDR-TB treatment initiation and reduced costs to MDR-TB patients.35 These benefits 
came at a very high cost to the health system and therefore additional strategies (such 
as a pre-screening or triage testing) would need to be considered to bring these costs 
down in order to be sustainable to the health system.  
Cepheid, the developers of Xpert® MTB/RIF, has developed an upgrade to Xpert® 
MTB/RIF namely Xpert® MTB/RIF Ultra. The company plan to slowly phase-out 
Xpert® MTB/RIF to be eventually completely replace by Xpert® MTB/RIF Ultra.30,31 
Ultra has a higher sensitivity but lower specificity than Xpert. The model indicated that 
even though more TB and RMP-R TB cases will be detected by Ultra, the lower 
specificity (in particular for individual with a history of previous TB treatment) will result 
in more individuals incorrectly being detected with TB and unnecessarily been started 
on TB treatment. Alternative strategies, such as alternative diagnostic algorithms, will 
have to be considered to find a balance between increased detection of TB cases and 
unnecessarily starting patients on TB treatment due to false positive results. 
The findings from the studies presented in this dissertation highlight the important role 
that an operation model can play in informing decision maker on the optimal use of 
new diagnostic test in an operational setting, even after the rollout of the new test. 
Operational modelling can therefore be an effective tool to be used to assist the health 
department to optimise the way in which tests are currently used and could serve to 
inform policy decisions about the implementation of new more sensitive diagnostic 
tests. 
6.13 Recommendations for further research 
In this dissertation, I used an operational model to model the effect of interventions for 
health system strengthening on TB and RMP-R TB detection, however, we did not 
model all possible interventions. Future studies are required to identify and test further 
health system interventions with the operational model, for example, interventions to 
further reduce the delay in starting TB and MDR-TB treatment and initial loss to 
treatment. Studies conducted in South Africa indicated that 15.5% to 34.7% of 
laboratory confirmed TB cases did not start TB treatment.9,10,36–38 A nationwide 
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retrospective cohort study conducted in South Africa to assess second-line treatment 
initiation and delay among laboratory confirmed RMP-R TB cases39 indicated that in 
2013 (after full rollout of Xpert in South Africa), only 51% to 73% of laboratory 
confirmed RMP-R TB cases initiated MDR-TB treatment with the median delay in 
starting treatment of between 15 and 36 days. These cases not initiating TB and MDR-
TB treatment as well as delays in initiating treatment contribute to the ongoing 
transmission of TB and MDR-TB in the community.  
Further studies are required to determine the long-term population level impact of 
introducing new TB and RMP-R TB diagnostic tests. The long-term population level 
impact of health system strengthening interventions for the optimal use of these new 
diagnostics also needs to be determined. Such studies will use transmission modelling 
to predict the long-term impact on the community by projecting TB incidence, 
prevalence, and mortality.19,40 There are however few studies that combine the 
strengths of both transmission modelling and operational modelling. Such a study was 
conducted to determine the effects of new diagnostic tests from the patient, health 
system, and population perspective in United Republic of Tanzania by incorporating 
and linked a detailed operational model with a transmission model.41 We therefore 
propose a study to follow a similar approach, as was done for United Republic of 
Tanzania, and develop a combined operational and transmission model.  
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